<allTrials totalCount="135" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-12-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-12-21T00:00:00.000Z">23612807</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre randomised placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease</title>
      <scientificTitle/>
      <acronym>CANOX trial</acronym>
      <studyHypothesis>Long-term oxygen therapy (LTOT) is the only component of the management of chronic obstructive pulmonary disease (COPD) that improves survival in patients with severe daytime hypoxemia. In Canada, LTOT is usually provided by a stationary oxygen concentrator and is recommended to be used for at least 15 - 18 hours a day. Several studies have demonstrated a deterioration in arterial blood gas pressures and oxygen saturation during sleep in patients with COPD. Sleep-related oxygen desaturation often occurs in patients not qualifying for LTOT. The suggestion has been made that the natural progression of COPD to its end stages of chronic pulmonary hypertension, severe hypoxemia, right heart failure, and death is dependent upon the severity of desaturation occurring during sleep. This is an attractive hypothesis and is supported by the fact that hypoxemic episodes during sleep are accompanied by substantial increases in pulmonary arterial pressure and often by important cardiac arrhythmias. Supplemental nocturnal oxygen alleviates both the acute increases in pulmonary arterial pressure and the cardiac arrhythmias.  

It has been suggested that, over the long run, nocturnal oxygen therapy (N-O2) may halt the progression of long-standing cor pulmonale and prolong survival. Probably due to the fact that the recommendations of scientific societies regarding the indications for and use of N-O2 in COPD not qualifying for conventional LTOT are presently imprecise, a number of patients are currently treated with N-O2 although the beneficial effects of this therapy have not been confirmed.

Hypothesis:
In patients with Chronic Obstructive Pulmonary Disease (COPD) not qualifying for Long Term Oxygen Therapy (LTOT) but who present significant nocturnal arterial oxygen desaturation, nocturnal oxygen therapy provided for a period of 3 years is effective in decreasing mortality or delaying the requirement for LTOT, and is cost-effective and favourably compares to other medical interventions</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes of this trial are mortality from all cause or requirement for LTOT (composite outcome).</primaryOutcome>
      <secondaryOutcome>1. Quality of life and utility measures
2. Costs from a societal perspective 
3. Compliance with oxygen therapy</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Pending as of 20/10/2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23612807</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MOP-36329</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A 3-year, multicentre, placebo-controlled, randomised trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="883624d6-4d6d-4c28-9130-caa5da73b5cf">
	  <name>Centre de Pneumologie</name>
	  <address/>
	  <city>Québec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>G1V 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with a diagnosis of COPD supported by an history of past or current smoking and obstructive disease with forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) less than 60%
2. Presence of mild-to-moderate daytime hypoxemia with a daytime partial pressure of oxygen in arterial blood (paO2) in the range of 56 - 69 mmHg
3. Patients fulfilling our definition of nocturnal oxygen desaturation: greater than or equal to 30% of the recording time with transcutaneous arterial oxygen saturation less than 90% on two consecutive recordings</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Patients fulfilling the usual criteria for continuous oxygen therapy (CONT-O2) at study entry: 
1.1. PaO2 less than or equal to 55 mmHg, or
1.2. PaO2 less than or equal to 59 mmHg with clinical evidence of at least one of the following: 
1.2.1. Pulmonary hypertension
1.2.2. Right ventricular hypertrophy
1.2.3. Cor pulmonale
1.2.4. Haematocrit greater than or equal to 55%
2. Patients with sleep apnea (defined by an apnoea/hypopnoea index of greater than or equal to 15 events/hour
3. Patients currently on nocturnal oxygen therapy (N-O2)
4. Patients with known left heart or congenital heart diseases, interstitial lung diseases, bronchiectasis as the main cause of their obstructive disease, lung carcinoma or other severe diseases that could influence survival (hepatic cirrhosis and chronic renal failure)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Nocturnal oxygen therapy group: N-O2 will be delivered overnight to allow the oxygen saturation to be greater than 90%
2. Placebo: the patients allocated in the control group will receive room air delivered by sham concentrator</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nocturnal oxygen therapy</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15743-0</funderId>
      <contactId>Contact53681_15743</contactId>
      <sponsorId>Sponsor52235</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53681_15743">
    <title>Dr</title>
    <forename>Yves</forename>
    <surname>Lacasse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre de Pneumologie
Hôpital Laval
2725 chemin Ste-Foy</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 4747</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yves.lacasse@med.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52235">
    <organisation>Laval University (Canada)</organisation>
    <website>http://www.ulaval.ca/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Cité Universitaire
C.P. 2208</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1K 7P4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yves.lacasse@med.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.23856.3a</gridId>
    <rorId>https://ror.org/04sjchr03</rorId>
  </sponsor>
  <funder id="Funder15743-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MOP-36329)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">34931928</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of homocysteine-lowering vitamin supplementation on migraine disability</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does vitamin therapy including folic acid reduce homocysteine and migraine disability, and is the effect dependent on MTHFR genotype?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Migraine disability, as measured using the Migraine Disability Assessment (MIDAS) score at baseline and 6 months.</primaryOutcome>
      <secondaryOutcome>1. Migraine frequency. Duration of follow-up: 6 months
2. Migraine pain: MIDAS pain score 1-10 (10 = most severe) at baseline and 6 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Griffith University Ethics Committee on 11 November 2005 (ref: 3425)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34931928</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11a24be8-9a86-4feb-b250-fa2667ed342a">
	  <name>Griffith University</name>
	  <address/>
	  <city>Gold Coast</city>
	  <state/>
	  <country>Australia</country>
	  <zip>9726</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Current diagnosis of regular migraine with aura attacks
2. &gt;18 and &lt;70 years old</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Co-morbid vascular or neuropsychiatric disease
2. Pregnant
3. Currently taking B vitamins</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine with aura</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine with aura</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Daily B vitamin (B6, B9, B12) therapy vs placebo for 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17311-0</funderId>
      <contactId>Contact55272_17311</contactId>
      <sponsorId>Sponsor53840</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55272_17311">
    <title>Prof</title>
    <forename>Lyn</forename>
    <surname>Griffiths</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Griffith University
Gold Coast campus</address>
      <city>Gold Coast</city>
      <country>Australia</country>
      <zip>9726</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Griffiths@griffith.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53840">
    <organisation>Griffith University (Australia)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof Lyn Griffiths
Gold Coast campus
Griffith University Qld 4222</address>
      <city>Gold Coast</city>
      <country>Australia</country>
      <zip>9726</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Griffiths@griffith.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1022.1</gridId>
    <rorId>https://ror.org/02sc3r913</rorId>
  </sponsor>
  <funder id="Funder17311-0">
    <name>Brain Foundation of Australia</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">35143689</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Candesartan in renal artery stenosis (CARLAS)</title>
      <scientificTitle/>
      <acronym>CARLAS</acronym>
      <studyHypothesis>Despite beneficial effects on blood pressure with endovascular treatment, the prognosis remains ominous in patients with renal artery stenosis because of increased cardiovascular mortality. In patients with atherosclerotic renal artery stenosis, the mortality is increased six-fold compared to an age-matched population. It is reasonable to speculate that the high cardiovascular mortality in patients with renal artery stenosis could partly be explained by increased inflammatory activity caused by activation of the renin-angiotensin system. We believe that Percutaneous Transluminal Renal Angioplasty (PTRA) followed by angiotensin receptor blockade may improve this disease state. 

The angiotensin receptor blocker candesartan given to patients with renovascular hypertension post-PTRA, will improve long-term renal function  (3 years) and decrease the risk of restenosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Renal function measured by EDTA-clearance and frequency of restenosis 3 years after PTRA.</primaryOutcome>
      <secondaryOutcome>Cardiovascular events 3 years after PTRA.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethical Committees of the Universities of Göteborg and Lund on the 14th of April 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35143689</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S 131-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A two-center randomized controlled open study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d7bae0d5-a852-4018-85f3-2d76806b2d80">
	  <name>Department of Nephrology</name>
	  <address/>
	  <city>Göteborg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Blood pressure above 140 mmHg/90 mmHg
2. Confirmation of renal artery stenosis by either duplex ultrasonography, CT-angiography or MR-angiography</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Renal size &lt;7.5 cm at the stenotic side 
2. Age &gt;80 years 
3. Pregnancy or nursing mother 
4. Terminal renal failure (Glomerular Filtration Rate [GFR] &lt;15 ml/min) 
5. Treatment with Angiotensin-Converting Enzyme (ACE) inhibitors or angiotensin receptor blockers 
6. Renovascular hypertension of other etiology than atherosclerosis or Flow-Mediated Dilation (FMD) 
7. Chronic glomerular disease with urinary albumin excretion (in mg/24h) (tU-alb) &gt;1g/day 
8. Diabetic nephropathy with tU-alb &gt;0.3 g/day 
9. Contraindication for renal angiography/PTRA (eg. serious contrast allergy)
10. Other forms of secondary hypertension 
11. Serious malignant disease 
12. Treatment with immune-modulating medications eg. cyclosporin and oral steroids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal artery stenosis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Renal artery stenosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study is carried out at two centers in Sweden (Göteborg and Malmö). 

Four weeks after renal angioplasty, all subjects will be randomized to anti-hypertensive treatment with either candesartan (oral) (intervention group) or conventional anti-hypertensive treatment (control group). The choice of drug used for the treatment of each participant in the control group will depend on his/her condition. The choices are betablockers, calcium antagonists, diuretics and alphablockers. 

The maximum daily doses: 200 mg for metoprolol (betablocker), 20 mg for felodipine (calcium antagonist), as much as needed for furosemide (diuretic), 8 mg for doxazosin (alphablocker). Candesartan was titrated up to a dose of 16 mg once daily.

Duration of intervention: three years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Candesartan</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17182-0</funderId>
      <funderId>Funder17182-1</funderId>
      <funderId>Funder17182-2</funderId>
      <funderId>Funder17182-3</funderId>
      <funderId>Funder17182-4</funderId>
      <funderId>Funder17182-5</funderId>
      <funderId>Funder17182-6</funderId>
      <funderId>Funder17182-7</funderId>
      <funderId>Funder17182-8</funderId>
      <contactId>Contact55143_17182</contactId>
      <sponsorId>Sponsor53708</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55143_17182">
    <title>Prof</title>
    <forename>Hans</forename>
    <surname>Herlitz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Nephrology
Sahlgrenska University Hospital</address>
      <city>Göteborg</city>
      <country>Sweden</country>
      <zip>413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 31 3428477</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hans.herlitz@medic.gu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53708">
    <organisation>AstraZeneca (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Argongatan 2D</address>
      <city>Mölndal</city>
      <country>Sweden</country>
      <zip>431 86</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 31 7788500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mikael.forsby@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418151.8</gridId>
    <rorId>https://ror.org/04wwrrg31</rorId>
  </sponsor>
  <funder id="Funder17182-0">
    <name>The Ernhold Lundström Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-1">
    <name>Research Funds at Malm General (University) Hospital (Malm Allmnna Sjukhus - MAS) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-2">
    <name>The Albert Påhlsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-3">
    <name>The Hulda Ahlmroth Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-4">
    <name>The Göteborg Medical Society (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-5">
    <name>The Swedish Medical Society</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-6">
    <name>The Swedish Association for Kidney Patients</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-7">
    <name>AstraZeneca, Mölndal (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-8">
    <name>The Swedish state under the LUA/ALF agreement</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">08808171</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of the follow-up of depressed patients by  nurses</title>
      <scientificTitle/>
      <acronym>MADEIRA</acronym>
      <studyHypothesis>1. The average depressive symptoms at the end of six months of follow-up among the group of depression patients treated by the primary care nurse and the group treated by the family doctor do not exceed the difference of 2.5 on the BDI scale, which is considered a difference not clinically relevant. 
2. There will be no significant difference in change in the quality of life between the two groups. 
3. Level of satisfaction will be similar in both groups, or greater among patients followed by nurses than the participants who are treated by the doctors
4. Adherence to treatment will be similar in both groups, or higher in patients followed by the nurses</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Differences between groups in the average of decrease in depression symptoms, measured by BDI at 6 months
2. Increase in quality of life, measured by the 12-item Short Form health survey (SF-12) at 6 months
3. Increase in satisfaction with the professional, measured by the satisfaction questionnaire of Baker at 6 months</primaryOutcome>
      <secondaryOutcome>1. Percentage of acceptance of the intervention (comparison of the two groups): patient satisfaction and losses that occur at different times of follow-up
2. Average of differences between the two groups with respect to:
2.1. Frequency and duration of visits
2.2. Referrals
2.3. Drug treatment
3. Comparison of adherence to treatment between the two groups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Research Ethics Committee of the Jordi Gol i Gurina Primary Care Research Institute (IDIAP), Barcelona, on 4 July 2006 (ref: P06/39)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08808171</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PI061281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3dc29f4-7c76-4de9-9699-4a82e7579c5d">
	  <name>Lope de Vega 138</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08005</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients between 25 and 70 years of age
2. Rating of 20 or more points in the Beck Depression Inventory Scale (BDI) 
3. Whose family practitioner thinks they suffer from depression and they need to initiate anti-depressant treatment</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>460</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>460</totalTarget>
      <exclusion>1. Pregnancy or breastfeeding
2. Background of severe psychiatric disorders: psychosis, paranoia, severe personality disorders, delusional thoughts
3. Existence of suicidal ideation or attempts
4. Two or more episodes of major depression, or one or more episodes that might require hospitalization
5. Patients who have received antidepressant medication in the past year
6. Patients with mental health problems who have been referred to psychiatric specialists for these reasons 
7. Substance abuse and/or drugs 
8. Treatment for Parkinson's disease or epilepsy
9. Temporal residents (plan to move in the next six months) 
10. Unable to communicate in Spanish or Catalan languages</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Major depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Half of the participants will be allocated to the intervention group and another half into the control group. This trial involves 23 doctors and 23 nurses from 12 primary care teams in Barcelona.

Intervention group: Implementation of a depression management protocol, based on evidence-based clinical guidelines, by the primary care nurse. This protocol includes pharmacological treatment with fluoxetine or another Selective Serotonin Re-uptake Inhibitor (SSRI), and the participants will have at least 6 appointments with the nurses during the 6 months of follow-up. At each visit, each patient will be informed about the disease and pharmacological treatment. In addition, the nurse will ask the patient about changes in mood and try to enhance compliance. Nurses will also provide emotional support. If the patient does not improve, he will be referred to his doctor. 

Control group: Six-month follow-up by family doctors. Family doctors will provides usual care management. They can prescribe fluoxetine or another SSRI. Participants will have at least 6 appointments with their doctor during the 6 months of follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17301-0</funderId>
      <contactId>Contact55262_17301</contactId>
      <sponsorId>Sponsor53830</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55262_17301">
    <title>Dr</title>
    <forename>María Isabel</forename>
    <surname>Fernández San Martín</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Lope de Vega 138</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53830">
    <organisation>Jordi Gol i Gurina Primary Care Research Institute (IDIAP Jordi Gol i Gurina) (Spain)</organisation>
    <website>http://www.idiapjgol.org/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Gran Via de les Corts Catalanes
587 àtic</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08007</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.452479.9</gridId>
    <rorId>https://ror.org/0370bpp07</rorId>
  </sponsor>
  <funder id="Funder17301-0">
    <name>Carlos III Health Institute of the Spanish Ministry of Health and Consumption (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo), Health Research Fund   (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-12-14T00:00:00.000Z">46535923</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comprehensive care of infants: development and evaluation of an intervention strategy to enhance the promotion of health and quality of life of infants 2007 - 2010</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does a public health intervention aimed at promoting improved feeding practices delivered at home and facility levels increase the duration of exclusive breastfeeding in the first 6 months of life and reduce the prevalence of obesity among infants 6 - 12 months?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Prevalence of exclusive breastfeeding among infants up to 6 months of age
2. Prevalence of "recommended infant feeding practices" (continued breastfeeding and three complementary feeds/day) at 6 - 11 months
3. Prevalence of Body Mass Index (BMI)/age equal of greater than 2SD at 6 - 11 months</primaryOutcome>
      <secondaryOutcome>1. Diarrhoea and pneumonia in the 2 weeks before interview
2. Hospitalisations in the past year (and their cause)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. World Health Organization (WHO) Ethics Review Committee on the 21st November 2007 (ref: NCH07006)
2. Comite de Etica de la Investigacion (Cuba) on the 20th November 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46535923</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NCH 07006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>This is a cluster-randomised controlled trial of a public health intervention</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Cuba</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="081e3cb5-9509-44bc-b8c1-e475ee7fe854">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants are all infants living in the community area served by health centres included in the study.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>12800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12800</totalTarget>
      <exclusion>The only exclusion criteria identified is the patient's refusal to participate.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infant feeding practices</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Infant feeding</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group:
Promotion of improved feeding at the health facility and community levels using multiple channels:
1. Face-to-face
2. Community based media
3. Community groups

Control group:
Receives usual care.

Some of the details of the intervention, such as the frequency or duration of contact or exposure to the channels will only be fully defined at the end of the formative research phase. Interventions at the health facility level may include in-service training of the physicians and nurses in the health centres to improve their communication and counselling skills. Training of health workers and community counselors in this course will, we believe, be an important component of the intervention. The intervention may also include changes in management procedures to make them more compatible with family needs and expectations. Access to off-hour advice, privacy of consultations, triage and waiting time and characteristics of the waiting room are some of the examples of areas that may be considered for improvement. 

Interventions at the community level will make maximal use of appropriate existing channels either to be the primary sources of dissemination of messages or to re-enforce them. In addition to face-to-face communications individually or in group, the team will also consider the use of local mass media (e.g. local radio, pamphlets, banners, and posters), work and social clubs. The intervention will probably include the provision of information and the development with families of problem-solving approaches/strategies to deal with significant constraints. Face-to-face counselling will be one of the key components. Additional components may be included to remove existing barriers or promote actions that will support an increase in prevalence of a desired behaviour (for example, making breastfeeding counsellors available in the community for greater ease of access to counselling and support when mothers face a feeding difficulty).

Eighteen months after the introduction of the intervention, when we expect that the intervention will have been fully functional in all intervention clusters for at least 12 months, the post-intervention survey will be conducted to measure the impact on infants up to 12 months old. The length of exposure to the intervention will depend on the age of the infant and the period he/she has been residing in the community. Control clusters will continue to be provided the usual type of health care.

Contact details for Principal Investigator:
Dr Ibargollen Negrin Longina
Ministerio de Salud Publica
MCH Division
Calle 23 entre M y N. Vedado
Havana
Cuba 
Tel: +53 (0)7 833 2336</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17359-0</funderId>
      <contactId>Contact55320_17359</contactId>
      <sponsorId>Sponsor53889</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55320_17359">
    <title>Dr</title>
    <forename>Jose Carlos</forename>
    <surname>Martines</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 2634</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">martinesj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53889">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/child-adolescent-health</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 2634</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mertinesj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17359-0">
    <name>World Health Organization (WHO) (Switzerland) (ref: NCH 07006)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-12-07T00:00:00.000Z">79227925</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Vitamin and mineral supplementation in reducing morbidity in Human Immunodeficiency Virus (HIV)-infected children in developing countries: an efficacy study</title>
      <scientificTitle/>
      <acronym>Mnuts/supps/HIV/children</acronym>
      <studyHypothesis>Micronutrient deficiencies contribute to immune dysfunction and can lead to increased infectious morbidity in Human Immunodeficiency Virus (HIV)-1-infected children. We hypothesised that micronutrient supplementation could reduce infectious morbidity in HIV-1-infected children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Relative frequency of adverse or serious infective episodes, or death.</primaryOutcome>
      <secondaryOutcome>1. Viral load and CD4 count changes
2. Biochemical variables such as micronutrient levels measures
3. Relative frequency of minor infective episodes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Research Ethics Committee (REC) of the University of Cape Town on 03/12/2001 (ref: RECRES 118/2001).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79227925</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind randomised, placebo-controlled clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-04-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e26de706-133f-4f14-bb36-1f67fae659a5">
	  <name>Ambulatory Paediatrics</name>
	  <address/>
	  <city>Cape Town</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>7700</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinically stable (not acutely ill)
2. Vertically transmitted HIV-1 infected children
3. Attending the Infectious Diseases Clinic at Red Cross Children's Hospital
4. Aged six months to six years</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="6.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>495</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>495</totalTarget>
      <exclusion>1. HIV-infected children aged less than six months
2. Children with an intercurrent infection or axillary temperature of more than 38°C
3. Children with any invasive opportunistic infection including tuberculosis
4. Children with bronchiectasis
5. Children who had received high dose vitamin A, trace elements or zinc supplements within the preceding eight weeks
6. Children recently hospitalised within the preceding six weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-04-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Micronutrient supplementation of HIV-1-infected children</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human Immunodeficiency Virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised into one of the three arms:
Group A - placebo
Group B - trace element supplement
Group C - high dose zinc supplement (3 mg/kg elemental zinc)

Trial drugs are given orally daily over six months and children are seen monthly for 12 weeks from start to end of the study.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin and mineral supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15831-0</funderId>
      <contactId>Contact53771_15831</contactId>
      <sponsorId>Sponsor52324</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53771_15831">
    <title>Dr</title>
    <forename>Heloise</forename>
    <surname>Buys</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ambulatory Paediatrics
School of Child and Adolescent Health
Red Cross Children's Hospital
Klipfontein Road
Rondebosch</address>
      <city>Cape Town</city>
      <country>South Africa</country>
      <zip>7700</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52324">
    <organisation>Secure-The-Future Bristol-Myers Squibb (South Africa)</organisation>
    <website>http://www.bms.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bristol-Myers Squibb 
HIV Research Institute
47 van Buuren Road
Bedfordview</address>
      <city>Gauteng</city>
      <country>South Africa</country>
      <zip>2008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)11 4566459</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">richardwanlass@bms.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15831-0">
    <name>Secure-the-Future Bristol-Myers Squibb (South Africa) (ref: RES094/02)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-12-06T00:00:00.000Z">22412590</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study for the treatment of heart failure with Pycnogenol</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pycnogenol, standardized French maritime pine bark extract, has shown beneficial effects on various cardiovascular health parameters such as blood pressure and cholesterol levels in both preclinical as well as clinical trials. The aim of this study is to investigate the effect of 200 mg daily of Pycnogenol on objective and subjective symptoms in patients with heart failure New York Heart Association (NYHA) status II.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patients undergo tests for maximal workload and pressure-heart product at 0, 4, 8, and 12 weeks after enrollment. 

Maximal workload: As determined by a symptom-limited bicycle exercise test in the seated position. 
Pressure-heart rate product: Immediately after 2 min work at 50 W, systolic blood pressure and heart rate are recorded. Pressure-heart rate product is calculated by units of systolic blood pressure (mmHg) x heart rate per minute divided by 100.</primaryOutcome>
      <secondaryOutcome>Patients will report scores for dyspnea and fatigue for the foregoing 4 weeks upon enrollment (baseline) and repeat evaluation at 4, 8, and 12 weeks after enrollment. Symptom scores will be evaluated by asking patients about the severity of the following symptoms: 
1. Early fatigability
2. Dyspnea
3. General capability
4. Lassitude
5. Feeling depressed
6. Anxiety
 
Scores range from 0 = not present, 1 = occasionally mild, 2 = frequently mild, 3 = moderate, 4 = severe.
Blood analysis: Routine clinical chemistry in addition to the assays of BNP (NT-proBNP), C-Reactive Protein and troponin T.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee at Okuizumo Hospital in Shimane prefecture, Japan, on 24 May 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22412590</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HF2007AM</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>12 week randomised, double-blind placebo-controlled matched pairs study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Japan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="45ceb3d9-4390-4acf-a1d9-cc5ea1d96bf1">
	  <name>Kyoto University Graduate School of Medicine</name>
	  <address/>
	  <city>Kyoto</city>
	  <state/>
	  <country>Japan</country>
	  <zip>606 8507</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients over 40 years of age with chronic congestive heart failure (NYHA class II), known for at least 6 months which were previously untreated or treated with a diuretic and/or a low dose of an ACE inhibitor. Patients must have an exercise capacity of at least 75 watts as assessed by seated bicycle ergometry.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. NYHA status I, III or IV
2. Treatment with digitalis within the previous 6 months
3. Exercise capacity of &gt;75 W for 2 min at the test during run-in
4. Unstable angina or myocardial infarction within the last 6 months
5. Atrial fibrillation or ventricular arrhythmia greater than or equal to Lown III
6. Cardiac valvular disease or hypertrophic cardiomyopathy
7. Significant hypertension or hypotension (&lt; 60 mmHg or greater than or equal to 105 mmHg diastolic or &lt; 90 mmgH or &gt; 175 mmHg systolic)
8. Electrolyte disturbances, hyperuricemia, hypovolemia
9. Impaired renal function (creatinine &gt;1.8 mg/dL) or hepatic function
10. Obstructive airways disease 
11. Insulin-dependent diabetes
12. Malignant or other serious disease
13. Hypersensitivity to study drug
14. Pregnancy, unreliable contraception, breast-feeding mothers
15. Participation in another clinical trial within the last 6 weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg Pycnogenol (standardized extract of French maritime pine bark) or placebo for 12 weeks. Patients receiving diuretics before enrollment should continue usage and not change dose/intake intervals. Drug intake will be controlled and any unwanted effect reported at each visit.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pycnogenol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16783-0</funderId>
      <contactId>Contact54741_16783</contactId>
      <sponsorId>Sponsor53297</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54741_16783">
    <title>Dr</title>
    <forename>Akira</forename>
    <surname>Matsumori</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kyoto University Graduate School of Medicine
Department of Cardiovascular Medicine
54 Kawahara-cho Shogoin
Sakyo-ku</address>
      <city>Kyoto</city>
      <country>Japan</country>
      <zip>606 8507</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53297">
    <organisation>Kyoto University (Japan)</organisation>
    <website>http://www.kyoto-u.ac.jp/index-e.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Akira Matsumori
Kyoto University Graduate School of Medicine
Department of Cardiovascular Medicine
54 Kawahara-cho Shogoin
Sakyo-ku
</address>
      <city>Kyoto</city>
      <country>Japan</country>
      <zip>6068507</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.258799.8</gridId>
    <rorId>https://ror.org/02kpeqv85</rorId>
  </sponsor>
  <funder id="Funder16783-0">
    <name>Kyoto University, Cardiomyopathy and Myocarditis Research Fund (Japan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-11-27T00:00:00.000Z">11132850</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of oral intra-dialysis supplement  in haemodialysis patients with malnutrition</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Nutritional support in the form of oral supplement during the sessions of haemodilaysis improves the nutritional status of the patients, increases the oral food intake, improves the functional situation and quality of life and reduces the morbidity and mortality.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data will be collected at the beginning of the study (basal), and at three and six months (final):
1. Serum albumin, measured by blood analysis
2. Prealbumin, measured by blood analysis</primaryOutcome>
      <secondaryOutcome>Collected at the beginning of the study (basal), collected at the beginning of the study (basal), and at three and six months (final):
1. Prevalence of malnutrition
2. Anthropometric nutritional parameters
3. Analytical nutritional parameters
4. Body composition (collected at the beginning of the study [basal] and at the sixth month [final] only)
5. Quality of life
6. Functional scale
7. Appetite
8. Oral food intake. Later on this information will be passed through a special program in order to calculate the total caloric intake and food composition (protein, carbohydrates and fat including saturated, mono- and poly-unsaturated fat)
9. Hospital admissions (collected as and when these events happen)
10. Mortality (collected as and when these events happen)
11. Morbidity and mortality rate (collected as and when these events happen)

Measurements taken to assess these outcomes will include:
1. Anthropometric measures: dry body weight, Body Mass Index (BMI), Brachial Muscle Circumference (BMC), triceps skin fold
2. Blood tests: Complete Blood Count (CBC), urea prior and post dialysis, creatinine, electrolytes, lipid profile, serum iron, ferritin, vitamin B12, folic acid, Parathyroid Hormone (PTH), calcium, phosphate, vitamin D3, transferrin, albumin, prealbumin, bicarbonate (HCO3) prior and post dialysis, insulin, fasting blood sugar, Homeostasis Model Assessment (HOMA) index, C-Reactive Protein (CRP)
3. Body composition: electrical Bioimpedance Analysis (BIA) monofrequency
4. Nutritional assessment: SGA and MIS
5. Questionnaires: charlson index, karnofsky scales (evaluated by interviewing each patient and by checking his medical history report at the beginning of the study, third month and sixth month), 36-item Short Form health survey (SF-36) and 8-item Council on Nutrition Appetite Questionnaire (CNAQ)
6. Dietary recall (48 hours): day of dialysis and day off will be collected from patients interview</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of Clinical Investigation of the Hospital Clinico San Carlos on the 24th January 2007 (ref: 1.2/07). Signed by secretary of the committee Dr. M. Garcia Arenillas.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11132850</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>06/178</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single-blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a1294e2-0024-483c-b430-5b14eb4b4e31">
	  <name>Avenida Marques de Corbera 6, 6d</name>
	  <address/>
	  <city>Madrid</city>
	  <state/>
	  <country>Spain</country>
	  <zip>28017</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients over 18 years old 
2. Maintained haemodialysis (at least 6 months on dialysis)
3. Malnutrition criteria (Subjective Global Assessment [SGA] grade B or C or Malnutrition Inflammation Score [MIS] score greater than 8) and at least  two altered analytical parameters (albumin less than 3.7 g/dl, prealbumin less than 30 g/l, total cholesterol less than 200 mg/dL with C-Reactive Protein [CRP] within normal range)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Lack of  signed consent 
2. Difficulty in understanding Spanish language
3. Patients diagnosed of cancer except skin cancer
4. Patients went through surgical operation in the last three months 
5. Patients with Dementia or Alzheimer disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malnutrition</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Malnutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Specific oral supplement formula for patients on haemodialysis (Nepro) plus dietetic consultation for the case group, versus only dietetic consultation for the control group. 
The formula is Nepro, a product of Abbott laboratory. Dosage is 236 ml in each session of haemodialysis, providing 472 kcal and 7 g of protein per 100 ml. 

Duration of intervention: 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17255-0</funderId>
      <contactId>Contact55216_17255</contactId>
      <sponsorId>Sponsor53782</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55216_17255">
    <title>Dr</title>
    <forename>Waeel Ibrahim</forename>
    <surname>Alkrekshi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Avenida Marques de Corbera 6, 6d</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28017</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 62 78 88 95 0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krekshi@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53782">
    <organisation>Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Hospital Clinico san Carlos 
C/ Martin Lagos S/N</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 33 03 64 3</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krekshi@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17255-0">
    <name>Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) - in cooperation with the Hospital Clinco San Carlos (Spain), Department of Endocrinology and Nutrition</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-11-22T00:00:00.000Z">38444899</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of a Cognitive Behavioural group Therapy (CBT) for compulsive buying disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Disorder specific group Cognitive Behavioural Therapy (CBT) can improve the compulsive buying behaviour.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Compulsive Buying Scale (CBS)
2. Yale-Brown Obsessive Compulsive Scale - Shopping Version (Y-BOCS-SV)
3. German Compulsive Buying Scale (G-CBS)

All participants were assessed at baseline. Participants assigned to CBT were assessed at the end of treatment and at the end of a 6-months follow-up period. Individuals assigned to the WLC were reassessed 12 weeks after the baseline assessment. All assessments were conducted by research staff members who remained blind to the treatment assignment throughout the study. Participants completed all self-report questionnaires during the assessment visits.</primaryOutcome>
      <secondaryOutcome>1. Symptom Check-List-90-R (SCL-90-R)
2. Barratt Impulsiveness Scale (BIS-11)
3. Saving Inventory - Revised (SI-R)

All participants were assessed at baseline. Participants assigned to CBT were assessed at the end of treatment and at the end of a 6-months follow-up period. Individuals assigned to the WLC were reassessed 12 weeks after the baseline assessment. All assessments were conducted by research staff members who remained blind to the treatment assignment throughout the study. Participants completed all self-report questionnaires during the assessment visits.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of the University Hospital of Erlangen (Germany) on the 27th August 2003 (ref: 3008).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38444899</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, efficacy study comparing CBT with waiting list control.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f9e568b-66e2-4c36-97f4-4c77e2eb42ee">
	  <name>Department of Psychosomatic Medicine and Psychotherapy</name>
	  <address/>
	  <city>Erlangen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-91054</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Current compulsive buying problems according to the criteria of McElroy et. al. (1994)
2. Aged 18 and over</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Active suicidal ideation
2. Current mania</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Compulsive buying disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Adult personality disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This trial is a randomised controlled trial comparing a treatment group with a waiting list control group (2 arms). Because of logistical difficulties a simultaneous conduction of groups was not feasible in this monocentric study. Patients were assigned to groups upon enrolment, which were subsequently randomised to one of two conditions. Thirty-one participants were assigned to one of five CBT groups, and 29 individuals to one of five Waiting List Control (WLC) groups. Participants were blind to the randomisation. 

Intervention:
12-weekly outpatient disorder specific group CBT-sessions specifically aiming at interrupting and controlling the problematic buying behaviour, establishing healthy purchasing patterns, restructuring maladaptive thoughts and negative feelings associated with shopping and buying, and developing healthy coping skills. 

Control:
Waiting list control. 

Treatment lasted 12 weeks with one 90-minutes session per week. Groups were conducted with 5 - 8 participants. Follow-up was for 6 months after finishing the treatment for all participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17868641 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2ce6bf78-f597-49da-913e-394ef7dc99f1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17868641"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16920-0</funderId>
      <funderId>Funder16920-1</funderId>
      <contactId>Contact54881_16920</contactId>
      <sponsorId>Sponsor53444</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54881_16920">
    <title>Dr</title>
    <forename>Astrid</forename>
    <surname>Mueller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychosomatic Medicine and Psychotherapy
University Hospital of Erlangen
Schwabachanlage 6</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>D-91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 85 34890</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">astrid.mueller@uk-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53444">
    <organisation>University Hospital of Erlangen (Germany)</organisation>
    <website>http://www.elan.uk-erlangen.de/e404/index_ger.html</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung (ELAN) fund 
Universitatsstrasse 40</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>D-91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 85 23708</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">annette.pfeiffer@zuv.uni-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411668.c</gridId>
    <rorId>https://ror.org/0030f2a11</rorId>
  </sponsor>
  <funder id="Funder16920-0">
    <name>University Hospital of Erlangen (Germany) - Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung (ELAN) fund</name>
    <fundRef/>
  </funder>
  <funder id="Funder16920-1">
    <name>Bavarian Savings Bank Foundation (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-15T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-11-15T00:00:00.000Z">40223079</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria in Nangarhar, Takhar and Faryab provinces, Afghanistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Monitor efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To measure the clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine among patients aged above six months suffering from uncomplicated falciparum malaria and chloroquine for vivax malaria, by determining the proportion of patients with:
1.1. Early Treatment Failure (ETF)
1.2. Late Clinical Failure (LTF)
1.3. Late Parasitological Failure (LPF)
1.4. Adequate Clinical and Parasitological Response (ACPR) 
As indicators of efficacy
2. To differentiate recrudescences from new infections by the Polymerase Chain Reaction (PCR) analysis
3. To evaluate the incidence of adverse events</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Ministry of Public Health Afghanistan on the 15th September 2007
2. World Health Organization (WHO) Ethics Review Committee (ERC) on the 13th November 2007 (ref: RPC 243)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40223079</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC243</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>One arm non-comparative study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Afghanistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9b1172ad-0422-4c61-b991-7967ad7d478f">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age above 6 months
2. Mono-infection with P. falciparum or P. vivax
3. Parasitaemia, 1000 - 100,000 asexual forms per µl for falciparum malaria and above 250 asexual forms per µl for vivax malaria
4. Axillary temperature of 37.5°C or oral/rectal temperature of 38°C
5. Ability to swallow oral medication
6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule
7. Informed consent from the patient or from a parent or guardian in case of children</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Presence of general danger signs among children less than 5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions (see Annex 1)
2. Mixed or mono-infection with another Plasmodium species
3. Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the National Center for Health Statistics [NCHS]/WHO normalised reference values, or who has symmetrical oedema involving at least the feet or who has a Mid Upper Arm Circumference [MUAC] less than 110 mm)
4. Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, Human Immunodeficiency Virus [HIV]/Acquired Immune Deficiency Syndrome [AIDS])
5. History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment
6. Positive pregnancy test or lactating (if adults included)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Artesunate (12 mg/kg) and sulfadoxine (25 mg/kg single dose) - pyrimethamine (1.25 mg/kg single dose) over 3 days for falciparum malaria
2. Chloroquine 25 mg/kg over 3 days for vivax malaria

Contact details for Principal Investigator: 
Dr Ghulam Rahim Awab 
District/Phase - 4
Jalalabad City 
Nangarhar 
Afghanistan
Tel: +93 (0)70 004 4853
Email: awabgr@yahoo.com</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate, sulfadoxine-pyrimethamine, chloroquine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17277-0</funderId>
      <contactId>Contact55238_17277</contactId>
      <sponsorId>Sponsor53806</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55238_17277">
    <title>Dr</title>
    <forename>Pascal</forename>
    <surname>Ringwald</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53806">
    <organisation>World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/malaria/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17277-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">94348100</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The influence of surgical interventions with and without cardiopulmonary bypass on Ca2+ signalling in alveolar macrophages</title>
      <scientificTitle/>
      <acronym>Cacao</acronym>
      <studyHypothesis>A direct G-protein-stimulated ratiometric calcium ion (Ca2+) signal in alveolar macrophages decreases after surgical interventions with cardiopulmonary bypass.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Calcium signal intensity, measured immediately preoperatively and after the surgical procedure.</primaryOutcome>
      <secondaryOutcome>Postoperative pulmonary infection, measured on day of discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Charite - Universitaetsmedizin Berlin ethikkommission on the 8th March 2003 (ref: EA1/146/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94348100</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VO 741/6-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective cohort trial with two control groups.</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73ba5a82-5919-40a1-8d7d-91a9dcad47cc">
	  <name>Klinik fur Anaesthesiologie und Operative Intensivmedizin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Elective coronary bypass graft surgery
2. Elective panendoscopy
3. Elective thoracic surgery</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Relevant pulmonary diseases with oxygenation deficit
3. Liver disease stage greater than Child B
4. Human Immunodeficiency Virus (HIV)-infection
5. Corticosteroid therapy
6. Organ transplantation
7. Perioperative infection
8. Chronic inflammatory disease
9. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pulmonary dysfunction after surgery</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Postprocedural respiratory disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Bronchoscopy with Broncho-Alveolar Lavage (BAL) and blood samples before and after surgery. Routine bronchoscopy is used as recommended in a guideline. Duration of treatment is defined by the length of hospital stay. Duration of the diagnostic procedure is approximately 10 minutes. Total duration of follow up also is defined by the length of the hospital stay.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16964-0</funderId>
      <contactId>Contact54925_16964</contactId>
      <sponsorId>Sponsor53490</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54925_16964">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik fur Anaesthesiologie und Operative Intensivmedizin
Charite Campus Mitte und Campus Virchow Klinikum
Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53490">
    <organisation>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder16964-0">
    <name>Humboldt University of Berlin (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">22416062</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An open-label, prospective, non-comparative clinical trial to evaluate the efficacy and safety of rosuvastatin in high risk Indian population with diabetes and dyslipidemia</title>
      <scientificTitle/>
      <acronym>RESIDD</acronym>
      <studyHypothesis>Rosuvastatin is effective in treating high risk Indian population of diabetic patients who have abnormal lipid levels.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean change in total cholesterol
2. Mean change in LDL cholesterol
3. Mean change in High Density Lipoprotein (HDL) cholesterol
4. Mean change in triglycerides
5. Number of patients achieving ATP III target LDL of less than 100 mg/dl

Primary and secondary time points will be measured by evaluating the blood parameters on week 6 and week 12 against the baseline collected at the time of enrolment.</primaryOutcome>
      <secondaryOutcome>1. Mean change in the level of hs-CRP
2. Mean change in level of apoprotein B
3. Mean change in apoB/apoA1 ratio
4. Mean change in apoprotein A1
5. Mean change in lipoprotein a
6. Change in glycosylated haemoglobin at the end of study period
7. Incidence of hepatic dysfunction defined by liver enzyme elevation more than three times in the absence of other systemic cause
8. Compliance and side effects
9. Mean change in the level of creatinine kinase

Primary and secondary time points will be measured by evaluating the blood parameters on week 6 and week 12 against the baseline collected at the time of enrolment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Dhanvantry Independent Ethics Committee on the 11th June 2007 (ref: RANB11/06/2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22416062</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT/RNBX &#150; CV-LIFE/07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label, prospective, non-comparative clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f130b798-6dec-4cc2-8d53-6976e1e04790">
	  <name>Ranbaxy Laboratories Ltd</name>
	  <address/>
	  <city>Gurgaon</city>
	  <state/>
	  <country>India</country>
	  <zip>122001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diabetes type II defined by American Diabetes Association criteria of fasting venous plasma glucose of greater than or equal to 126 mg/dl, two-hour post prandial plasma glucose of greater than or equal to 200 mg/dl or already on treatment of diabetes
2. Dyslipidemia defined by Low Density Lipoprotein (LDL) cholesterol more than 100 mg/dl or on prior statin therapy
3. Age of greater than or equal to 30 and less than or equal to 70 years
4. Informed consent by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>1. Failure to give informed consent 
2. A history of hypersensitivity to statins
3. Evidence of fundoscopy grade 2 hypertensive or diabetic retinopathy
4. Serum creatinine greater than 1.5 mg/dl  
5. Overt proteinuria 
6. Pregnant or lactating mothers 
7. Evidence/history of heart failure
8. Systolic blood pressure above 180 mmHg and diastolic blood pressure above 110 mmHg 
9. Recent history of cerebrovascular disease, myocardial infarction, unstable angina, new onset Left Bundle Branch Block (LBBB) in the past 4 weeks
10. Documented case of homozygous familial hypercholesterolemia
11. Type I Diabetes Mellitus (DM)
12. Use of concomitant medications (cyclosporin, systemic itraconazole or ketoconazole, erythromycin, or clarithromycin, glucocorticoids or verapamil) known to affect the lipid profile or with potency safety concern
13. Recent ongoing inter-current infection/high sensitivity C-Reactive Protein (hsCRP) greater than 10 mg/L
14. Active liver disease or hepatic dysfunction (defined as Alanine aminotransferase [ALT], aspartate aminotransferase [AST], Gamma-Glutamyl Transferase [GGT], alkaline phosphate or bilirubin levels greater than or equal to 1.5 the upper limit of normal)
15. Diagnosed to have any other endocrinal or metabolic disease other than Type II DM that is known to influence serum lipids and lipoproteins
16. Patients having history suggestive of myalgia/myositis/arthralgia
17. Serious or unstable medical or psychological condition that could compromise the patient&#146;s safety or successful trial participation
18. History of alcohol consumption greater than 2 drinks/day (30 ml) or 10 drinks per week</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes patients with dyslipidemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Dyslipidemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Once the enrolment of the patient is through he will be kept on:
1. Tab. rosuvastatin 10 mg once a day if his LDL level ranges between 100 mg/dL to 130 mg/dL for first 6 weeks, or
2. Tab. rosuvastatin 20 mg once a day if his LDL level is above 130 mg/dL for first 6 weeks

Week 6 (first follow-up):
The patients lipid profile will be evaluated and if the patient&#146;s LDL does not come under 100 mg/dL as per the guidelines of National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III then the dose will be doubled, i.e., patients on rosuvastatin 10 mg will receive rosuvastatin 20 mg and patients getting rosuvastatin 20 mg will be given rosuvastatin 40 mg. It will remain once a day therapy.

Week 12 (second and last follow-up - end of study):
Patient&#146;s blood will be evaluated for the endpoints and the continuation of therapy will be on the treating clinician.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16894-0</funderId>
      <contactId>Contact54853_16894</contactId>
      <sponsorId>Sponsor53411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54853_16894">
    <title>Dr</title>
    <forename>Santosh</forename>
    <surname>Jha</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ranbaxy Laboratories Ltd
Plot-90
Sector-32</address>
      <city>Gurgaon</city>
      <country>India</country>
      <zip>122001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)991 003 4380 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dr.santoshjha@ranbaxy.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53411">
    <organisation>Ranbaxy Laboratories Ltd (India)</organisation>
    <website>http://www.ranbaxy.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Santosh Jha
Plot-90
Sector-32</address>
      <city>Gurgaon</city>
      <country>India</country>
      <zip>122001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)991 003 4380 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dr.santoshjha@ranbaxy.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418931.6</gridId>
    <rorId>https://ror.org/030yyf771</rorId>
  </sponsor>
  <funder id="Funder16894-0">
    <name>Ranbaxy Laboratories Ltd (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-05T00:00:00.000Z">27834915</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the sustained effect of Viniyoga in the rehabilitation of hypertensive patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that patients who receive training in Viniyoga will continue practising the method 15% more often than those who receive training in Progressive Relaxation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess whether more participants in the intervention group will maintain the method taught compared to those in the control group, assessed at three weeks (i.e. at the moment of discharge from our hospital) and six months after the discharge from the hospital.</primaryOutcome>
      <secondaryOutcome>The following will be measured at six months: 
1. Hospital Anxiety and Depression Scale [HADS] 
2. 36-item Short Form health survey (SF-36)
3. Heart rate variability 
4. Blood pressure
5. Use of antihypertensive medication</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Arztekammer Nordrhein in May 2007 (ref: 2007113).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27834915</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-06T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4e2a5114-26e8-4988-af08-b62d9c275ec0">
	  <name>Klinik Roderbirken</name>
	  <address/>
	  <city>Leichlingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-42799</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Arterial Hypertension.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Congestive heart failure (New York Heart Association [NYHA] II or more)
2. Relevant rhythm disorders
3. Relevant pulmonary disease
4. Dialyses
5. Surgery within the last four weeks
6. ST-elevation myocardial infarction within the last four weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Arterial hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Arterial hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Viniyoga or Progressive Relaxation group training (maximum 10 people per group), 45 minutes per session, five days a week for three weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16602-0</funderId>
      <contactId>Contact54560_16602</contactId>
      <sponsorId>Sponsor53115</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54560_16602">
    <title>Mrs</title>
    <forename>Claudia</forename>
    <surname>Fusshoeller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik Roderbirken</address>
      <city>Leichlingen</city>
      <country>Germany</country>
      <zip>D-42799</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)2175 824310</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claudia.Fusshoeller@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53115">
    <organisation>Refonet (Germany)</organisation>
    <website>http://refonet.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Burgweg 3</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>D-53474</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claudia.Fusshoeller@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder16602-0">
    <name>Refonet (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-31T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-10-31T00:00:00.000Z">44961472</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pycnogenol® to reduce use of commercial anti-hypertensive medications: a randomised, double-blind, placebo-controlled, prospective, 15-week study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pycnogenol®, a natural product, a  "complementary or alternative medicine", will reduce the use of antihypertensive medicines (Angiotensin Converting Enzyme [ACE] inhibitors) and Cardiovascular Disease (CVD) risk factors in subjects with both hypertension and type 2 diabetes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at 12th week of treatment:
1. Blood pressure, measured on the left arm after 10 minutes rest (Korotkoff sounds I and V were taken as the systolic and diastolic blood pressures)
2. Serum endothelin-1
3. Fasting Low Density Lipoprotein (LDL)-cholesterol
4. Glycosylated haemoglobin (HbA1c)
5. Fasting plasma glucose
6. Urinary albumin concentration</primaryOutcome>
      <secondaryOutcome>Measured at 4th and 8th week of treatment:
1. Blood pressure, measured on the left arm after 10 minutes rest (Korotkoff sounds I and V were taken as the systolic and diastolic blood pressures)
2. Serum endothelin-1
3. Fasting Low Density Lipoprotein (LDL)-cholesterol
4. Glycosylated haemoglobin (HbA1c)
5. Fasting plasma glucose
6. Urinary albumin concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Human Subjects Protection Program at University of Arizona on the 16th August 2003 (ref: 03-129).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN44961472</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, randomised double-blind placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2fa26299-0db8-4134-b100-0a56346418d8">
	  <name>Mel and Enid Zuckerman College of Public Health</name>
	  <address/>
	  <city>Tucson</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>85724-5155</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women, 40 - 75 years of age
2. Non-insulin dependent type 2 diabetes
3. Receiving pharmaceutical treatment (ACE-inhibitors) for hypertension 
4. Pre-trial systolic blood pressure of 130 - 150 mmHg</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Type 1 diabetes
2. Use of insulin
3. Any supplements other than single daily multivitamin
4. Having any major illness such as cancer, asthma, or heart failure
5. Any previous cardiac events
6. Pregnancy, or being nursing mother</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular risk factors in diabetes</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cardiovascular risk factors</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral administration of Pycnogenol® pills (25 mg, 5 times a day) or matched inactive placebo for 12 weeks. Total duration of follow-up is 15 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pycnogenol®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17202-0</funderId>
      <contactId>Contact55163_17202</contactId>
      <sponsorId>Sponsor53729</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55163_17202">
    <title>Prof</title>
    <forename>Ronald</forename>
    <surname>Watson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Mel and Enid Zuckerman College of Public Health
University of Arizona, Health Science Center
1295 N. Martin
P. O. Box 245155 [FedEx building 202 room 252]</address>
      <city>Tucson</city>
      <country>United States of America</country>
      <zip>85724-5155</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53729">
    <organisation>Horphag Research Ltd (Switzerland) </organisation>
    <website>http://www.horphag.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 80
Avenue Louis-Casai 71
Cointrin</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>CH-1216</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487164.8</gridId>
    <rorId>https://ror.org/003n34405</rorId>
  </sponsor>
  <funder id="Funder17202-0">
    <name>Horphag Research Ltd (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-30T00:00:00.000Z">03887874</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Imaging-based Thrombolysis trial in Acute Ischemic Stroke -III</title>
      <scientificTitle/>
      <acronym>ITAIS- III</acronym>
      <studyHypothesis>Whether the patients without occlusion or significant stenosis of the large vessels should receive thrombolysis had been focused on and questioned for a long time. However, there is still no large Randomised Controlled Trial (RCT) to prove if these patients can benefit from thrombolysis. The objective of this trail is to investigate: 
1. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, whether the IntraVenous (IV) thrombolysis can improve the clinical outcome if the mismatch exists on CTP/Computed Tomography Angiography-Source Images (CTA-SI) scan in 3-9 hr time-window
2. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, whether the IV thrombolysis can improve the blood perfusion of brain if the mismatch exists on CT perfusion (CTP)/CTA-SI scan in 3-9 hr time-window
3. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, but the mismatch exists on CTP/CTA-SI scan in 3-9 hr time-window, whether the safety of IV thrombolysis is better than the NINDS trial which was in 3 hr window or implemented on the patients with large vessels occlusion or significant stenosis in 3-9 hr time-window.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of participants who achieve the following: 
1. Reperfusion improvement, assessed 24 to 48 hours post-treatment and defined as either greater than or equal to 30% reduction of Mean Transit Time (MTT) volume of abnormality
2. Good clinical outcome at 90 days defined as a modified Rankin score (mRS) of 0-1
3. Intracerebral haemorrhage within 24-36 h after thrombolysis</primaryOutcome>
      <secondaryOutcome>Proportion of participants who achieve the following: 
1. mRS 0 to 2 at 90 days 
2. Barthel Index (BI) score 75 to 100 at 90 days 
3. NIHSS 4 points improvement or 0-1 at 2 hours after treatment 
4. NIHSS 4 points improvement or 0-1 at 24 to 48 hours 
5. NIHSS 4 points improvement or 0-1 at day 7</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval gained from the Beijing Tiantan Hospital Capital Medical University Ethics Board on October 10, 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03887874</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, multi-center, assessor-blind controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9a281d3-ee60-428f-b959-e23ff373ca0e">
	  <name>Neurology Department</name>
	  <address/>
	  <city>Beijing</city>
	  <state/>
	  <country>China</country>
	  <zip>100050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Female or male inpatients 
2. Age 18-80 years 
3. Clinical diagnosis of ischaemic stroke 
4. Onset of symptoms within 3-9 hours prior to initiation of thrombolysis treatment 
5. Stroke symptoms present for at least 30 minutes and has not significantly improved before treatment 
6. The National Institutes of Health Stroke Scale (NIHSS) score greater than or equal to 4 
7. m-CT screening to be started within 8.5 hrs after stroke onset 
8. Perfusion abnormality of CT scan &gt;2cm in diameter involving hemisphere 
9. CT Perfusion/CTA source image mismatch greater than or equal to 20% 
10. CTA shows occlusion or significant stenosis of large vessels (Thrombolysis In Cerebral Ischemia [TICI] grade is 0 or 1) 
11. Patients are willing to receive thrombolysis treatment and to give informed consent 
12. Patients are willing and able to comply with the study protocol</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Evidence of IntraCranial Haemorrhage (ICH), brain tumors, vascular malformation, aneurysm, SubArachnoid Hemorrhage (SAH) 
2. Major infarct involving greater than 1/3 of Middle Cerebral Artery (MCA) territory on the CTA-SI 
3. Presenting obvious neurologic deficits because of past stroke (mRS &gt;2) 
4. Severe stroke as assessed clinically (e.g. The National Institute of Health Stroke Scale [NIHSS] &gt;25) and/or by appropriate magnetic imaging techniques. 
5. Seizure at onset of stroke 
6. Prior stroke within the last 3 months 
7. Patients with any history of prior stroke and concomitant diabetes 
8. Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory 
9. Platelet count of below 100,000/mm3
10. Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to nonhypertensive limits. Uncompensated hypertension is defined as systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;=110 mm Hg on 3 repeated measures at least 10 minutes apart 
11. Blood glucose &lt;50 or &gt;400 mg/dl 
12. Known haemorrhagic diathesis within the last 6 months 
13. Patients receiving oral anticoagulants e.g. warfarin sodium, and coagulant response time (INR) &gt;1.5 
14. Known history of or suspected intracranial haemorrhage including subarachnoid haemorrhage 
15. Pregnancy or lactation 
16. Any history of severe central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) 
17. Haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy) 
18. Bacterial endocarditis, pericarditis
19. Prolonged traumatic external heart massage, or recent (less than 10 days) obstetrical delivery or recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture) 
20. Acute pancreatitis 
21. Documented ulcerative gastrointestinal disease during the last 3 months, 
22. Oesophageal varices, arterial aneurysm, arterial/venous malformation 
23. Neoplasm with increased bleeding risk 
24. Severe liver disease including hepatic failure, cirrhosis, portal hypertension, oesophageal varices and active hepatitis 
25. Major surgery or significant trauma in past 10 days 
26. Known serious sensitivity to alteplase</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute ischemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Acute ischemic stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients included were divided into recombinant tissue Plasminogen Activator (rt-PA) (0.9 mg/kg) intravenous thrombolysis group and regular treatment group according to the intention of doctors and patients.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Recombinant tissue Plasminogen Activator (rt-PA)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17196-0</funderId>
      <contactId>Contact55157_17196</contactId>
      <sponsorId>Sponsor53722</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55157_17196">
    <title>Prof</title>
    <forename>Yongjun </forename>
    <surname>Wang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neurology Department
Beijing Tiantan Hospital 
Tiantan Xili 6 
Chongwen District </address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yongjunwang111@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53722">
    <organisation>Beijing Tiantan Hospital (China) </organisation>
    <website>http://www.bjtth.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Beijing Tiantan Hospital 
Tiantan Xili 6 
Chongwen District</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yongjunwang111@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411617.4</gridId>
    <rorId>https://ror.org/003regz62</rorId>
  </sponsor>
  <funder id="Funder17196-0">
    <name>The Ministry of Science and Technology and the Ministry of Health of the People's Republic of China - the key scientific research program of the 11th National Five-Year Planning of China</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-30T00:00:00.000Z">05620936</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Development of a simple protocol to enhance compliance in home management of malaria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Malaria is a disease caused by the protozoan plasmodium falciparum. It is still rampant in sub-Saharan Africa and endemic in Nigeria with perennial transmission. It causes febrile illness which could be severe in children accounting for 25% of infant mortality and 8-12% of death under age of five years. Malaria is responsible for 40-60% of out patient consultation. It presents in two clinical types - uncomplicated and severe malaria. 

Study Domain: Parasitic infection; child care and health education/behaviour change

Study hypotheses:  
1. There will be no significant difference in the outcome of malaria in children whose mothers or caregivers used treatment protocol to treat malaria at home and those whose mothers did not use the protocol. 
2. There will be no significant difference in the correctness of use of chloroquine by mothers who used the treatment protocol and those who did not use the protocol. 
3. There will be no significant difference in the correctness of use of chloroquine by trained mothers and mothers who were not trained.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The mothers/caregivers were asked about the treatment given to the child during visits by the research assistants. The mothers/caregivers were asked to record these details in their diary, which was checked on Day 7 from recruitment at the time of collecting Day 7 blood sample for microscopy examination. These data were used to assess the following: 

1. Correct use of chloroquine, measured in terms of dose, frequency and duration 
2. Timeliness of commencing treatment (commencing treatment within 24 hours of noticing fever in child) 
3. Treatment outcome, measured by mean parasite clearance time, fever clearance time, and progression of illness as reported by mothers/caregivers 
4. Use of the protocol. Proportion of mothers who referred to the treatment protocol in the treatment of last episode of malaria in children</primaryOutcome>
      <secondaryOutcome>1. Attack rate of malaria over a period of one year 
2. Sensitivity and specificity of presumptive diagnosis of malaria by mothers/caregivers</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The joint University of Ibadan/University College Hospital Institutional Ethical Review Board. Date of Approval: 29th June 2000</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05620936</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, single-blind, randomised controlled field study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Nigeria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="773fd67e-3d02-42e4-aba1-c87a70aaee4e">
	  <name>Department of Epidemiology</name>
	  <address/>
	  <city>Ibadan</city>
	  <state/>
	  <country>Nigeria</country>
	  <zip>PMB 5116</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers with children 10 years or less who have febrile illness presumed to be malaria 
2. Willingness of mothers to allow their child remain in study for a period of 14 days 
3. Mothers who consent to their child having finger prick to collect blood for blood smears</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>152</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>152 children (76 in each arm)</totalTarget>
      <exclusion>1. Child with severe illness or requiring parenteral medication 
2. Child with other diseases, co-morbid with febrile illness 

Withdrawal Criteria: 
1. Parents of children choosing not to continue with the study 
2. Progression of illness in child</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomisation of the communities to the intervention and control groups was done by ballots. 

Interventions carried out at the intervention site: 
1. Training of 'mother trainers' and community members about cause, symptoms and signs of the clinical types, treatment and prevention of malaria including referral. 

2. Development of a treatment protocol using participatory approach and distribution of the protocol to households. The development of the protocol was done in phases using modified focus group sessions with several community checks at different stages of development. The participants were the 'mother trainers', selected community members, research team and a graphic artist. The treatment protocol consists of treatment guidelines for each of the clinical types of malaria compiled together on a cardboard. The protocol illustrated the presentation of clinical types of malaria, the appropriate steps to take for each type and the correct dose and schedule of treatment of uncomplicated malaria using chloroquine according to the age of the child. The protocol was in cartoon format and the local language was used. 

Mothers/caregivers in both arms of the study were requested to purchase the chloroquine used for treatment from their regular source which in most instances are the drug hawkers and patent medicine sellers. 

Control arm of the study: 
They were passive controls. The communities in the control arm of the study were left to continue their usual treatment practice for malaria in their children. No training or guideline was provided.

Duration of intervention: One year</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17213-0</funderId>
      <contactId>Contact55174_17213</contactId>
      <sponsorId>Sponsor53740</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55174_17213">
    <title>Dr</title>
    <forename>Ikeoluwapo </forename>
    <surname>Ajayi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Epidemiology
Medical Statistics and Environmental Health
College of Medicine
University of Ibadan </address>
      <city>Ibadan </city>
      <country>Nigeria</country>
      <zip>PMB 5116</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ikeajayi2003@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53740">
    <organisation>University of Ibadan (Nigeria)</organisation>
    <website>http://www.ui.edu.ng/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Ikeoluwapo Oyeneye Ajayi
Department of Epidemiology
Medical Statistics and Environmental Health
College of Medicine
University of Ibadan</address>
      <city>Ibadan </city>
      <country>Nigeria</country>
      <zip>PMB 5116</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+234 8 023 268431</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ikeajayi2003@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9582.6</gridId>
    <rorId>https://ror.org/03wx2rr30</rorId>
  </sponsor>
  <funder id="Funder17213-0">
    <name>Investigator funded (Nigeria)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-10T00:00:00.000Z">79667806</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The differential effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic indices and adipocytokines</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The weight reduction with the change of fat distribution influence on the adipokines and metabolic indices.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The changes of body fat distribution and adipocytokines, determined by computed tomography scan and measured both before and 16 weeks after the weight reduction program.</primaryOutcome>
      <secondaryOutcome>The relationship of body fat distribution and adipocytokines, determined by computed tomography scan and measured both before and 16 weeks after the weight reduction program.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of Yondong Severance Hospital, Yonsei University College of Medicine (South Korea) on the 6th September 2006 (ref: 3-2006-0044).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79667806</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective intervention study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8c6ddf10-9d3c-41c5-a239-5d99a0200273">
	  <name>Department of Family Medicine</name>
	  <address/>
	  <city>Seoul</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>135-270</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Apparently healthy, either sex, aged 18 - 60 years
2. Non-smokers 
3. Low alcohol consumers
4. Overweight or obese with an average Body Mass Index (BMI) of 23 kg/m^2 or greater</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="60.0"/>
      <gender>Both</gender>
      <targetEnrolment>52</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>52</totalTarget>
      <exclusion>1. A past history of cardiovascular disease
2. Diabetes
3. Moderate to severe hypertension (resting blood pressure greater than 170/100 mmHg)
4. Renal impairment (serum creatinine greater than 120 µmol/L) or overt proteinuria
5. Obesity caused by an endocrine disorder
6. Psychiatric disorders
7. Current pregnancy or breast-feeding
8. A body weight fluctuation of more than 5 kg in the previous six months
9. Taking any kind of medication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients received all three interventions for 16 weeks:
1. The subjects visited an obesity clinic twice per month and restricted their caloric intake to less than their usual intake by 600 kcal/day
2. All patients were encouraged to achieve the goal of five hours of aerobic exercise (physical activity of moderate intensity, such as brisk walking, light jogging or stationary ergometer usage) per week
3. They were also administered 10 - 15 mg of sibutramine (in the morning)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sibutramine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16940-0</funderId>
      <contactId>Contact54901_16940</contactId>
      <sponsorId>Sponsor53466</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54901_16940">
    <title>Dr</title>
    <forename>Ji-Won</forename>
    <surname>Lee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Family Medicine
Yonsei University College of Medicine
Yongdong Severance Hospital
Kangnam 
P.O. Box 1217</address>
      <city>Seoul</city>
      <country>Korea, South</country>
      <zip>135-270</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53466">
    <organisation>Yonsei University College of Medicine (South Korea) </organisation>
    <website>http://medicine.yonsei.ac.kr/en/index.asp</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>250 Sungsan-Ro 
Seodaemoon-gu</address>
      <city>Seoul </city>
      <country>Korea, South</country>
      <zip>120-752 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.15444.30</gridId>
    <rorId>https://ror.org/01wjejq96</rorId>
  </sponsor>
  <funder id="Funder16940-0">
    <name>Yonsei University College of Medicine (South Korea) - faculty research grant (2006)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-09T00:00:00.000Z">68305337</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of chiropractic spinal adjustments as a treatment protocol in the management of infantile colic: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Chiropractic manipulation is more effective than placebo for the treatment of infantile colic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Parental questionnaire at baseline, each subsequent treatment session and follow-up consultation. The questionnaire asked the following quetisons: 
1. Measured from the parents' perception, how long does the baby cry with each attack of colic?  
2. How often does the colic occur in 24 hours?  
3. Does the colic attack occur at any particular time of day or night?  
4. Does anything seem to precipitate an attack?  
5. For how long does the baby sleep between colic attacks?  
6. Does the baby still require medicine to relieve the colic?  
7. How would you rate the baby's response to treatment (1-5)?  
8. Has the baby had any other illnesses?</primaryOutcome>
      <secondaryOutcome>Increased joint motion assessed at baseline, each subsequent treatment session and follow-up consultation.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Responsible Committee on Human Experimentation, and the Research Ethics Committee of Technikon Natal, Durban, South Africa. Approved in 1998.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68305337</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0ef1a2e0-2797-44f9-950b-f1da42f66641">
	  <name>Murdoch University</name>
	  <address/>
	  <city>Murdoch</city>
	  <state/>
	  <country>Australia</country>
	  <zip>6150</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. The infant was to undergo a thorough examination by the consulting paediatrician to determine the health of the infant and to exclude any underlying organic problem, thereby ensuring a strict diagnosis of infantile colic
2. The infant was to be 0 to 8 weeks of age at the commencement of treatment to exclude the possibility of spontaneous cessation of the colic at 3 months
3. Apart from the colic, the infant was to suffer from no other condition/disease
4. If any medication had been administered to the infant to relieve the symptomatology of colic prior to the commencement of treatment (whether prescribed or over-the-counter drugs) the infant was required to remain on the same medication for the duration of the study, if the medication was required
5. Written informed consent was to be obtained from a parent before participation in the study</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Any participant that did not meet the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infantile colic</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Infantile colic</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chiropractic manipulation/mobilization for spinal adjustments vs placebo treatment. One hour per session, 6 sessions over a 2-week period with a follow-up consultation after 1 month.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16103-0</funderId>
      <contactId>Contact54049_16103</contactId>
      <sponsorId>Sponsor52603</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54049_16103">
    <title>Dr</title>
    <forename>Brian</forename>
    <surname>Nook</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Murdoch University
School of Chiropractic
Room ECL 1.009
South Street</address>
      <city>Murdoch</city>
      <country>Australia</country>
      <zip>6150</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 08 9360 7690</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.nook@murdoch.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52603">
    <organisation>Technikon Natal School of Chiropractic (South Africa)</organisation>
    <website>http://www.dut.ac.za/front%20page.aspx</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Durban University Of Technology - Durban Central Offices
41/43 Centenary Road</address>
      <city>Durban</city>
      <country>South Africa</country>
      <zip>4001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)31 308 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">CharmaK@dut.ac.za</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412114.3</gridId>
    <rorId>https://ror.org/0303y7a51</rorId>
  </sponsor>
  <funder id="Funder16103-0">
    <name>Technikon Natal School of Chiropractic (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2007-10-03T00:00:00.000Z">25515380</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Occupational orientation in medical neurorehabilitation (Berufliche Orientierung in der Medizinischen Neurorehabilitation [BOMeN])</title>
      <scientificTitle/>
      <acronym>BOMeN</acronym>
      <studyHypothesis>The trial studies survivors of stroke or brain injury with a special occupational difficulty concerning the reintegration to work. For these patients return-to-work is accompanied by explicit strains because of the coincidence of physical and cognitive impairments. Furthermore patients with acquired brain injury often focus only on the physical deficits and do not show adequate awareness for cognitive constraints. 

Hypotheses: 
1. Until 15 months after rehabilitation the ratio of (re-)employed persons in the intervention group is significantly higher than the ratio of (re-)employed persons in the control group
2. Until 15 months after rehabilitation the ratio of (re-)employable persons in the intervention group is significantly higher than the ratio of (re-)employable persons in the control group
3. Patients of the intervention group can be re-integrated significantly quicker than patients of the control group
4. Re-integrated patients who participated in the intervention group show significantly less days of incapacity for work than re-integrated patients who participated in the control group
5. Patients who participated in the intervention group show a significantly higher satisfaction with life and health than patients who participated in the control group
6. Patients who participated in the intervention group show a significantly higher motivation for rehabilitation than patients who participated in the control group
7. The intervention treatment will gain a higher valuation than the control treatment by the parties involved  (patients and rehabilitation workers)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following variables are measured by standardized or self-developed questionnaires: 
1. Re-employment (patients) 15 months after rehabilitation
2. (Re-)employability (patients) 15 months after rehabilitation
3. Days of incapacity to work (patients), measured using the Indicators of the Status of Rehabilitation questionnaire (Indikatoren des Reha-Status [IRES]) 15 months after rehabilitation
4. Expectations concerning the rehabilitation (patients), measured using the Questionnaire on Expectations and Motivation Concerning Rehabilitation (Fragebogen zu Reha-Erwartungen und Reha-Motivation [FREM]) at the start and end of rehabilitation
5. Motivation for rehabilitation (patients), measured using the Diagnostic Investigation of Motivation Concerning Work questionnaire (Diagnostik von Arbeitsmotivation [DIAMO]) at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
6. Satisfaction with life and health (patients) (the 36-item Short Form health survey [SF-36]/the World Health Organization Quality of Life Questionnaire [WHO-QoL-BREF]) at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
7. Satisfaction with rehabilitation procedure and contents (patients and rehabilitation workers). Timepoints for patients: at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation. Timepoints for workers: once in Summer 2008.</primaryOutcome>
      <secondaryOutcome>1. Cognitive functional status at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
2. Motivation for work at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Arztekammer Westfalen-Lippe and the Medical Faculty of the Westfalischen Wilhelms Unitersigy of Munster. Approved on 24th May 2007 (ref: 2007-235-f-S)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25515380</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>GfR 06/006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="750eeeaf-3705-4a02-b7ce-7b0eea1010ac">
	  <name>Johanniterstrasse 7</name>
	  <address/>
	  <city>Bad Oeynhausen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>32545</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All participants must meet all of the following conditions: 
1. Positive prognostic estimation of occupational ability 
2. Stroke or craniocerebral trauma 
3. Estimated Functional Independence Measure (FIM) greater than or equal to 90 
 
Also, all participants must meet at least one of the following conditions: 
1. Advice for medical rehabilitation based on paragraph 51.1 of the Social Security Statutes, Book No. 5 (SGB V)
2. Inability to work for 3 months during the last 12 months 
3. Ability to work is less than 6 hours 
4. Not in paid work before start of rehabilitation 
5. Necessary occupational reorientation 
6. Application for a pension 
7. Risk of early retirement</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>306</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>306</totalTarget>
      <exclusion>1. Older than 60 years 
2. Acute psychiatric disorder 
3. Acute addiction 
4. Restrictive aphasic disorder
5. Insufficient knowledge of German language 
6. Estimated FIM &lt;90 
7. Neurological diseases other than stroke or craniocerebral trauma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neurorehabilitation for survivors of stroke and brain injury</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Neurorehabilitation for survivors of stroke and brain injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Patients of the intervention group take part in a newly developed rehabilitation concept called Occupational Orientation in Medical Neurorehabilitation (BOMeN) which consists of nine sessions of 3 hours during a 4-week rehabilitation. In this therapy the patients get to know relevant information about stress, perspectives, motivation and the relevance of attention, memory, planning functions and motor skills for everyday working life. The contents are mediated by patient education, experiments of perception and ergotherapeutic exercises. Furthermore the neuropsychological, socialmedical and ergotherapeutical assessments are more related to work and therapy is integrated in a fixed schedule. Finally different disciplines show a higher degree of interworking. 

Control group: Medical Neurorehabilitation (MeN) patients of the control group take part in the conventional rehabilitation concept (MeN) which contains shorter units of assessment and therapy without an explicit relation to work. The average duration of treatment in both groups is controlled.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16876-0</funderId>
      <funderId>Funder16876-1</funderId>
      <contactId>Contact54835_16876</contactId>
      <sponsorId>Sponsor53393</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54835_16876">
    <title>Dr</title>
    <forename>Anke</forename>
    <surname>Menzel-Begemann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Johanniterstrasse 7</address>
      <city>Bad Oeynhausen</city>
      <country>Germany</country>
      <zip>32545</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 5731 151 773</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anke.menzel-begemann@ahb-klinik.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53393">
    <organisation>Association for Rehabilitation Sciences Nordrhein-Westfalen e.V. (Germany)</organisation>
    <website>http://www.rehaforschung-nrw.de</website>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Königsallee 71</address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40215 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16876-0">
    <name>Association for Rehabilitation Sciences Nordrhein-Westfalen e.V. (Gesellschaft für Rehabilitationswissenschaften Nordrhein-Westfalen e.V.) (ref: GfR 06006 / 623-06)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16876-1">
    <name>Houses of Holy Order of Johanniter Rehabilitation Centre (Johanniter-Ordenshäuser Bad Oeynhausen gemGmbH) (ref: BOMeN 98410)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-10-03T00:00:00.000Z">46330948</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial comparing group to individual prenatal care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It was hypothesised that group prenatal care would improve maternal mental health (depression and anxiety), psychosocial health (social support, stress, parenting morale, parenting self-efficacy) and infant birth outcomes (low birth weight, small for gestational age and preterm birth rates) compared to individual prenatal care among a community sample of women in Calgary, Alberta.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Maternal mental health: depression and anxiety - measured at study intake (prior to 20 weeks gestation), third trimester (32 - 36 weeks gestation) and 4 months postpartum 
2. Maternal psycho-social health:
2.1. Social support and stress - measured at study intake (prior to 20 weeks gestation) and 4 months postpartum 
2.2. Parenting morale and parenting self efficacy - measured at 4 months postpartum</primaryOutcome>
      <secondaryOutcome>1. Rates of infant birth outcomes (low birth weight, small for gestational age, preterm birth) - measured at birth 
2. Rates of breast feeding, uptake of parenting classes/supports, attendance at well child visits, immunisation rates - measured at 4 months postpartum</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Conjoint Health Research Ethics Board, University of Calgary and Calgary Health Region on the 7th June 2007 (ref: E-20821).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46330948</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8ab309bc-ee9f-4272-a795-3d8feb2be694">
	  <name>Alberta Children's Hospital (ACH)</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T3B 6A8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant woman living in Northeast Calgary
2. Less than 20 weeks gestation at study intake
3. Able to communicate in English, Punjabi, Mandarin, Hindi, Arabic, Urdu or Spanish</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Female</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200</totalTarget>
      <exclusion>1. Pregnant woman living outside Northeast Calgary
2. Greater than 20 weeks gestation at study intake
3. Unable to communicate in English, Punjabi, Mandarin, Hindi, Arabic, Urdu or Spanish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Maternal mental health</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Post-natal mental disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pregnant women are randomised to: 
1. Standard individual prenatal care
2. Group prenatal care

Control: Standard Prenatal Care 
Women randomly assigned to individual prenatal care will receive a standard schedule of one-on-one prenatal visits with a physician. The timing and frequency of visits will be decided by each womens' physician, although it is anticipated that they will follow the clinical practice guidelines, Healthy Beginnings: Guidelines for Care during Pregnancy and Childbirth provided by the Society for Obstetrics and Gynaecologists of Canada (SOGC). Women with high medical risk pregnancies will be referred for obstetrical care. 

Intervention: Group Prenatal Care 
Women randomly assigned to group prenatal care will receive an initial individual prenatal visit with a physician to confirm their pregnancy and subsequently will be grouped with 8 - 12 other women who are at a similar stage in pregnancy. Each group will meet with a health care provider for nine group sessions including one-on-one time with the provider for a prenatal check-up, time to conduct self measurements of their weight and blood pressure and a group discussion covering a topic appropriate to their stage of pregnancy. The group discussion will be co-facilitated by the physician and a perinatal educator who will encourage group members to participate in discussing topics of interest related to pregnancy, childbirth, parenting, and personal growth. These group sessions will take place at approximately 16, 20, 24, 28, 32, 34, 36, 38 weeks gestation and 2 weeks postpartum. Women will also receive individual prenatal visits at 37 and 39 weeks gestation. Women with high medical risk pregnancies will be referred for obstetrical care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16761-0</funderId>
      <funderId>Funder16761-1</funderId>
      <contactId>Contact54719_16761</contactId>
      <sponsorId>Sponsor53275</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54719_16761">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Tough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Alberta Children's Hospital (ACH)
c/o Decision Support Research Team, Room C4-301
2888 Shaganappi Trail NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T3B 6A8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53275">
    <organisation>Calgary Health Region (Canada) - Three Cheers for the Early Years </organisation>
    <website>http://www.calgaryhealthregion.ca/3cheers/home.htm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>5th Floor
1509 Centre Street South</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2G 2E6</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413574.0</gridId>
    <rorId>https://ror.org/02nt5es71</rorId>
  </sponsor>
  <funder id="Funder16761-0">
    <name>Calgary Health Region (Canada) - Three Cheers for the Early Years</name>
    <fundRef/>
  </funder>
  <funder id="Funder16761-1">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-13T00:00:00.000Z">21996121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of In-exsufflator Treatment on hospitalisation for Respiratory Exacerbation in Neuromuscular Disease</title>
      <scientificTitle/>
      <acronym>In-ex TREND study</acronym>
      <studyHypothesis>We will be looking specifically at a heterogeneous group of neuromuscular disorders which, either as a secondary consequence of degeneration of the spinal nerves (spinal muscular atrophy, amyotrophic lateral sclerosis) or as a primary muscle defect (muscular dystrophies, myopathies) result in progressive loss of muscle strength. Respiratory complications are the primary cause of morbidity and mortality associated with these diseases, as involvement of the respiratory muscles leads to either progressive hypoventilation or recurrent atelectasis and pneumonia secondary to decreased cough efficacy.

For this study we will look at those children with neuromuscular disorders who are admitted to hospital with a respiratory deterioration (hypoxemia and/or the presence of new onset radiologically proven atelectasis or consolidation).

Hypotheses:
We expect that the addition of the Emerson in-exsufflator to a standard treatment regimen for acute respiratory deterioration:
1. Will result in a decreased duration of hospitalisation in a population of children with neuromuscular disease
2. Resulting in hospitalisation will decrease the time requiring supplemental oxygen in a population of children with neuromuscular disease
3. Resulting in hospitalisation will result in a more rapid improvement in chest X-ray changes in a population of children with neuromuscular disease
4. Resulting in hospitalisation will decrease the length of stay in intensive care unit or days invasively ventilated in a population of children with neuromuscular disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to discharge: an estimate of the primary end-point, time to discharge with standard care, was based on the clinical experience of the principal investigators and is currently being verified with a three-year retrospective chart review at Childrens Hospital of Eastern Ontario (CHEO). The mean length of stay in these patients is estimated to be 10 days. Discussions with several paediatric respirologists have taken place, focusing on what magnitude of difference in time to discharge would be clinically important between treatment and control groups. The consensus was a Minimally Clinically Important Difference (MCID) of three days' reduction from the average current length of stay in the study population. These numbers translate to a hazard ratio of 1.4. A two-sided time-to-event test at a = 0.05 will be used to detect a significant difference in time to discharge between the two arms.</primaryOutcome>
      <secondaryOutcome>1. Time (in days) to improvement in oxygenation (no longer requiring supplemental oxygen for 24 hours)
2. X-ray changes: improvement or progression (increasing atelectasis, consolidation)
3. Development of acute hypercapnic respiratory failure requiring intubation and mechanical ventilation
4. Days in intensive care unit</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Each site will submit to their local hospital ethics boards. Ethics approval received from the Children's Hospital of Eastern Ontario Research Ethics Board (REB) on the 2nd October 2007 (ref: 07/24E).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21996121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centre randomised unblinded controlled trial of the mechanical inexsufflator. Randomisation sequence will be stratified by centre with a block-size randomisation protocol.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f835c857-2436-4192-ab3d-fb30544e6fe5">
	  <name>Children's Hospital of Eastern Ontario</name>
	  <address/>
	  <city>Ottawa</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1H 8L1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients aged 3 to 17 years
2. Patients have a known neuromotor disorder affecting respiratory muscles  
3. Admitted to hospital with a respiratory deterioration (hypoxemia in the presence of new onset radiologically proven atelectasis or consolidation)</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="17.0"/>
      <gender>Both</gender>
      <targetEnrolment>128</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>128</totalTarget>
      <exclusion>1. Refusal to participate
2. Already using the Emerson in-exsufflator at home on a regular basis
3. Development of new uncompensated hypercapnic respiratory failure requiring intubation and mechanical ventilation
4. History of bullous emphysema, known susceptibility to pneumothorax or pneumomediastinum, or known to have had any recent barotraumas</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Children with neuromuscular disorders who are admitted to hospital with a respiratory deterioration (hypoxemia and/or the presence of new onset radiologically proven atelectasis or consolidation).</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Neuromuscular disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Conventional treatments, as deemed appropriate by the treating physician:
1.1. Physiotherapy 
1.2. Nutritional support
1.3. Antibiotics (fever, elevated White Blood Cells [WBC])
1.4. Non-invasive positive pressure ventilation
2. Conventional treatments and Emerson in-exsufflator

Using Friedman's formula for survival analysis study design, 62 patients per arm would achieve 80% power to detect a hazard ratio of 1.4.  To account for potential withdrawals and withdrawal of consent, estimated at about 2.5%, four additional participants will be recruited for a grand total of 128 participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16646-0</funderId>
      <contactId>Contact54604_16646</contactId>
      <sponsorId>Sponsor53159</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54604_16646">
    <title>Dr</title>
    <forename>Sherri</forename>
    <surname>Katz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Children's Hospital of Eastern Ontario
401 Smyth Road
w1406</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">skatz@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53159">
    <organisation>Children's Hospital of Eastern Ontario (Canada)</organisation>
    <website>http://www.cheo.on.ca/english/hub.shtml</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Sherri Katz, MD
401 Smyth Road
W1406</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">skatz@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder16646-0">
    <name>Fight Spinal Muscular Atrophy (FightSMA) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-01T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">73594603</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neurocognitive functioning and brain plasticity in high-grade glioma patients: a magnetoencephalography pilot</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that a relationship is present between functional connectivity, network features and neurocognitive performance in Glioblastoma Multiforme (GBM) patients. We also expect treatment and recurrence of the tumour to lead to remodelling of the neuronosynaptic maps and network features (i.e. plasticity), and hypothesise that these dynamic changes correlate with improvements of cognition.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Main study parameters are neurocognitive functioning and Magnetoencephalogram (MEG)-measures (synchronisation likelihood and small-world features).</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from ethics boards of two centres participating in the study:
1. Academic Medical Centre (AMC) Medisch Ethische Commissie, received on the 16th July 2007 (ref: MEC 07/134) 
2. VU University Medical Center Medical Ethical Board, received on the 12th June 2007 (ref: 2007/108)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73594603</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NWOpilot01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, observational, case-control study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Case-control study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e55e6895-8e36-4e25-bfe3-16a4843cdfcd">
	  <name>Department of Medical Psychology, D343</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>For newly diagnosed patients: 
1. Adult (greater than 18 years)
2. Radiologically suspected GBM prior to surgery
3. Histologically confirmed GBM after surgery
4. Treatment consisting of surgery followed by combined radiotherapy and chemotherapy
5. Written informed consent

For patients with GBM recurrence: 
1. Adult (greater than 18 years)
2. Histologically confirmed GBM
3. Treatment consisting of surgery followed by chemotherapy
4. Written informed consent

For matched healthy controls: 
1. Adult (greater than 18 years)
2. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>For patient groups: 
1. Use of centrally acting drugs, including corticosteroids, other than antiepileptic drugs
2. Psychiatric disease or symptoms
3. Insufficient mastery of the Dutch language
4. Inability to communicate adequately

For controls: 
1. Use of centrally acting drugs (including analgesics)
2. Psychiatric disease or symptoms
3. Disorders of the central nervous system
4. Insufficient mastery of the Dutch language</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Glioblastoma multiforme, high grade Glioma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Glioma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Using prospective cognitive data and MEG recordings of ten newly diagnosed glioblastoma multiforme patients and ten glioblastoma multiforme patients with tumour recurrence we will investigate:
1. The impact of tumour- and treatment-related factors on functional connectivity and neural network features, and
2. The correlation between changes in these measures and cognitive function

If such treatment- and/or tumour-related cerebral plasticity and its correlation with cognition can be established in this pilot, future prospective studies will focus in more detail on:
1. The effects of different treatment modalities (e.g. less or more extensive surgery, radiotherapy), and 
2. The contribution of tumour-related symptoms (e.g. epilepsy) and their treatment (e.g. anti-epileptic drugs) on neural network function and cognition

This knowledge will eventually assist in the guidance of clinical decision-making in these patients.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16852-0</funderId>
      <contactId>Contact54810_16852</contactId>
      <sponsorId>Sponsor53367</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54810_16852">
    <title>Dr</title>
    <forename>M.</forename>
    <surname>Klein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medical Psychology, D343
Vrije University Medical Centre</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 8432</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.klein@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53367">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Medical Psychology</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16852-0">
    <name>Vrije University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">68179235</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment of itch with naltrexon in patients with burns</title>
      <scientificTitle>Treatment of itch with naltrexone in patients with burns: an explorative, randomised, double blind, placebo-controlled, cross-over clinical trial</scientificTitle>
      <acronym>BITE (Burns Itch TreatmEnt study)</acronym>
      <studyHypothesis>The primary objective of this study is to evaluate the efficacy and safety of naltrexone in the treatment of itch in patients with burn wounds.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean itch intensity score at endpoint, defined as the mean of the last 7 diary entries while the patient is receiving study medication. The percentage change in itch intensity score from baseline is calculated as:
1 - (mean itch intensity score end point/mean itch intensity score baseline) x 100%</primaryOutcome>
      <secondaryOutcome>1. Additional aspects of itch (e.g. frequency, duration) 
2. The effect of treatment as perceived by the patient, pain, and various aspects of anxiety and sleep:
2.1. Itch presence, measured at baseline 1
2.2. Demographics, measured at baseline 1	 
2.3. Burn injury characteristics, measured at baseline 1
2.4. Polymorphism µ-receptor (DNA), measured at intervention week 2
2.5. Blood plasma level, measured at intervention week 2 and intervention week 4
2.6. Scar: 
2.6.1. Patient and Observer Scar Assessment Scale (POSAS), measured at baseline 1 and intervention week 4
2.6.2. Dermaspect, measured at baseline 1 and intervention week 4
2.7. Itch: 	
2.7.1. Visual Analogue Scale (VAS) measured daily throughout treatment
2.7.2. Body-Image Ideals Questionnaire (BIQ), measured at baseline 1, intervention week 1, intervention week 2, baseline 2, intervention week 3, intervention week 4
2.8. Sleep:	
2.8.1. Visual Analogue Scale (VAS) measured daily throughout treatment	
2.8.2. Medical Outcomes Study (MOS)-Sleep, measured at baseline 1, intervention week 1, baseline 2, intervention week 3	
2.9. Pain: Visual Analogue Scale (VAS) measured daily throughout treatment	
2.10. Anxiety: Hamilton Anxiety and Depression Scale (HADS), measured at baseline 1, intervention week 1, baseline 2, intervention week 3	
2.11. Treatment effect: Patient Global Impression of Change (PGIC), measured at intervention 2 and intervention 4
2.12. Adverse Drug Reaction, measured daily during the intervention and wash out periods

Timepoints:
Baseline 1: 7 days
Intervention week 1: 7 days
Intervention week 2: 7 days
Wash-out 1: three days
Baseline 2: 7 days
Intervention week 3: 7 days
Intervention week 4: 7 days
Wash-out 2: 3 days</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics board (Stichting Beoordeling Ethiek Biomedisch Onderzoek, Medisch Ethische toetsingscommissie [METC Assen]) on the 4th July 2007 (ref: MZH 2007-20).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68179235</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, crossover group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="82152da2-0c53-4642-aff0-31c64f0e709b">
	  <name>Martini Hospital</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Eligible for inclusion are patients:
1. With (almost) healed burns who have been admitted to the burn centre
2. Who are 18 years of age or older with itch 4 - 6 weeks post burn</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Patients will be excluded when meeting one of the following exclusion criteria: 
1. Total Body Surface Area (TBSA) of more than 20%
2. Liver insufficiency (in this study that means more than two times the normal range of the liver enzymes: Aspartate Aminotransferase [ASAT] greater than 80 U/L and/or Alanine Aminotransferase [ALAT] greater than 80 U/L and/or Alkaline Phosphatase [AP] greater than 250U/L and/or Gamma Glutamyl Transpeptidase [GGT] greater than 100U/L)
3. Acute hepatitis
4. History of drug/alcohol abuse
5. Known sensitivity for any of the following substances: naltrexonehydrochloride, lactose monohydrate, crospovidone, powder cellulose, microcrystalline cellulose, colloid silicon dioxide, magnesium stearate, hypromellose, macrogole 4000, Titanium dioxide (E171), Black iron oxide (E172), Red iron oxide (E172), Yellow iron oxide (E172), carboxymethylamylum sodium type A, precirole
6. Pregnant
7. Breast feeding
8. Having used opioids 10 days prior to the start of treatment
9. Using itch medication other than the study medication and unwilling to stop
10. Psychiatric disorder
11. Other disease associated with itch (e.g. eczema, atopic dermatitis, cholestatic pruritus)
12. Insufficiently proficient in Dutch to give informed consent and/or fill out the questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Burns</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Burns</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will take either naltrexone or placebo for two weeks and are randomised to start with one or the other. Before the two treatment periods a baseline measurement of 7 days will be done. In between the two treatment periods there will be a wash-out period of 3 days. The naltrexone dose will be 50 mg once daily. On the first day patients will receive two times 25 mg of naltrexone with at least one hour in between. The procedure on the first day will be mimicked where the placebo is concerned.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16867-0</funderId>
      <contactId>Contact54825_16867</contactId>
      <sponsorId>Sponsor53382</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54825_16867">
    <title>Dr</title>
    <forename>A.</forename>
    <surname>Wieringa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martini Hospital
Department of Pharmacy
P.O. Box 30033</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 524 5771</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andre.wieringa@mzh.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53382">
    <organisation>Martini Hospital (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 30033</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.416468.9</gridId>
    <rorId>https://ror.org/017b69w10</rorId>
  </sponsor>
  <funder id="Funder16867-0">
    <name>Association of Dutch Burn Centres (ADBC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-30T00:00:00.000Z">35782567</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Applications of body surface mapping in cardiac resynchronisation therapy and ventricular tachycardia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Electrocardiographic Imaging (ECGI) using potentials derived from the body surface can be used to identify electrical dyssynchrony within the Left Ventricle (LV), along with activation patterns and regions of slow conduction. It could therefore be used to predict response to cardiac resynchronisation therapy, and ultimately to guide placement of the LV pacing lead to the optimal site.
2. ECGI using body surface potentials acquired noninvasively is of comparable accuracy to endocardial data acquired invasively in determining sites of pacing of the LV endocardium and patterns of activation.
3. ECGI is comparable to endocardial data acquired invasively in locating the origin of Ventricular Tachycardia (VT) substrates and may provide useful information over and above endocardial data to aid radiofrequency ablation of this tachyarrhythmia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>CRT study: 
Response to CRT (assessed clinically using echo, 6 minute walk distance, cardiopulmonary stress testing, and functionally using quality of life questionnaire and NYHA symptom class). This can be assessed in conjunction with pacing site localisation using ECGI in relation to regions of slow conduction/scar tissue. 

ECGI validation and VT studies: These are qualitative studies whereby ECGI data and data acquired invasively are compared directly. Therefore there is no discrete end-point.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Office for Research Ethics Committees in Northern Ireland (ORECNI), approved on 16/09/2005 (ref: 05/NIR01/139)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35782567</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RGHT000233</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="55431f13-2a0b-419e-a74b-acee2a2b0231">
	  <name>Regional Medical Cardiology Centre</name>
	  <address/>
	  <city>Belfast</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT12 6BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cardiac Resynchronization Therapy (CRT) study: 
1. Poor LV function with ejection fraction on echocardiogram (ECHO) &lt;35%
2. Symptomatic with New York Heart Association (NYHA) class 2-4
3. Dilated LV (&gt;55 mm)
4. Any QRS duration (representing the duration of ventricular depolarisation)
LV dysfunction can be of any aetiology. All patients must be able and willing to give writted informed consent. 

ECGI validation study: 
Patients must require EPS/ablation of tachyarrhythmias requiring LV access e.g. VT ablation/EPS, Brugada EPS, left sided pathways. All must be willing and able to give written informed consent. 

VT study: 
All patients must require EPS for induction of LV tachyarrhythmias or ablation of VT. Again all must give written informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 (CRT study, 50; ECGI validation study, 10; VT study, 10)</totalTarget>
      <exclusion>CRT study:
1. Ejection fraction on ECHO &gt;35%
2. Unable or unwilling to come back for 6 month follow-up
3. Unable or unwilling to give written informed consent

ECGI validation and VT studies:
1. Procedures not requiring access to the LV
2. Bleeding conditions
3. Clotting disorders
4. Unwilling to give written informed consent
5. Age &lt;18 years</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Left ventricular dysfunction</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Left ventricular dysfunction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. CRT study 
This is a pilot study during which 50 consecutive patients undergoing CRT implantation will be identified and worked up appropriately (there is no control group in this study and all participants will be given the same intervenions). All participants will undergo baseline assessment to include echocardiography, 6 minute walk testing, cardiopulmonary stress testing, quality of life assessment (questionnaire) and N-terminal Pro-BNP measurement. Body Surface Mapping (BSM) will be performed at baseline and the day following device implantation during different pacing modalities. They will then be followed up with a single visit at 6 months, at which time all of these tests will be repeated. 

2. ECGI validation study: 
A qualitative study comparing ECGI with data acquired invasively using noncontact endocardial mapping as gold standard. 10 patients undergoing invasive ElectroPhysiological Studies (EPS) requiring access to the left ventricle will be recruited. All patients will have an ECHO at baseline and undergo simultaneous body surface mapping and invasive endocardial mapping during muti-site pacing of the LV endocardium. BSM utilises a plastic 80-electrode mapping harness applied to the anterior and posterior torso. Noncontact endocardial mapping uses the previously validated EnSite 3000 system. This study will enable a qualitative comparison of both imaging modalities for localisation of pacing sites as well as activation sequences. There will be no follow-up for the patients in this sub-study.

3. VT study: 
10 patients requiring VT ablation or simply EPS for induction of ventricular arrhythmias will be studied using both invasive and noninvasive modalities. This is a purely qualitative study.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17993307 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1134c235-a071-4c2c-b0be-73b3f73c68e6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17993307"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16486-0</funderId>
      <contactId>Contact54444_16486</contactId>
      <sponsorId>Sponsor52999</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54444_16486">
    <title>Prof</title>
    <forename>Jennifer</forename>
    <surname>Adgey</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Regional Medical Cardiology Centre
1st Floor West Wing
Royal Victoria Hospital</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52999">
    <organisation>Royal Victoria Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Professor Ian Young
Royal Research Office
Royal Victoria Hospital
Grosvenor Road</address>
      <city>Belfast</city>
      <state xmlns:isrctn="http://www.67bricks.com/isrctn">Northern Ireland</state>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.416232.0</gridId>
    <rorId>https://ror.org/03rq50d77</rorId>
  </sponsor>
  <funder id="Funder16486-0">
    <name>Frances and Augustus Newman Foundation (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-12T00:00:00.000Z">96658320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Inhaled fluticasone in acute severe asthma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>High dose inhaled fluticasone is superior to standard treatment with intravenous hydrocortisone in patients with acute severe asthma.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>FEV1 and PEF at 90 minutes and 180 minutes from the time of administering the drug.</primaryOutcome>
      <secondaryOutcome>1. Symptom assessment, at 90 minutes and180 minutes from the time of administering the drug
2. Adverse effect of fluticasone at 90 minutes and180 minutes from the time of administering the drug</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by Christian Medical College Ethics committee on the 18th October 2005 (ref: IRB(EC)23/10/05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN96658320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RES/10/2005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, double dummy, single centre, parallel group design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c11cad31-f27a-4f7b-9887-bf4d7cc61328">
	  <name>Department of Pharmacology</name>
	  <address/>
	  <city>Vellore</city>
	  <state/>
	  <country>India</country>
	  <zip>632002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 18 to 55
2. Asthma patients with Peak Expiratory Flow (PEF) and Forced Expiratory Volume in one second (FEV1) less than 50% of the predicted
3. Asthmatic for six months or more</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>110</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>110</totalTarget>
      <exclusion>1. Underlying chronic lung disease
2. Fever more than 100.4°F
3. Smoker greater than five pack years
4. Patients with no legal representative or legal representative not willing to give consent
5. Life threatening asthma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute severe asthma, acute exacerbation of asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Baseline Measurements: 
Subjects, those who are randomised will be asked to perform baseline Peak Expiratory Flow (PEF) and Forced Expiratory Volume at one second (FEV1). Blood samples will be drawn for blood Theophylline level, pre-treatment serum potassium, Haemoglobin (Hb), Total Leucocyte Count (TLC), Differential Leucocyte Count (DLC) and Glucometer Random Blood Sugar (GRBS).  Bedside Electrocardiogram (ECG) will be done before initiation of the treatment.

Drug dose, route and time of administration:
One group will receive two doses of Fluticasone 2 mg via nebulizer half an hour apart and single dose of intravenous (IV) placebo. The other group will receive single dose of Hydrocortisone 200 mg IV and two doses of placebo via nebulizer half an hour apart. In addition, all patients will receive salbutamol 2.5 mg and ipratropium bromide 0.5 mg via nebulizer alternating every 15 minutes for three hours.

Monitoring:
PEF and FEV1 to be measured at 0, 30, 60, 90, 120, 150 and 180 minutes from the time of administering the drug, for close monitoring of the patient although the primary outcome measurement is at 90th and 180th minute.  If there is no improvement at 90th minute, the subject will be withdrawn from the trial and standard care will be given. If there is sign of worsening of the subject's condition from the baseline, at any point of time after the start of the trial, the subject will be immediately admitted into intensive care unit. 

During the period of drug administration the patient will be continuously monitored for adverse effect. At the end of three hours serum potassium level and GRBS level will be assessed. At the end of three hours, those who fulfilled the discharge criteria will be discharged and the rest will be admitted in the ward for further management. 

Follow up: 
At the time of discharge, all subjects will be advised to take Tab. Prednisolone 30 mg Once Daily (OD) and Tab. Ranitidine 150 mg twice daily for seven days along with Metered Dose Inhaler (MDI) Salbutamol 100 mcg two puffs when necessary (PRN) and MDI Fluticasone 250 mcg two puffs twice daily (BD) for one month. All of them will be advised follow up in Pulmonary Medicine Out-Patients Department (OPD) or Pulmonary Function laboratory at one month from the date of admission, to repeat PEF and FEV1.   

If there is any aggravation of symptoms prior to the day of follow up, all patients are advised to report to the Emergency Department immediately.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16678-0</funderId>
      <contactId>Contact54636_16678</contactId>
      <sponsorId>Sponsor53191</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54636_16678">
    <title>Dr</title>
    <forename>K.R.</forename>
    <surname>Dhanasekar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pharmacology 
Christian Medical College
Thorapadi Post
Bagayam, Tamil Nadu</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53191">
    <organisation>Christian Medical College (India)</organisation>
    <website>http://www.cmch-vellore.edu/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Bagayam
Thorapadi Post
Tamil Nadu</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11586.3b</gridId>
    <rorId>https://ror.org/00c7kvd80</rorId>
  </sponsor>
  <funder id="Funder16678-0">
    <name>Christian Medical College (India) - FLUID research grant (ref: R.C. Min No: 5735, RES/10/2005).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-25T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-03-01T00:00:00.000Z">72748991</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia</title>
      <scientificTitle/>
      <acronym>SøvnStudien</acronym>
      <studyHypothesis>The primary objective is to evaluate whether valerian root (valerian) improves the self-assessed quality of sleep compared with placebo for people with primary insomnia</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of participants in each group with an improvement in self-assessed quality of sleep of &gt; or = 0.5 units between the average score for the 2 weeks before and 2 weeks during treatment</primaryOutcome>
      <secondaryOutcome>1. Proportion of participants in each group with an improvement of &gt; or = 0.5 units between the average score for the 2 weeks before and 2 weeks during treatment for each of the four variables: 
1.1 Sleep latency
1.2 Number of awakenings
1.3 Total sleep time
1.4 Energy level during the day

2. Mean changes in the five outcomes listed above

3. Global self-assessment

If a difference is not found between the treatment groups for the primary and secondary variables, the following explorative variables will be analysed:
1. Proportion of participants in each group with any improvement in mean difference (i.e. all score changes &gt; 0) between the average score for the 2 weeks before and 2 weeks during treatment for each of the five variables: 
1.1 Quality of sleep
1.2 Sleep latency
1.3 Number of awakenings
1.4 Total sleep time
1.5 Energy level during the day

2. Difference in the profile of the five endpoints during the intervention period taking into account the baseline period, including a potential time effect</secondaryOutcome>
      <trialWebsite>http://sovnstudien.forskningspuls.no/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Regional Committee for Medical Research Ethics for Southern Norway (Regional komité for medisinsk forskningsetikk, Sør- Norge) 5 January 2006, Ref: S-05280</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72748991</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2005001TVT</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, parallel group, placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-29T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4cd12084-91df-42fd-a3c6-13a0e1b4e932">
	  <name>Norwegian Knowledge Centre for the Health Services</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>N-0130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 &#150;75 years, both inclusive
2. Insomnia lasting more than one month
3. Pittsburgh Sleep Quality Index (PSQI) score of &gt; 5
4. Provide name of primary physician
5. Access to internet and own email address
6. At least 10 days of the sleep diary completed prior to randomisation</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>550</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500 to 550</totalTarget>
      <exclusion>1. Secondary insomnia
2. Use of hypnotics by prescription
3. Depression
4. Alcohol or drug abuse 
5. Psychotherapy within the past six months
6. Sleep apnoea, periodic limb movements disorder or restless legs syndrome
7. Pregnant or lactating women or women of childbearing potential who do not use an approved method of contraception (oral contraceptives orIntrauterine device [IUD])
8. Shift workers
9. History of hypersensitivity to valerian or its constituents
10. Participant rating of &#145;usually&#146; or &#145;always&#146; to the following questions in the Global Sleep Assessment Questionnaire:
During the past four weeks, how often:
a. Did you hold your breath, have breathing pauses, or stop breathing in your sleep?
b. Did you have restless or "crawling" feelings in your legs at night that went away if you moved your legs?
c. Did you have repeated rhythmic leg jerks or leg twitches during your sleep?
d. Did you have nightmares, or did you scream, walk, punch, or kick in your sleep?
e. Did any of the following disturb you in your sleep: 
f. Pain? 
g. Other physical symptoms?
h. Medications? 
i. Did you snore loudly?
11. Current participation in another trial using an investigational compound</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-29T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary insomnia</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Coated Valerian Forte tablets 200 mg extract per tablet, corresponding to 1200 mg Valeriana officinalis. 3 tablets to be taken every night for 14 days

Information about the study will be televised nationally on a weekly health program. Viewers interested in participation will be invited to visit the web pages of the study to enrol. Participant registration and data collection will be by use of Internet.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17940604 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8cc482e2-f5b6-4155-9ed5-54daca75364f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17940604"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16073-0</funderId>
      <contactId>Contact54019_16073</contactId>
      <sponsorId>Sponsor52571</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54019_16073">
    <title>Dr</title>
    <forename>Andrew David</forename>
    <surname>Oxman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Knowledge Centre for the Health Services 
P.O. Box 7004
St. Olavs plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>N-0130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">oxman@online.no</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52571">
    <organisation>Norwegian Knowledge Centre for the Health Services (Norway)</organisation>
    <website>http://www.kunnskapssenteret.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>P.O. Box 7004
St. Olavs plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>N-0130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">post@kunnskapssenteret.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425407.0</gridId>
    <rorId>https://ror.org/01thff661</rorId>
  </sponsor>
  <funder id="Funder16073-0">
    <name>Norwegian Knowledge Centre for the Health Services (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-28T00:00:00.000Z">14949974</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Methods for evaluating the extent to which different ways of presenting evidence of the effects of health care help people make decisions that are consistent with their own values: a randomised trial</title>
      <scientificTitle/>
      <acronym>HIPPO pilot</acronym>
      <studyHypothesis>Pilot study - development of methodology to: 
1. Analyse which of several presentations of evidence of treatment effects best help people to make treatment decisions congruent with their own values
2. Compare visual analogue scales and category rating scales as value elicitation instruments</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Acceptance or rejection of statin treatment
2. Estimated probability to accept or reject statin treatment in relation to value score</primaryOutcome>
      <secondaryOutcome>1. To investigate the feasibility of conducting Internet-based randomised trials comparing different risk reduction presentations
2. To compare two methods of eliciting values
3. Four ways of weighting the elicited values to calculate a total value
4. To generate hypotheses and calculate sample size for a confirmatory study comparing six summary statistics for communicating evidence of reduced risk of Coronary Heart Disease (CHD) with statin therapy for treatment of high cholesterol</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the ethics review board at the University at Buffalo on the 15 May 2002 with several renewals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14949974</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HIPPO 1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-31T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0891a4c2-6486-4c45-a201-171abb237fc7">
	  <name>Norwegian Knowledge Centre for the Health Services</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>0130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18 years old
2. Fluent in English or Norwegian
3. Must give informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>770</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>770</totalTarget>
      <exclusion>Not meeting inclusion requirements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-31T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>N/A</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2>N/A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Six different summary statistics presenting ten year risk reduction effect of statins on coronary heart disease in the treatment of hypercholesteremia.

The methodological aspects reported in this study include comparison of two value elicitation instruments (visual analogue scales and category rating scales), four theory-grounded approaches to weighting elicited values, and six summary statistics to evaluate the extent to which they promote decisions consistent with elicited values. In addition, we report hypothesis generation and sample size calculation for a randomised controlled trial comparing the same six summary statistics for communicating evidence of reduced risk of coronary heart disease, as well as on the feasibility of conducting this type of Internet-based randomised trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16017-0</funderId>
      <contactId>Contact53963_16017</contactId>
      <sponsorId>Sponsor52512</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53963_16017">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Oxman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Knowledge Centre for the Health Services
P.O. Box 7004 
St Olavs Plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0130 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52512">
    <organisation>Norwegian Research Council (Norway)</organisation>
    <website>http://www.forskningsradet.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>P.O. Box 2700 
St. Hanshaugen</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.13985.36</gridId>
    <rorId>https://ror.org/00epmv149</rorId>
  </sponsor>
  <funder id="Funder16017-0">
    <name>Norwegian Research Council (Norway) (project 135210 - A series of randomised trials comparing different ways of presenting health evidence on the Internet)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-14T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">91751187</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bowel Preparation for elective Left-Sided Colonic Surgery</title>
      <scientificTitle/>
      <acronym>BP LSCS</acronym>
      <studyHypothesis>The objective of this study is to ascertain the best method of bowel preparation, prior to elective left-sided colonic surgery in terms of patient comfort and surgical efficacy. Sodium phosphate enemas (Colex) and bisacodyl (tablet and suppository) are to be compared. The occurrence of infections (wound, peritonitis) and anastomotic leaks will be monitored.

Null hypotheses are:
1. Patients in both groups experience pain and discomfort equally
2. The surgeon finds no difference in the condition of the left hemicolon intraoperatively
3. No difference in incidence of infection is found
4. No difference in incidence of anastomotic leaks is found</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Questionnaires will be used to assess the opinions of patients and surgeons. The parameters are recorded in a five point scale.</primaryOutcome>
      <secondaryOutcome>The occurrence of infection (wound or peritonitis) and anastomotic leaks is determined by standard postoperative care and is established when the clinical diagnosis is made.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (Medisch Ethische Toetsingscommissie Atrium MC - Maaslandziekenhuis) on the 30th October 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91751187</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NL14234.096.06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e5e425f8-a382-41d5-8089-433c45252b58">
	  <name>Atrium Medisch Centrum Heerlen</name>
	  <address/>
	  <city>Heerlen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6401 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The study population will consist of adult patients undergoing elective left-sided colonic surgery. Left-sided colonic surgery includes the following procedures: 
1. Left hemicolectomy
2. Sigmoid resection
3. Low anterior resection
4. Hartmann procedure
5. Reconstruction of colostomy
6. Abdominoperineal resection by Miles

Procedures on the transverse colon will also be included as this can result intraoperatively in a left hemicolectomy. Reasons for surgery vary, examples are malignancy, diverticulitis, Crohns disease and ulcerative colitis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Exclusion criteria are:
1. Use of Klean-Prep
2. Contra-indications for use of bisacodyl and Colex
3. Emergency procedures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bowel preparation, sodium phosphate enema, solonic surgery, bisacodyl</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colonic surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions in the bisacodyl group:
1. Evening before surgery (8 p.m.) - bisacodyl tablet 5 mg, four tablets, oral administration 
2. Morning of surgery (6 a.m.) - bisacodyl suppository 10 mg, one suppository, rectal administration

Intervention in the Colex group:
1. Evening before surgery (8 p.m.) - Colex 133 ml, enema, rectal administration
2. Morning of surgery (6 a.m.) - Colex 133 ml, enema, rectal administration</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bisacodyl, sodium phosphate (Colex)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16225-0</funderId>
      <contactId>Contact54180_16225</contactId>
      <sponsorId>Sponsor52734</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54180_16225">
    <title>Dr</title>
    <forename>C</forename>
    <surname>van der Leeuw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Atrium Medisch Centrum Heerlen
Chirurgie</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 CX </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)64 847 7103</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.vanderLeeuw@student.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52734">
    <organisation>Atrium Medisch Centrum (The Netherlands)</organisation>
    <website>http://www.atriummc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 4446</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414040.5</gridId>
    <rorId>https://ror.org/0367sye10</rorId>
  </sponsor>
  <funder id="Funder16225-0">
    <name>Atrium Medisch Centrum (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">08189331</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic control with Glucose-Insulin-Potassium infusion in acute myocardial infarction</title>
      <scientificTitle/>
      <acronym>GIPS II</acronym>
      <studyHypothesis>Treatment with Glucose-Insulin-Potassium (GIK) infusion during the acute phase of myocardial infarction has been proposed as therapeutic intervention for protection of the ischaemic myocardium.

Current evidence suggests an effect in patients with acute myocardial infarction without signs of heart failure at admission treated with reperfusion therapy (i.e. primary coronary angioplasty). There is also evidence for the treatment with insulin-glucose infusion in combination with strict metabolic control for at least three months thereafter for patients with type two diabetes mellitus (i.e. a history of diabetes mellitus, previously treated with oral hypoglycaemic agents or blood glucose level at admission greater than or equal to 11.1 mmol/l) and acute myocardial infarction.

Recently, it has been shown that obtaining and maintaining normoglycaemia (i.e. plasma-glucose concentrations of 4.4 and 6.1 mmol/l) in patients admitted to a Surgical Intensive Care Unit will lead to a marked reduction in morbidity and mortality.

This study will address what the effects will be of metabolic intervention with or without the infusion of GIK on 30-day and one-year mortality in patients eligible for reperfusion therapy (i.e. primary coronary angioplasty or thrombolysis).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>30-day mortality (death from any cause and cardiovascular death).</primaryOutcome>
      <secondaryOutcome>1. One-year mortality
2. Analysis of pre-specified subgroups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (Medisch Ethische Toetsings Commissie) on the 2nd May 2003 (ref: 02.1280).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08189331</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="347a2e6e-a288-4fc2-bdb1-44adeeb4b079">
	  <name>Diagram B.V. Zwolle</name>
	  <address/>
	  <city>Zwolle</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8011 NB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute myocardial infarction diagnosed by:
1.1. Chest pain suggestive for acute myocardial infarction
1.2. Symptom-onset less than six hours after hospital admission
1.3. Electrocardiogram (ECG) with ST-T segment elevation more than 1 mV in two or more leads
2. Patients are eligible for either primary coronary angioplasty or thrombolysis
3. Patient who has given his or her informed consent to take part in the study</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>900</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>900</totalTarget>
      <exclusion>1. Unwillingness to participate
2. Presence of heart failure (either one of these symptoms):
2.1. Heart rate more than 90 beats/minute
2.2. Systolic blood pressure less than 100 mmHg with anterior myocardial infarction
2.3. Killip class greater than or equal to II (third heart sound, greater than or equal to hand-wide rales)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute myocardial infarction</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Myocardial infarction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>An infusion of 80 mmol potassium chloride in 500 ml 20% glucose with a rate of 2 ml/kilogram body weight/hour over an 12 hour period in a peripheral venous line. The infusion is started as soon as possible after admission to the hospital after determination of blood-glucose level in combination with reperfusion therapy. A continuous infusion of short-acting insulin (50 units Actrapid HM [Novo Nordisk, Copenhagen, Denmark] in 49.5 ml of 0.9 percent sodium chloride) with the use of a perfusor-pump will also be started.
Blood-glucose levels will be measured hourly. Baseline insulin infusion dose and adjustments of insulin dose will be based on a nomogram to obtain and maintain blood-glucose levels of 6.0 to 10.0 mmol/l.

The insulin infusion will be stopped one hour prior to the discontinuation of the glucose-potassium infusion. After the Glucose-Potassium (GK) infusion is stopped insulin may be continued based on glucose measurements according to conventional care or until the infusion rate is less than 1 IU/hour.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Glucose-Insulin-Potassium (GIK) infusion</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16631017 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5bb19281-2972-4a52-9a1b-eab75f430b02" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-04-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16631017"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16229-0</funderId>
      <funderId>Funder16229-1</funderId>
      <contactId>Contact54184_16229</contactId>
      <sponsorId>Sponsor52738</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54184_16229">
    <title>Dr</title>
    <forename>J</forename>
    <surname>Klijn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Diagram B.V. Zwolle 
Van Nahuysplein 6 </address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8011 NB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)38 426 2997</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.klijn@diagram-zwolle.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52738">
    <organisation>Isala Klinieken (The Netherlands)</organisation>
    <website>http://www.isala.nl/Pages/default.aspx</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Locatie Weezenlanden
Department of Cardiology
Groot Wezenland 20</address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8011 JW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.452600.5</gridId>
    <rorId>https://ror.org/046a2wj10</rorId>
  </sponsor>
  <funder id="Funder16229-0">
    <name>Netherlands Heart Foundation (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16229-1">
    <name>Guidant (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-23T00:00:00.000Z">13256080</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>In the pathogenesis of medullary thyroid carcinoma a mutation of the rearranged during transfection (RET) tyrosine kinase system plays an essential role. In animal models the tyrosine kinase inhibitor imatinib showed tumor regression. So a phase II study in patients with progressive medullary thyroid carcinoma with imatinib may open new treatment possibilities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective is to determine the objective response rate (partial and complete responses) in subjects with advanced medullary thyroid carcinoma.</primaryOutcome>
      <secondaryOutcome>1. To determine the time to tumour progression
2. To evaluate overall survival
3. To evaluate the safety profile of Glivec® in advanced medullary thyroid carcinoma</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13256080</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CSTI571BNL07; METC 03-044</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational phase II study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6c01d901-b34b-4ed8-bc1c-28ab1f3c4bf2">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients over 18 years of age
2. The subject has advanced histologically proven medullary thyroid cancer. Advanced disease is defined as locally recurrent disease or metastatic disease that is not amenable to curative resection. The subject must have measurable disease.
3. The subject has not received anti-tumor radiotherapy or chemotherapy therapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) of the start of imatinib administration
4. The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of zero to two  
5. Adequate end organ function, defined as the following: 
5.1. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)
5.2. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2.5 x ULN
5.3. Creatinine less than 1.5 x ULN
5.4. Absolute neutrophil count (ANC) more than 1.5 x 10^9/L
5.5. Platelets more than 100 x 10^9/L
6. Female patients of childbearing potential must have negative pregnancy test within seven days before initiation of study drug dosing. Postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to three months following discontinuation of study drug.
7. Life expectancy of more than three months (in the absence of any intervention)
8. The subject has voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent prior to any study specific procedures</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>1. The subject is less than five years free of another primary malignancy except: 
1.1. If the other primary malignancy is not currently clinically significant nor requiring active intervention, or 
1.2. If the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
2. The subject is with known brain metastases
3. The subject has received any other investigational agents within 28 days of first day of study drug dosing
4. The subject has a current history of a class three to four cardiovascular disability status in accordance with the New York Heart Association Functional Classification:
4.1. Class three is defined as marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes fatigue or dyspnea
4.2. Class four is defined as being unable to carry on any physical activity without symptoms and symptoms are present even at rest. Also, if any physical activity is undertaken, symptoms are increased
5. Female patients who are pregnant or breast-feeding
6. Patient has another severe and/or life-threatening medical disease
7. The subject has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis)
8. The subject has a known diagnosis of human immunodeficiency virus (HIV) infection
9. The subject has received chemotherapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry
10. The subject had a major surgery within two weeks prior to study entry
11. The subject uses therapeutic anticoagulation with warfarins. Low-molecular weight heparin (e.g. Fragmin®) or heparin is permitted.
12. The subject with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Medullary thyroid carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Thyroid carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral treatment with 600 - 800 mg imatinib daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Imatinib mesylate (Glivec®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17579194 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a509938-e8a4-44aa-a743-ad3ef43c3380" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17579194"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16197-0</funderId>
      <contactId>Contact54152_16197</contactId>
      <sponsorId>Sponsor52706</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54152_16197">
    <title>Dr</title>
    <forename>B A</forename>
    <surname>Zonnenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
Department of Medical Oncology
Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 6308</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">B.Zonnenberg@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52706">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16197-0">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-08T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-01-05T00:00:00.000Z">27796329</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to evaluate the effectiveness of community Paramedic Practitioners managing Older People calling 999 with minor conditions</title>
      <scientificTitle/>
      <acronym>PPOPS</acronym>
      <studyHypothesis>Aims:
1. Comparing differences in patient experience and satisfaction of community paramedic practitioners with the existing standard service.
2. Comparing the clinical and cost effectiveness of community paramedic practitioners with the existing standard service.
3. Assessing the effects of community paramedic practitioners on ambulance service and Emergency Department (ED) performance.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Emergency Department attendance or hospital admission between zero and 28 days
2. Interval from time of call to time of discharge
3. Patient satisfaction with the service received</primaryOutcome>
      <secondaryOutcome>1. Investigations and treatments prescribed
2. Subsequent use of health services within 28 days
3. Health status and mortality at 28 days
4. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by North Sheffield LREC on the 31st March 2003, (ref: NS2002 9 1452).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27796329</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>577/1962</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Other</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1611d966-66ad-4b25-b275-e9f995803909">
	  <name>Health Services Research</name>
	  <address/>
	  <city>Sheffield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>S1 4DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients aged 60 years and above were eligible for study inclusion following a call to the ambulance service if the call:
1. Originated from a Sheffield postcode
2. Was received between 08:00 am and 20:00 pm
3. Presenting with a complaint that fell within the scope of practice of the paramedic practitioners</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>2200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2200</totalTarget>
      <exclusion>No exclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Minor injuries such as falls, lacerations, epistaxis, minor burns, foreign body - ENT (Ears, Nose and Throat) only</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Minor injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention:
A community based paramedic scheme intended to deliver patient centred care to older people calling the emergency services with conditions triaged as not immediately life threatening.

Control group:
Care as usual. In practice, this was an ambulance, followed by conveyance to an ED (unless the patient refused to travel to hospital).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17916813 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ae64ec4f-12a5-4aac-82b3-5370f6a31010" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17916813"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15822-0</funderId>
      <contactId>Contact53762_15822</contactId>
      <sponsorId>Sponsor52315</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53762_15822">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Mason</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Health Services Research 
School of Health and Related Research
University of Sheffield
Regent Street</address>
      <city>Sheffield</city>
      <country>United Kingdom</country>
      <zip>S1 4DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52315">
    <organisation>The Health Foundation (UK)</organisation>
    <website>http://www.health.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>90 Long Acre</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC2E 9RA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.453604.0</gridId>
    <rorId>https://ror.org/02bzj4420</rorId>
  </sponsor>
  <funder id="Funder15822-0">
    <name>The Health Foundation (UK) (ref: 577/1962)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">10862635</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study of efficacy of anakinra in acute gouty arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Treatment with anakinra will decrease the signs and symptoms of acute gout.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain of arthritis
2. Signs of arthritis</primaryOutcome>
      <secondaryOutcome>Biological markers of inflammation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics committee approval is pending, approval expected in January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10862635</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label pilot study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8209f180-fa32-4d47-a7be-2b06811eabd2">
	  <name>Rheumatology Service</name>
	  <address/>
	  <city>Lausanne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1011</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute gout as defined by American College of Rheumatology (ACR) criteria
2. Acute arthritis due to gout which is unresponsive to conventional therapy with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), colchicine or steroids
3. Patients with acute gout who have had side effects or intolerance to either NSAIDs, colchicine or steroids</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Patients with on-going or untreated infectious diseases 
2. Patients with rheumatoid arthritis, lupus or vasculitis
3. Patients concurrently treated with anti-Tumour Necrotising Factor (TNF) therapies 
4. Patients with active cancer</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute gout</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Acute gout</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with 100 mg anakinra daily subcutaneously for three days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Anakinra</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352828 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="94ae020d-57fe-44c5-86c7-dedff977db67" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352828"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15830-0</funderId>
      <contactId>Contact53770_15830</contactId>
      <sponsorId>Sponsor52323</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53770_15830">
    <title>Prof</title>
    <forename>Alexander</forename>
    <surname>So</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology Service
Centre Hospitalier Universitaire Vaudois (CHUV)
Av Pierre Decker</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52323">
    <organisation>University Hospital Complex of Vaud (Centre Hospitalier Universitaire Vaudois [CHUV]) (Switzerland)</organisation>
    <website>http://www.chuv.ch/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Rheumatology
Department of Medicine
University of Lausanne</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)21 314 14 50</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">secretariat.so@chuv.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8515.9</gridId>
    <rorId>https://ror.org/05a353079</rorId>
  </sponsor>
  <funder id="Funder15830-0">
    <name>Service of Rheumatology of the Centre Hospitalier Universitaire, Vaudois (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-29T00:00:00.000Z">05215453</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of rosiglitazone, compared to sulphonylurea, on endothelial function in Chinese patients with type two diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Rosiglitazone improves endothelial function independent of its effect on glycemic control
2. Rosiglitazone affects soluble receptor of advanced glycation end products independent of its effect on glycemic control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Changes in endothelial function in patients with type two diabetes</primaryOutcome>
      <secondaryOutcome>1. Changes in blood pressure and metabolic parameters such as C-reactive protein. 
2. Changes in serum soluble Receptor for Advanced Glycation End products (sRAGE) and advanced glycation end products.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster on the 19th March 2004 (ref: UW 04-045 T/367).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05215453</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HKCTR-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4c924cb5-d2de-4e32-b345-b444606abd22">
	  <name>The University of Hong Kong</name>
	  <address/>
	  <city>Pokfulam</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chinese men and women aged 30 to 70 years
2. Type two diabetes (defined by the World Health Organization [WHO] criteria) diagnosed after 30 years of age
3. On diet with/without sulphonylurea (less than or equal to half-maximum dose) with/without metformin for at least six months
4. No change in anti-diabetic, lipid lowering and anti-hypertensive in preceding 12 weeks
5. Body Mass Index (BMI) more than or equal to 23 and less than or equal to 35 kg/m^2
6. Systolic blood pressure less than or equal to 160 mmHg and diastolic blood pressure less than or equal to 90 mmHg
7. HbA1c levels between 7.5 and 10.5% inclusively (normal less than or equal to 6.1%) on at least two occasions in the past three months
8. Female patients must be post-menopausal (i.e. more than six months without menstrual period), surgically sterilised, or using hormonal contraceptives or intrauterine devices</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Pregnancy or lactation
2. Any clinically significant abnormality identified on the screening physical examination, laboratory tests, or electrocardiogram which, in the judgement of the investigator, would preclude the safe completion of the study
3. Use of anti-diabetic drugs other than metformin or sulphonylurea within 12 weeks
4. Use of any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication
5. Patients with a documented history of significant hypersensitivity to any drugs including thiazolidinedione and sulphonylurea (e.g., difficulty in swallowing or breathing, or tachycardia)
6. Active alcohol or drug abuse within the last six months
7. Presence of clinically significant renal or hepatic disease:
7.1. Serum creatinine above Upper Normal Range (UNR) (creatinine more than 128 umol/L for males and more than 107 umol/L for females)
7.2. Proteinuria more than 1 gm/day
7.3. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), total bilirubin, or alkaline phosphatase more than two times above UNR
8. Significant anaemia (haemoglobin less than 11 g/dl for males or less than 10 g/dl for females)
9. Patients with haemoglobinopathies
10. Leukocyte count less than 3.0 x 10^9/L or platelet count less than 120 x 10^9/L
11. Patients with severe angina, coronary insufficiency, heart failure (New York Heart Association [NYHA] class III or IV), or history of cardiovascular event in the past six months
12. Patients with electrocardiographic evidence of left ventricular hypertrophy based upon the maximal voltage of Sv1 plus the maximal voltage of Rv5 or Rv6 more than 3.5 mV and ST-T segment changes
13. Symptomatic diabetic neuropathy of sufficient severity to require treatment for control of symptoms (e.g. painful peripheral neuropathy, symptomatic orthostatic hypotension, urinary retention, pedal ulcers, gastric stasis, etc.)
14. Patients with history of psychiatric illness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type two diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to receive add-on therapy with either rosiglitazone 4 mg or glibenclamide 5 mg (or gliclazide 80 mg) daily while keeping the doses of their usual anti-diabetic agents constant. After four weeks, the doses of the add-on therapy were doubled in subjects with fasting blood glucose level greater than 8.0 mmol/l and without symptomatic or asymptomatic hypoglycemia defined as blood glucose level less than 3.0 mmol/l. The dosages of all anti-diabetic agents were then kept constant for another 20 weeks.

There was no washout period and all study medications were administered orally.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosiglitazone and sulphonylurea</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17639302 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6123f1f0-fd23-4e64-9de6-95404d331462" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17639302"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15807-0</funderId>
      <funderId>Funder15807-1</funderId>
      <contactId>Contact53747_15807</contactId>
      <sponsorId>Sponsor52299</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53747_15807">
    <title>Prof</title>
    <forename>Karen</forename>
    <surname>Lam</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The University of Hong Kong
Queen Mary Hospital</address>
      <city>Pokfulam</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52299">
    <organisation>Hong Kong University Research Committee (Hong Kong)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>7/F., Shui On Centre
6-8 Harbour Road</address>
      <city>Wanchai</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.194645.b</gridId>
    <rorId>https://ror.org/02zhqgq86</rorId>
  </sponsor>
  <funder id="Funder15807-0">
    <name>Hong Kong University Research Committee (Hong Kong) (project no. HKU 7637/05M)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15807-1">
    <name>HK Innovation and Technology Support Programme (Hong Kong) (project no. ITS/048/03)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-03T00:00:00.000Z">75663024</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>BAsel Stent KostenEffektivitaets Trial (Basel Stent cost-effectiveness trial)</title>
      <scientificTitle/>
      <acronym>BASKET (BAsel Stent KostenEffektivitaets Trial)</acronym>
      <studyHypothesis>Drug Eluting Stents (DES) are not cost-effective in a real world setting when compared to bare metal stents.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Six month cost-effectiveness with effectiveness defined as reduction of major adverse cardiac events - i.e., cardiac death, non-fatal myocardial infarction and target vessel revascularisation.</primaryOutcome>
      <secondaryOutcome>1. Mortality from other cause, target vessel ischemia by myocardial perfusion Single Photon Emission Computed Tomography (SPECT).
2. Effectiveness of DES in patients with myocardial infarction and saphenous vein graft disease. 
3. Cost-effectiveness as defined above after 18 and 36 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the local ethics committee of the University of Basel, March 27, 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75663024</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a0aeba82-f29d-4e72-8396-2a0c41b87555">
	  <name>Cardiology Department</name>
	  <address/>
	  <city>Basel</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-4031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Coronary artery disease suitable for interventional therapy.

All patients referred for cardiac catheterisation and subsequent Percutaneous Coronary Intervention (PCI) irrespective of clinical indication, who are able to provide written informed consent.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>826</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>826</totalTarget>
      <exclusion>1. In-stent-restenosis
2. Target vessel diameter equal to or greater than 4 mm
3. No informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>PCI in a real world setting (chronic and acute disease). Patients randomised 2:1 to drug eluting versus bare metal stents.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16154019 Results
2007 Other publications in https://pubmed.ncbi.nlm.nih.gov/17980734 -month cost-effectiveness analysis:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="caafc7de-7862-4d1f-82d5-708af2be21aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16154019"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="7d0a1e1f-460a-453d-9b2d-132a7eaa8735" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17980734"/>
	<description>-month cost-effectiveness analysis:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15761-0</funderId>
      <funderId>Funder15761-1</funderId>
      <contactId>Contact53699_15761</contactId>
      <sponsorId>Sponsor52253</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53699_15761">
    <title>Prof</title>
    <forename>Matthias</forename>
    <surname>Pfisterer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cardiology Department
University Hospital
Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>CH-4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52253">
    <organisation>University Hospital Basel (Switzerland)</organisation>
    <website>http://www.universitaetsspital-basel.ch/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>CH-4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410567.1</gridId>
    <rorId>https://ror.org/04k51q396</rorId>
  </sponsor>
  <funder id="Funder15761-0">
    <name>University Hospital, Basel (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15761-1">
    <name>Cardiac Research Foundation, Basel (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-10-18T00:00:00.000Z">98820688</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Hydrocortisone Treatment modality on Glycemic Control in patients with Septic Shock</title>
      <scientificTitle/>
      <acronym>HTGCSS</acronym>
      <studyHypothesis>Continuous hydrocortisone infusion will reduce the fluctuations in blood glucose levels in septic shock patients when compared to bolus treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mean blood glucose levels in study groups and the number of hyperglycemic (more than 7 mmol/l) and hypoglycemic (less than 3 mmol/l) episodes.</primaryOutcome>
      <secondaryOutcome>Shock reversal during the five day study period and the amount of nursing workload needed to maintain normoglycemia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics commitee of Päijät-Häme Central Hospital, approval gained on 25th February 2005 (Code Q 71).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98820688</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised prospective trial. Patients are randomised to receive hydrocortisone either by bolus or by continuous infusion in blocks of four patients. Study is not blinded nor placebo controlled.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3af8922-4a06-4341-9f28-dc949462f82b">
	  <name>Kuopio University Hospital</name>
	  <address/>
	  <city>Kuopio</city>
	  <state/>
	  <country>Finland</country>
	  <zip>70211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Septic shock patients meeting the criteria for septic shock according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>1. Patients under 18 years of age
2. Patients with diabetes 
3. Patients receiving glucocorticoids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vasopressor-dependent septic shock</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Septic shock</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Septic shock patients who are considered to benefit from the corticosteroid treatment are randomly assigned to receive hydrocortisone either by bolus treament or by continuous infusion with equivalent dose (200 mg/day). During the study period a strict normoglycemic goal is maintained with continuous insulin infusion.  Duration of hydrocortisone treatment was five days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydrocortisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17306016 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e5afb3c6-a5f9-452c-8211-0c7896675f98" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17306016"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15387-0</funderId>
      <funderId>Funder15387-1</funderId>
      <contactId>Contact53319_15387</contactId>
      <sponsorId>Sponsor51866</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53319_15387">
    <title>Dr</title>
    <forename>Esko</forename>
    <surname>Ruokonen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kuopio University Hospital
PO Box 1777</address>
      <city>Kuopio</city>
      <country>Finland</country>
      <zip>70211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51866">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+358 3 81911</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pekka.loisa@phks.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder15387-0">
    <name>Medical Research Fund of Tampere University Hospital (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15387-1">
    <name>Medical Research Fund of Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-10-16T00:00:00.000Z">87889245</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Circuit Weight Training to lower Blood Pressure in Obese individuals with Resistant Hypertension</title>
      <scientificTitle/>
      <acronym>CT, ORH &amp; BP</acronym>
      <studyHypothesis>In comparison with the Usual Care group (UC), obese hypertensive individuals undergoing 12 weeks of Circuit Weight Training (CWT), will exhibit greater reductions in blood pressure.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy of prescribing circuit weight training in reducing blood pressure of obese resistant hypertensives</primaryOutcome>
      <secondaryOutcome>1. Effiacy of circuit weight training in reducing weight
2. Increasing cardio-respiratory endurance
3. Improving glycemic control and lipid profiles 
4. Enhancing Health Related Quality of Life (HRQL)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University of Alberta Health Research Ethics Board (HREB) (ref no: 6276).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87889245</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RF-06-0419</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>This study has been cancelled due to the private fitness centre pulling out of the trial.</reasonAbandoned>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="af1cc191-7497-485f-8b7a-5662bc1d5ca9">
	  <name>Clinical Pharmacology and Internal Medicine</name>
	  <address/>
	  <city>Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2B7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 25 to 70 years
2. Obese (Body Mass Index [BMI] more than 30 kg/m^2)
3. Mean 24 hour ambulatory blood pressure of 150/99 mmHg or less (on drug therapy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 (20 randomised into either group)</totalTarget>
      <exclusion>1. White-coat hypertension
2. Secondary hypertension
3. Unstable cardiovascular disease
4. Not residing in Edmonton or the surrounding area</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Obesity and /or resistant hypertension</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Circuit Weight Training (CWT) group: Individuals will be prescribed an exercise regimen based on baseline fitness and strength assessments and their exercise blood pressure response. Loads prescribed will be low resistance but high volume (two to three sets of 15 repetitions). Subjects will be asked to train on at least three non-consecutive days of the week and given free membership to local health club facilities for the duration of the intervention (12 weeks). Adherence to CWT intervention will be monitored via electronic attendance records at the health club facilities

Usual Care (UC) Group: Individuals randomly assigned to the usual care group will be asked to continue their current level of activity for the duration of the intervention (12 weeks).

Both groups will recieve the same nutritional counselling at the start of the intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15075-0</funderId>
      <contactId>Contact52912_15075</contactId>
      <sponsorId>Sponsor51462</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52912_15075">
    <title>Dr</title>
    <forename>Raj</forename>
    <surname>Padwal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Pharmacology and Internal Medicine
University of Alberta 
2E3.22 Walter C. Mackenzie Health Sciences Center
8440 - 112 Street
Edmonton</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T6G 2B7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 780 407 8153</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rpadwal@ualberta.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51462">
    <organisation>University of Alberta (Canada)</organisation>
    <website>http://www.ualberta.ca</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>114 St - 89 Avenue
Edmonton</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T6G 2E1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17089.37</gridId>
    <rorId>https://ror.org/0160cpw27</rorId>
  </sponsor>
  <funder id="Funder15075-0">
    <name>University of Alberta Hospital Foundation (Canada) (ref: RF-06-0419)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-09-29T00:00:00.000Z">14811769</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical comparison of self-etching primer with conventional etch during fixed appliance treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does self etching primer provide satisfactory clinical performance with similar failure rates compared to conventional etch?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage bond failure rate.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14811769</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0155160660</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8fe58a4c-788f-4b7b-b6f6-f7ac7f82a4e5">
	  <name>Dept of Oral and Maxollofacial Surgery</name>
	  <address/>
	  <city>Bury</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BL9 7TD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients requiring fixed appliance treatment.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Patients who require bands or have heavily restored teeth.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Oral Health</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomised controlled trial: self-etching primer compared to conventional etch.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18042825 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e4978f90-3539-449c-b9bb-e97148a52403" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18042825"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15527-0</funderId>
      <funderId>Funder15527-1</funderId>
      <contactId>Contact53460_15527</contactId>
      <sponsorId>Sponsor52007</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53460_15527">
    <title>Mr</title>
    <forename>PA</forename>
    <surname>BANKS</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Oral and Maxollofacial Surgery
Fairfield General Hospital
Rochdale Old Road</address>
      <city>Bury</city>
      <country>United Kingdom</country>
      <zip>BL9 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52007">
    <organisation>Record Provided by the NHSTCT Register - 2006 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15527-0">
    <name>Pennine Acute Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15527-1">
    <name>NHS R&amp;D Support Funding (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-28T00:00:00.000Z">37259753</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The GRONORUN study: is a gradual training program for novice runners effective in preventing running related injuries? A randomised controlled trial</title>
      <scientificTitle/>
      <acronym>GRONORUN</acronym>
      <studyHypothesis>A more gradual training program for novice runners will result in a reduction of running related injuries in novice runners.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The incidence of running related injuries.</primaryOutcome>
      <secondaryOutcome>1. The severity of running related injuries
2. The compliance with the training programme and drop out</secondaryOutcome>
      <trialWebsite>http://www.gronorun.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37259753</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c346205c-2b20-4402-a42c-363c6517be25">
	  <name>P.O. Box 30001</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Novice runners (maximum of 30 minutes a month) between 18 and 65 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>532</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>532</totalTarget>
      <exclusion>No injury of lower limb in the past three months before the start of the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Running related injuries</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Running related injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A gradual training programme lasting 13 weeks is performed by the intervention group according to prepare for a four mile run. The increase of running load is 10% per week (time). 

The control group will train for the four mile run using a classic training program lasting eight weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Protocol article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17331264 Study protocol
2008 Results article in https://pubmed.ncbi.nlm.nih.gov/17940147 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d1987121-8850-448a-8b07-9eae378d5e6c" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2007-03-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17331264"/>
	<description>Study protocol</description>
	<productionNotes/>
      </output>
      <output id="230c004d-7728-47c5-8795-b9b35bee3400" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17940147"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15422-0</funderId>
      <contactId>Contact53355_15422</contactId>
      <sponsorId>Sponsor51902</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53355_15422">
    <title>Dr</title>
    <forename>S W</forename>
    <surname>Bredeweg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3611023</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bredeweg@sport.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51902">
    <organisation>University Medical Center Groningen (UMCG), University Center for Sport, Exercise and Health (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3613366</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.j.pepping@sport.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15422-0">
    <name>The Netherlands Organisation for Health Research and Development (Zon-MW) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-17T00:00:00.000Z">18723747</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of ibuprofen-arginine on serum levels of nitric oxide metabolites in patients with chronic lower back pain: a single-blind, placebo-controlled pilot trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The present study investigates whether ibuprofen-arginine has a cyclooxygenase-independent pain modulating property besides its known anti-inflammatory effect.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>No metabolites.</primaryOutcome>
      <secondaryOutcome>Pain intensity (VAS).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Kantonale Ethics commission Zurich) on the 8th November 2002 (ref: 427).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18723747</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2003DR4004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A single-blind, placebo-controlled pilot trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="244eea26-6ebb-438e-9e9c-4ad64620ef94">
	  <name>Department of Rheumatology</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Non-specific chronic lower back pain (Visual Analogue Scale [VAS] greater than or equal to 60).</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Specific lower back pain.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lower back pain</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Lower back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ibuprofen-arginine 400 mg (verum) was administered orally once.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ibuprofen-arginine 400 mg (verum)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17013995 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1f3089cf-2288-41bb-8407-b8b4e77cfcae" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17013995"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14814-0</funderId>
      <contactId>Contact52586_14814</contactId>
      <sponsorId>Sponsor51111</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52586_14814">
    <title>Dr</title>
    <forename>Haiko</forename>
    <surname>Sprott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology
Institute of Medical Research
University Hospital of Zurich
Gloriastrasse 25</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>CH-8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)44 255 3010</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">haiko.sprott@usz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51111">
    <organisation>Zambon Svizzera S.A. (Switzerland)</organisation>
    <website>http://www.inpharzam.ch/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Via Industria 13
Casella postale 200</address>
      <city>Cadempino</city>
      <country>Switzerland</country>
      <zip>CH-6814</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)91 960 4118</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Ralf.Ruffmann@zambongroup.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487420.d</gridId>
    <rorId>https://ror.org/04zrd1t35</rorId>
  </sponsor>
  <funder id="Funder14814-0">
    <name>Zambon Svizzera S.A. (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-08T00:00:00.000Z">63217062</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of intrauterine insemination (IUI) in subfertile couples with an isolated cervical factor: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. We hypothesised a beneficial effect of IUI in couples with an isolated cervical factor
2. Furthermore we hypothesised that the post-coital test can identify those couples who would benefit from IUI without ovarian hyperstimulation</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was ongoing pregnancy within six months. Ongoing pregnancy was defined as the presence of foetal cardiac activity at transvaginal sonography at a gestational age of at least 12 weeks.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints were total number of clinical pregnancies, miscarriages and multiple pregnancies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63217062</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="84bdb550-270a-48fb-af67-705fc644fdfa">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Couples with a cervical factor and otherwise no factors that reduced their fertility i.e. a prognosis for a treatment independent ongoing pregnancy in the next year higher than 30%. A cervical factor was diagnosed by a well-timed, non-progressive post-coital test (PCT) with normal semen parameters.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>All other subfertile couples</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subfertility</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Subfertility</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Couples were randomly allocated to IUI for six months or expectant management for six months. In the first three IUI cycles no controlled ovarian hyperstimulation (COH) was given. If these attempts failed subsequent IUI cycles were performed with COH.

Couples allocated to expectant management were followed until an ongoing pregnancy occurred within six months. If no pregnancy occurred, follow-up ended after this period. If a pregnancy miscarried, follow-up continued until the next pregnancy or the end of the six months period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17482611 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eea86a69-b58e-4776-861e-8e3455edcc8b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17482611"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14749-0</funderId>
      <contactId>Contact52518_14749</contactId>
      <sponsorId>Sponsor51038</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52518_14749">
    <title>Mrs</title>
    <forename>P</forename>
    <surname>Steures</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Center of Reproductive Medicine
OFO-project
H4-213
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5663857</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ofoproject@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51038">
    <organisation>Academic Medical Center Amsterdam (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.0</gridId>
  </sponsor>
  <funder id="Funder14749-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-02-01T00:00:00.000Z">85737357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intermittent malaria treatment and iron supplementation for the control of malaria and anaemia in infants in the Forest Belt of rural Ghana: a double-blind randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To establish whether preventive treatment or iron supplementation given at EPI prevented either severe anaemia or malaria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To assess the effectiveness of intermittent malaria treatment (1.25 mg pyrimethamine plus 25 mg sulfadoxine/kg) given at  10 weeks, 14 weeks and 9 months through the EPI programme in the control of malaria and severe anaemia in infancy
2. To determine the effect of intermittent malaria treatment in infancy on the risk of malaria and anaemia in childhood after completion of trial
3. To evaluate the effect of daily iron supplementation (2 mg/kg) given from 10 weeks to 12 months through the EPI programme on the control of malaria and severe anaemia
4. To assess the socio-cultural factors influencing acceptability of treatment modalities 
5. To evaluate the cost effectiveness of interventions</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 17th June 1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85737357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>980643</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-06-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-17T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ghana</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8263f984-cc13-47d9-8801-a317d17b67e1">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All infants aged at least 10 weeks attending a Mother and Child Health (MCH) Clinic or Child Welfare Clinic (CWC) in the Afigya-Sekyere District, Ashanti Region and are permanent residents in the district. Their mothers or main carers should have given informed consent to participate in the trial.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>450 infants/arm - 1800 infants in total randomised</totalTarget>
      <exclusion>Infants who are not permanent residents of Afigya-Sekyere District, Ashanti Region.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-06-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-17T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blind placebo controlled trial. One of the following treatments given to children at the time of DPT2, DPT3 and measles vaccination:
1. Iron supplementation and placebo
2. Placebo and sulphadoxine pyrimethamine
3. Iron supplementation and sulphadoxine pyrimethamine</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Iron supplementation, sulphadoxine pyrimethamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14724-0</funderId>
      <contactId>Contact52486_14724</contactId>
      <sponsorId>Sponsor51001</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52486_14724">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3813</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51001">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14724-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">52543592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of transfusions with platelets stored in platelet additive solution II versus plasma</title>
      <scientificTitle>A multicenter randomised study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma</scientificTitle>
      <acronym/>
      <studyHypothesis>Utilisation of platelets stored in additive solutions has several advantages. A former Randomised Controlled Trial (RCT) testing platelets stored in platelet additive solution II versus plasma excluded patients with factors of increased platelet consumption. In this study also this category of patients are included and we expect to find differences in outcome, as compared to the previous study.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1- and 24-hour corrected count increment.</primaryOutcome>
      <secondaryOutcome>1. Bleeding complications
2. Transfusion reactions
3. Transfusion interval</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the Leiden University Medical Center and HagaZiekenhuis ethics committees and conducted according to the Guidelines of Good Clinical Practice.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52543592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P03.113</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="def5a331-7199-4947-8d61-0992295f2d3c">
	  <name>Leyenburg Hospital,</name>
	  <address/>
	  <city>Den Haag</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2504 LN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients greater than 18 years expected to receive platelet transfusions.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>195</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>195</totalTarget>
      <exclusion>HLA- and/or HPA allo-immunisation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Platelet transfusion</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Transfusion</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Platelet transfusion, trigger based.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16825492 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="be13d427-03d4-43cc-8d4e-2c8868e51f71" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16825492"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14500-0</funderId>
      <contactId>Contact52162_14500</contactId>
      <sponsorId>Sponsor50712</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52162_14500">
    <title>Dr</title>
    <forename>J.L.H</forename>
    <surname>Kerkhoffs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leyenburg Hospital,
Department of Hematology,
P.O. Box 40551</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2504 LN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">JeanLouis.Kerkhoffs@bloodrtd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50712">
    <organisation>Leyenburg Hospital (The Netherlands) - Department of Hematology</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 40551</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2504 LN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413591.b</gridId>
    <rorId>https://ror.org/03q4p1y48</rorId>
  </sponsor>
  <funder id="Funder14500-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">48093674</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Transfusion induced complications = transfusion associated complications? study</title>
      <scientificTitle>The effects of leukocyte filtered versus buffy coat depleted erythocyte transfusions in major surgery patients</scientificTitle>
      <acronym>TACTICS</acronym>
      <studyHypothesis>Does removal of allogeneic white blood cells by filtration reduce postoperative complications?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Postoperative:
1. In-hospital mortality
2. Duration of intensive care stay</primaryOutcome>
      <secondaryOutcome>1. Postoperative multi organ failure
2. Postoperative infections
3. Length of hospital stay
4. Costs/benefits of universal leukocyte depletion for the Dutch health care
5. Role of perioperative medication

Follow up :
1. Long term survival
2. Cancer recurrence in GI patients
3. Predictive role of cytokines and related genes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48093674</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>n/a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d866563-6d00-4802-9cfc-a065aee450f6">
	  <name>Sanquin Blood Supply Foundation</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2310 CD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Acute aneurysm-, elective aneurysm-, orthopaedic- and large gastro-intestinal surgery patients.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1548</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1548</totalTarget>
      <exclusion>1. Under 18 years of age
2. Transfusions received within 3 months prior to inclusion
3. Pre existing medical indication for filtered red blood cell transfusions</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Blood transfusions complications</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Blood transfusions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Transfusions of filtered red blood cell concentrates versus transfusion of stored buffy coat depleted red blood cell concentrates.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15142885 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5c1e9b42-ce5c-478d-bd72-7f4d3ee43b53" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-05-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15142885"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14510-0</funderId>
      <funderId>Funder14510-1</funderId>
      <contactId>Contact52156_14510</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52156_14510">
    <title>Dr</title>
    <forename>J.A.</forename>
    <surname>Hilten, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sanquin Blood Supply Foundation
P.O. Box 2184</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2310 CD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5685060</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Joost.vanhilten@bloodrtd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14510-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14510-1">
    <name>Sanquin Bloodbank Amsterdam (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">17616323</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral vitamin B12 supplementation and cognitive performance in elderly people</title>
      <scientificTitle/>
      <acronym>Brain12 study</acronym>
      <studyHypothesis>Counteract the process of cognitive impairment in elderly people with mild vitamin B12 deficiency through oral supplementation with vitamin B12 or a combination of vitamin B12 with folic acid</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cognitive performance.</primaryOutcome>
      <secondaryOutcome>Blood biochemistry.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17616323</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1a4defcb-ece4-4701-bd32-b3af17793199">
	  <name>Wageningen University,</name>
	  <address/>
	  <city>Wageningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6700 EV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women aged 70 years or older
2. Mild vitamin B12 deficiency defined as vitamin B12 concentration between 100 and 300 picomol/L and MMA concentration greater than 0.32 micromol/L and creatinine concentration less than 120 micromol/L</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>195</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>195</totalTarget>
      <exclusion>1. Severe cognitive impairment
2. Anemia
3. Gastrointestinal surgery
4. Use of vitamin B12 injections or supplements containing &gt; 50 micrograms vitamin B12 and/or 25 micrograms folic acid
5. Less than 90% compliance during a 2 week placebo run in period
6. No written informed consent
7. Participation in other studies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin B12 deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin B12 deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 1,000 microgram vitamin B12/day
2. 1,000 microgram vitamin B12 and 400 microgram folic acid/day
3. Placebo</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin B12, folic acid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16895884 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51d2c940-f376-4a4f-9b39-cc183be83d1b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16895884"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14512-0</funderId>
      <funderId>Funder14512-1</funderId>
      <funderId>Funder14512-2</funderId>
      <contactId>Contact52235_14512</contactId>
      <sponsorId>Sponsor50733</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52235_14512">
    <title>Dr</title>
    <forename>Simone</forename>
    <surname>Eussen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Wageningen University,
Division of Human Nutrition
P.O. Box 8129</address>
      <city>Wageningen</city>
      <country>Netherlands</country>
      <zip>6700 EV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)317 485395</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">simone.eussen@wur.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50733">
    <organisation>The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)</organisation>
    <website>http://www.zonmw.nl</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 93245</address>
      <city>Den Haag</city>
      <state/>
      <country>Netherlands</country>
      <zip>2509 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 349 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@zonmw.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.438427.e</gridId>
    <rorId>https://ror.org/01yaj9a77</rorId>
  </sponsor>
  <funder id="Funder14512-0">
    <name>Nutricia Research Foundation (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001720</fundRef>
  </funder>
  <funder id="Funder14512-1">
    <name>European Union BIOMED (Europe)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14512-2">
    <name>Kelloggs' Benelux (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">77274716</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of a functional fitness training in children with cerebral palsy</title>
      <scientificTitle/>
      <acronym>FITPRO-CP</acronym>
      <studyHypothesis>Children with cerebral palsy will benefit from functional fitness training.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Aerobic capacity.</primaryOutcome>
      <secondaryOutcome>1. Activities of daily life
2. Participation
3. Competence
4. Quality of life</secondaryOutcome>
      <trialWebsite>http://www.netchild.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77274716</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>05-092</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, single blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9e626677-cf0b-4b84-bd7e-7c2f428e1f3e">
	  <name>Revalidatiecentrum De Hoogstraat</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3583 TM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Cerebral palsy
2. Gross Motor Function Classification System (GMFCS) I or II
3. Age 7 - 20 years
4. Informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Cardiac or respiratory conditions that may be affected by exercise
2. Surgical or orthopaedic procedures during or up to three months prior to the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cerebral parese (cerebral palsy)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Cerebral palsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fitness programme that consists of functional exercises. 45 minutes fitness training twice a week for 8 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17984410 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8a21e65c-59a9-4668-a23d-cc54e08428f9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17984410"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14343-0</funderId>
      <contactId>Contact52214_14343</contactId>
      <sponsorId>Sponsor50571</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52214_14343">
    <title>Dr</title>
    <forename>Olaf</forename>
    <surname>Verschuren</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Revalidatiecentrum De Hoogstraat
Rembrandtkade 10</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3583 TM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2561211</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">o.verschuren@dehoogstraat.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50571">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>WKZ, Department of Pediatric Physiotherapy
Lundlaan 6</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>3584 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2504030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.j.m.helders@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14343-0">
    <name>Dr WM Phelps-Stichting Voor Spastici (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">43635237</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>N-acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal Insufficiency</title>
      <scientificTitle/>
      <acronym>NACCINIC-trial</acronym>
      <studyHypothesis>On the assumption that N-acetylcysteine might prevent acute contrast induced nephropathy in critically ill patients, we study the effects of prophylactic intravenous administration of N-acetylcysteine in critically ill patients with renal insufficiency.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Rise in plasma creatinine greater than 25% within 48 hours after contrast administration
2. Need for Continuous Venous-Venous Haemofiltration (CVVH) therapy at any moment during stay in ICU
3. Duration of CVVH therapy, if initiated
4. Renal insufficiency (for which ongoing renal replacement therapy) at ICU-discharge</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43635237</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blind, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6a7c8ebc-91a9-40d8-8e44-9d100f1c27c1">
	  <name>Department of Intensive Care</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. (Chronic or acute) renal insufficiency (not presently on renal replacement therapy) defined as a plasma creatinine greater than 180 µmol/L
2. Planned diagnostic imaging procedure requiring the use of intravenous radiographic contrast agents
3. Admitted to one of the participating intensive care units</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>246</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>246</totalTarget>
      <exclusion>1. Pregnancy
2. No informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal insufficiency</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal insufficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomly assigned to receive either N-acetylcysteine before and after administration of the contrast agent (acetylcysteine group) or placebo at the same time points (control group).

N-acetylcysteine or placebo is given intravenously in a double blinded fashion. N-acetylcysteine is given at a dose of 5000 mg on the day before and on the day of administration of the contrast agent, for a total of two days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>N-acetylcysteine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14371-0</funderId>
      <contactId>Contact52196_14371</contactId>
      <sponsorId>Sponsor50646</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52196_14371">
    <title>Dr</title>
    <forename>M J</forename>
    <surname>Schultz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Intensive Care
Academic Medical Centre
University of Amsterdam
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.j.schultz@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50646">
    <organisation>Academic Medical Centre (AMC) (Netherlands)</organisation>
    <website>http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Obstetrics and Gynaecology
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder14371-0">
    <name>Academic Medical Center (AMC) (The Netherlands) - Department of Intensive Care</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">26340837</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of recombinant Granulocyte Colony-Stimulating Factor (G-CSF) on the results of chemotherapy (CHOP) in elderly patients with intermediate-/high-grade Non-Hodgkin's Lymphoma: a prospective phase III study</title>
      <scientificTitle/>
      <acronym>HOVON 25 NHL</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm B is better than in arm A.

Objectives:
1. Evaluation of the effect of G-CSF on response and survival of Non-Hodgkin's Lymphoma (NHL) to therapy
2. Evaluation of the effect of prophylactic G-CSF on treatment-related morbidity and mortality
3. Evaluation of possible beneficial effect of G-CSF on patient adherence to Relative Dose Intensity of the standard therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Complete Remission (CR) rate.</primaryOutcome>
      <secondaryOutcome>1. Relapse rate
2. Event-free survival
3. Overall survival
4. Treatment-related morbidity
5. Therapy-related hospital admissions
6. Mortality</secondaryOutcome>
      <trialWebsite>http://www.hovon.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26340837</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO25</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-09-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="37d439f3-1609-4968-b984-b4a94d2fa7e0">
	  <name>Erasmus University Medical Centre</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Previously untreated Non-Hodgkin&#146;s Lymphoma
2. Ann Arbor stage II, III or IV
3. Intermediate- or high grade malignancy (Working Formulation), confirmed by histology
4. Aged greater than or equal to 65 years
5. Informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>410</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>410</totalTarget>
      <exclusion>1. Treatment for NHL with chemotherapy or radiotherapy (local irradiation to life-threatening tumor infiltration is allowed)
2. Lymphoblastic lymphoma
3. Other malignant diseases, except localized squamous skin carcinoma
4. Severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45%
5. Inadequate liver or renal function, ie serum creatinine or serum bilirubin &gt; 15x the upper normal value, except when related to lymphoma organ infiltration
6. HIV positivity</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-09-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non Hogdkin's Lymphoma (NHL)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Non Hogdkin's Lymphoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised at entry between:
Arm A: CHOP every 3 weeks, 6 or 8 courses
Arm B: CHOP every 3 weeks, 6 or 8 courses and 300 mcg subcutaneous (s.c.) daily G-CSF

CHOP consists of cyclophosphamide, doxorubicin, vincristine and prednisone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Granulocyte Colony-Stimulating Factor (G-CSF), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12915593 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="afa2d729-16fe-4647-996a-08823c00a2ee" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-08-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12915593"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14519-0</funderId>
      <funderId>Funder14519-1</funderId>
      <funderId>Funder14519-2</funderId>
      <funderId>Funder14519-3</funderId>
      <funderId>Funder14519-4</funderId>
      <funderId>Funder14519-5</funderId>
      <contactId>Contact52269_14519</contactId>
      <sponsorId>Sponsor50732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52269_14519">
    <title>Prof</title>
    <forename>P</forename>
    <surname>Sonneveld</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus University Medical Centre
Department of Haematology
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 3589</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.sonneveld@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50732">
    <organisation>Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)</organisation>
    <website>http://www.hovon.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Vrije University Medical Centre (VUMC)
PO Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2693</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@hovon.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder14519-0">
    <name>Johnson &amp; Johnson (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
  <funder id="Funder14519-1">
    <name>Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14519-2">
    <name>Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14519-3">
    <name>Roche Nederland B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14519-4">
    <name>Amgen (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder14519-5">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">82155239</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Myelo-ablative chemo/radiotherapy and autologous stem cell transplantation as compared to only chemotherapy in patients with multiple myeloma</title>
      <scientificTitle/>
      <acronym>HOVON 24 MM</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm II (and Allogeneic Bone Marrow Transplant [ABMT]) is better than in arm I.

Objectives:
1. Evaluation of the effect of myeloablative chemo-/radiotherapy and autologous stem cell transplantation in comparison with chemotherapy alone with respect to the mentioned endpoints
2. Assessment of the value of risk factors at diagnosis with dose intensity of treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Remission rate.</primaryOutcome>
      <secondaryOutcome>1. Event-free survival
2. Overall survival
3. Quality of life
4. Cost-benefit</secondaryOutcome>
      <trialWebsite>http://www.hovon.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82155239</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Ho24</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-11-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7bfa1bb6-3c78-47da-9fe0-8f40eacf2c2d">
	  <name>University Medical Center Utrecht,</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>At entry:
1. Previously untreated multiple myeloma, stage 2 or 3 according to Salmon and Durie
2. Aged less than 66 years
3. World Health Organization (WHO) performance status 0 - 3
4. Informed consent

For Interferon (IFN) maintenance and Peripheral Blood Stem Cell Transplant (PBSCT) or Allogeneic Bone Marrow Transplant (ABMT):
1. At least Partial Remission (PR) after induction therapy
2. WHO performance status 0 - 2
3. Suitable peripheral stem or bone marrow graft
4. No active infections
5. Absence of severe cardiac, pulmonary, neurologic, psychiatric disease
6. Serum creatinine, bilirubin and transaminases of less than 2.5 x upper limit of normal values
7. Platelet count greater than 50 x 10^9/l
8. Absolute neutrophil count greater than 1 x 10^9/l
9. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>452</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>452</totalTarget>
      <exclusion>At entry:
1. Received more than 2 courses of melphalan, prednisone or vincristine, melphalan (M), cyclophosphamide, prednisone (VMCP)
2. Severe cardiac disease (= severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45% with presence of normal hemoglobin), severe pulmonary, neurologic or metabolic disease- Inadequate liver function, i.e., bilirubin greater than or equal to 25 x upper normal value
3. Prior malignancies except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma
4. Prior extensive radiotherapy involving the myelum (precluding total body irradiation)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-11-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multiple Myeloma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Multiple Myeloma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be treated with 3 x VAD (vincristine, doxorubicine, dexamethasone). Patients less than or equal to 55 years with a Human Leukocyte Antigen (HLA) identical sibling will proceed to Allo BMT. All other eligible patients will be randomised between:
1. Arm I: PBSC pheresis after cyclophosphamide priming (cyclophosphamide, mesnum, G-CSF), IDM (melphalan, G-CSF) every 8 weeks 2 courses. In case of PR/CR maintenance therapy with IFN-alpha-2a until relapse. PBSCT may be performed after reinduction or relapse
2. Arm II: PBSC pheresis after cyclophosphamide priming (cyclophosphamide, mesnum, G-CSF), IDM (melphalan, G-CSF) q 8 weeks 2 courses. In case of PR/CR intensive treatment with cyclophosphamide/TBI and autologous transplantation, maintenance with IFN-alpha-2a until relapse</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Vincristine, doxorubicine, dexamethasone (VAD), cyclophosphamide, mesnum, Granulocyte Colony Stimulating Factor (G-CSF), melphalan</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Other publications in https://pubmed.ncbi.nlm.nih.gov/12456509
2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12721248/
2004 Other publications in https://pubmed.ncbi.nlm.nih.gov/15110879</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b251b5f2-7450-4e71-a158-b7067a71a28e" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2003-03-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12456509"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="e850d249-44cd-489d-9280-f2cdf1a32a8d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12721248/"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="d42462f6-390b-450a-8d6f-951c25d4452d" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15110879"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14520-0</funderId>
      <funderId>Funder14520-1</funderId>
      <funderId>Funder14520-2</funderId>
      <funderId>Funder14520-3</funderId>
      <funderId>Funder14520-4</funderId>
      <funderId>Funder14520-5</funderId>
      <contactId>Contact52143_14520</contactId>
      <sponsorId>Sponsor50732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52143_14520">
    <title>Dr</title>
    <forename>H.M.</forename>
    <surname>Lokhorst</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht,
Department of Hematology,
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2507230</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.lokhorst@digd.azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50732">
    <organisation>Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)</organisation>
    <website>http://www.hovon.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Vrije University Medical Centre (VUMC)
PO Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2693</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@hovon.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder14520-0">
    <name>Roche Nederland B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14520-1">
    <name>Amgen (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder14520-2">
    <name>Johnson &amp; Johnson (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
  <funder id="Funder14520-3">
    <name>Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14520-4">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14520-5">
    <name>Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">72675518</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of intrauterine insemination with ovarian hyperstimulation in couples with an unexplained moderately reduced fertility</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>There is no additional benefit of Intrauterine Insemination (IUI) with Controlled Ovarian Hyperstimulation (COH) over expectant management for 6 months in couples with unexplained subfertility and a chance of a spontaneous pregnancy between 30% and 40%. Categorisation of unexplained subfertile couples by their prognosis can identify those couples who benefit from IUI with COH and those who do not.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was ongoing pregnancy within six months. Ongoing pregnancy was defined as the presence of foetal cardiac activity at transvaginal sonography at a gestational age of at least 12 weeks.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints were total number of clinical pregnancies, miscarriages and multiple pregnancies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72675518</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5cdeed0-ec89-4f2b-a556-6877a5431dcc">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All subfertile couples in whom no reason is found during the basic fertility work-up for their subfertility and in whom their spontaneous pregnancy chance in the next year, calculated by the results of the basic fertility work-up, is between 30% and 40%.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>All couples in whom a reason is found for their subfertility or who are having another prognosis calculated</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Unexplained Subfertility</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Subfertility</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After informed consent had been given, couples were randomly allocated between IUI with COH and expectant management for six months. 

Couples allocated to IUI with COH started treatment in the next cycle. Controlled ovarian hyper stimulation as well as semen preparation and insemination regimens were performed according to hospital-specific protocols. 

Couples allocated to expectant management were followed until an ongoing pregnancy occurred within six months, these pregnancies were finally followed until birth. If no pregnancy occurred, follow-up ended after this period. If a pregnancy miscarried, follow-up continued until the next pregnancy or the end of the six months period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16844491 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9a1635ce-3dfc-4f6d-8b38-e6f021c07e47" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16844491"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14407-0</funderId>
      <contactId>Contact52212_14407</contactId>
      <sponsorId>Sponsor50699</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52212_14407">
    <title>Mrs</title>
    <forename>P</forename>
    <surname>Steures</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Center of Reproductive Medicine
OFO-project, H4-213
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 3857</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ofoproject@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50699">
    <organisation>Academic Medical Centre (AMC) (Netherlands)</organisation>
    <website>http://www.amc.uva.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Meibergdreef 9</address>
      <city>Amsterdam</city>
      <state/>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder14407-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-23T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">45666086</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Leiden-Alloimmunisation-Likelihood (LAL) trial: alloimmunisation after pre-storage filtered, post-storage filtered and buffy-coat-depleted blood transfusion in cardiac surgery patients</title>
      <scientificTitle/>
      <acronym>LAL trial</acronym>
      <studyHypothesis>The use of by filtration-leukocyte reduced blood transfusions in patients undergoing cardiac surgery, will result in lower alloimmunisation frequencies compared to using buffy-coat depleted blood transfusions. This has previously been shown in frequently transfused patients that received transfusions over a longer period of time, and is now investigated in patients receiving several units of blood around a single event, cardiac surgery. Also being investigated in this study is whether post-storage filtration is as effective as pre-storage filtration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Anti-Human Leukocyte Antigen (HLA) antibody formation (tested by LCT) and anti-erythrocyte antibody formation (tested in 3 cell panel, with PEG). Samples for analyses are collected before surgery, on day 7 post-surgery, 3 - 10 weeks post-surgery and 20 - 30 weeks post-surgery.</primaryOutcome>
      <secondaryOutcome>1. Post-operative infections
2. Hospital stay
3. Intensive Care Unit (ICU)-stay
4. Mortality
5. Costs-effect-analyses
6. In combination with other Randomised Controlled Trials (RCTs), that have randomised between these same two blood products: long term effects on the incidence of  autoimmune diseases and malignancies</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45666086</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>n/a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, active controlled, parallel group trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1992-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1994-08-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bade7ee3-f043-4c46-8e30-6239c4df7423">
	  <name>Sanquin Blood Bank</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 BZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients planned for open heart surgery: Coronary Artery Bypass Graft (CABG), heart valve surgery or the combination of both.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>944</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>944</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Transfusions within last 6 months
3. Pre-existing medical indication for filtered blood products</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1992-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1994-08-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Blood transfusions in cardiac surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Blood transfusions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Use of by filtration leukocyte reduced blood transfusions versus use of buffy-coat depleted blood transfusions (=1990's standard in NL).</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1990 Other publications in https://pubmed.ncbi.nlm.nih.gov/2378025
1998 Other publications in https://pubmed.ncbi.nlm.nih.gov/9494026
2003 Other publications in https://pubmed.ncbi.nlm.nih.gov/12542735</publicationDetails>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="73e03fd0-ee81-4b92-ba13-6c57d75d8b60" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1990-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2378025"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="63ab26b4-c11a-4d92-8d91-c4cd25dce28c" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1998-02-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/9494026"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="c68100f1-6dbd-4a7a-ba1b-3b109d9450d3" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2003-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12542735"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14473-0</funderId>
      <funderId>Funder14473-1</funderId>
      <contactId>Contact52180_14473</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52180_14473">
    <title>Dr</title>
    <forename>L.M.G.</forename>
    <surname>van de Watering</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sanquin Blood Bank
Southwest region
Plesmanlaan 1a</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14473-0">
    <name>Red Cross Blood Bank Leidsenhage (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14473-1">
    <name>NPBI International B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-23T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">04886579</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dutch National Study to the palliative effect of irradiation comparing two different treatment schemes in Non-Small-Cell-Lung-Cancer (NSCLC)</title>
      <scientificTitle/>
      <acronym>0G98/009 LUNGTRIAL</acronym>
      <studyHypothesis>The treatment of Non-Small-Cell-Lung-Cancer (NSCLC) is still a challenge for the oncologist. In the last decade combined modality treatment in stage III and chemotherapy in stage IV improved the survival and quality of life (QOL) in NSCLC patients. Unfortunately a vast majority of patients will not be fit enough to undergo these intensive treatments, and those who underwent chemotherapy as palliative treatment may eventually still suffer from loco-regional complaints. 

In general, hemoptysis, chest pain, dysphagia, and dyspnoea can all be effectively palliated with acceptable toxicity with all kinds of different radiation treatment schemes. The effectiveness of these different treatment schemes however varies for each different symptom and is most effective for hemoptysis and chest pain in patients with an Eastern Cooperative Oncology Group (ECOG) grade status of 2 - 3. Which dose should be given is still controversial. 

In the first Medical Research Council (MRC) trial reported in 1991 no differences in palliative effect and in survival were seen between 13 x 3 Gy and 2 x 8.5 Gy. In a second MRC study in 1992 for poor prognostic patients only, no differences in palliation or survival were seen between 10 Gy single dose and 2 x 8.5 Gy. However in a study by Bezjak et al. a difference in survival between 20 Gy in 5 fractions and a 10 Gy single dose was demonstrated in favour of the multi-fractionation treatment. In a group-analysis, however, this survival advantage was not seen in patients with an ECOG score of 2 or more. Later data suggested a survival advantage of 13 x 3 Gy over 2 x 8.5 Gy in patients with good performance status. 

For patients in a bad general condition it still has to be proven whether 2 x 8.5 Gy is equally effective as 10 x 3 Gy. Based on these findings radiation oncologists in the Netherlands could not reach consensus on the appropriate fractionation schedule for palliative irradiation of bad prognosis NSCLC patients. The presented study therefore was focused on patients with bad general condition and/or significant weight loss with stage III NSCLC or stage IV patients, not suitable for chemotherapy, comparing 10 x 3 Gy with 2 x 8 Gy.

Purpose: 
This multicentre randomised National Study compared the efficacy of 2 x 8 Gy versus our standard 10 x 3 Gy in patients with inoperable stage IIIA/B (with ECOG score 2 - 4 and/or substantial weight loss) and stage IV Non-Small-Cell Lung Cancer (NSCLC). 

Hypothesis:
We expected both treatment arms to have an equal outcome for palliation as for prognosis, because of the above-mentioned results of the MRC studies.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Palliation of thoracic symptoms measured over 52 weeks after randomisation. A maximum of 33 questionnaires per patient would be sent in case follow-up could be completed. The first questionnaire was given before randomisation, the last questionnaire in the 52nd week after randomisation. Data about effectiveness of the treatment and QOL were based on the Rotterdam Symptom Checklist. Seven symptoms could be scored each on a four point validated scale from 1 (no complaints) to 4 (severe complaints). The baseline total symptom score had to be 8 indicating that the patient had at least one tumour related complaint. The maximum total symptom score could be 28 indicating the patient had all seven complaints in the worst degree. After response the lowest total symptom score could be 7, having no complaints at all. Palliation was defined as a average total score below the baseline score.</primaryOutcome>
      <secondaryOutcome>1. Toxicity, Quality of Life (QOL), and survival
2. Quality of life was measured using the EuroQol classification system (EQ-5D), consisting of five questions on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression 
3. In addition, information about acute toxicity as nausea, vomiting, and radiation oesophagitis induced dysphagia was collected, based on the of the National Cancer Institute of Canada Expanded Clinical Trials Group (NCIC CTG) Common Toxicity Criteria 
4. Patients were also asked to provide information about costs. Together with quality of life data, these data will be published separately in a cost-utility analysis
5. Follow up after 52 weeks was continued by the data manager, who made 3-monthly inquiries after survival of the patient</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04886579</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomsied, active controlled, parallel group trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b6320af7-204c-436a-a848-f0591479091f">
	  <name>Arnhems Radiotherapeutisch Instituut,</name>
	  <address/>
	  <city>Arnhem</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6815 AD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosis of NSCLC had to be cytologically or histologically confirmed
2. Tumour stage was IIIA or IIIB in combination with performance status 3 &#150; 4 and/or a weight loss of more than 5% in 3 months or greater than 10% in 6 months prior to diagnosis
3. Stage IV NSCLC, not suitable for chemotherapeutic treatment
4. A minimum total symptom score of 8, indicating a score greater than 1 for at least one of the following complaints caused by the tumour itself: 
4.1. Loss of appetite
4.2. Dyspnoea
4.3. Chest pain
4.4. Coughing
4.5. Hemoptysis
4.6. Hoarseness and/or dysphagia
5. Physically and mentally fit enough to participate in the study</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>303</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>303</totalTarget>
      <exclusion>1. Superior Vena Cava Syndrome (SVCS) at presentation
2. Prior radiotherapy to the chest and/or other malignant diseases in the past
3. Concurrent chemotherapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non Small Cell Lung Cancer (NSCLC)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Lung cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised, without stratification, either to the multiple fractionation scheme of 10 x 3 Gy, 4 - 5 times a week, or the hypo fractionation scheme of 2 x 8 Gy, given at day 1 and day 8. 

Irradiation was given with two opposing anterior-posterior fields with 6 - 18 MV photon beams. The treatment portals encompassed the tumour with a margin of 1.5 - 2 cm including adjacent pathological lymph nodes. No limitations were set for the Target Volume. Dose calculation was not corrected for tissue inhomogeneities. Co-medication, including corticosteroids and analgetics, and extra oxygen supply were allowed and registered.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15860852 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8f76f40c-98c7-40fc-b39c-cecb06626634" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15860852"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14474-0</funderId>
      <contactId>Contact52134_14474</contactId>
      <sponsorId>Sponsor50686</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52134_14474">
    <title>Dr</title>
    <forename>G.W.P.M.</forename>
    <surname>Kramer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Arnhems Radiotherapeutisch Instituut,
Wagnerlaan 47</address>
      <city>Arnhem</city>
      <country>Netherlands</country>
      <zip>6815 AD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)26 371 2493</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.kramer@arnhemrti.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50686">
    <organisation>Arnhems Radiotherapeutic Institute (ARTI) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Wagnerlaan 47</address>
      <city>Arnhem</city>
      <country>Netherlands</country>
      <zip>6815 AD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491092.7</gridId>
    <rorId>https://ror.org/048338z54</rorId>
  </sponsor>
  <funder id="Funder14474-0">
    <name>The Dutch Health Care Insurance Board (CVZ) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-23T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">76815071</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Risk adapted treatment of Acute Myelocytic Leukaemia (AML)</title>
      <scientificTitle/>
      <acronym>HOVON 29 AML/SAKK 30/95</acronym>
      <studyHypothesis>The hypotheses to be tested are that: 
1. The outcome in arm B is better than in arm A 
2. Following Peripheral Blood Stem Cell Transplant (PBSCT) is better than following Cycle III chemotherapy</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>CR rate.</primaryOutcome>
      <secondaryOutcome>1. Disease-free survival
2. Overall survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76815071</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO29</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-03-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-06T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="66c425ca-c0b1-4a3d-a51c-fb890ffbf30e">
	  <name>Erasmus Medical Centre</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3008 AE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>First randomisation:
1. Patients with newly diagnosed de novo Acute Myelocytic Leukaemia (AML) (including all cytological subtypes M0-M7)
2. Age 15 - 60 years inclusive
3. Patients have given informed consent
4. Leucocytosis (White Blood Cells [WBC] greater than 30 x 10^9/l) is not an exclusion criterion, but it will require postponement of Granulocyte-Colony Stimulating Factor (G-CSF) administration until WBC have declined to 20 x 10^9/l on chemotherapy

Patients after completion of CYCLE II and peripheral blood stem cell collection are eligible for second randomisation if:
1. Complete remission continues (marrow cytology and blood evaluation)
2. Poor risk status according to criteria of Appendix III
3. Not eligible for genotypically Human Leukocyte Antigen (HLA) matched allogeneic Bone Marrow Transplant (BMT)
4. Absence of congestive heart failure or pulmonary disease
5. Serum bilirubin as parameter of liver function abnormalities not elevated above 3 x normal value
6. Number of blood cells collected ('transplant'; PBSCT) being at least 2 x 10^8 nucleated cells/kg or 10 x 10^4 Colony-Forming Units Granulocyte-Macrophage (CFU-GM) per kg or 2 x 10^6 CD34-positive cells per kg. In case of no or insufficient PBSCT, an adequate autologous marrow graft must have been collected
7. Performance status of World Health Organization (WHO) grade 0, 1 or 2 at time of randomisation
8. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1105</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1105</totalTarget>
      <exclusion>First randomisation:
1. Patients with a concurrent active malignancy, except stage I cervix carcinoma and basocellular carcinoma
2. Patients previously treated with chemotherapy
3. Leukaemia following from a documented myelodysplasia with a duration of more than 6 months
4. Blastic crisis of chronic myeloid leukaemia or leukaemia developing from myeloproliferative diseases (e.g. polycythemia vera, myelofibrosis)
5. Renal or liver function abnormalities i.e. creatinine and bilirubin of more than 3 x normal value, except if directly attributable to the leukaemia (high serum lysosymes, hyperuricemia, leukaemic cell infiltration)
6. Human Immunodeficiency Virus (HIV) positive serology
7. Patients with severe cardiac, pulmonary or neurologic disease
8. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-03-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute Myeloid Leukaemia (AML)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Acute Myeloid Leukaemia (AML)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients (except AML-M3 or t[15;17]) will be randomised on entry between:

Arm A:
Cycle I: idarubicin + cytarabin
Cycle II: amsacrin + cytarabin

Arm B:
Cycle I: idarubicin + cytarabin + G-CSF
Cycle II: amsacrin + cytarabin + G-CSF

Patients with AML-M3 or t(15;17) will receive arm A treatment. Patients in Complete Remission (CR) with good risk will proceed to cycle III: Mitoxantrone + VP-16. Patients in CR with poor risk and a HLA matched donor will proceed to Allo BMT. Patients in CR with poor risk without a HLA matched donor will be randomised between cycle III chemotherapy and Busulfan/Cyclophosphamide marrow ablative treatment and PBSCT.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14495-0</funderId>
      <funderId>Funder14495-1</funderId>
      <funderId>Funder14495-2</funderId>
      <funderId>Funder14495-3</funderId>
      <funderId>Funder14495-4</funderId>
      <funderId>Funder14495-5</funderId>
      <contactId>Contact52252_14495</contactId>
      <sponsorId>Sponsor50732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52252_14495">
    <title>Prof</title>
    <forename>B.</forename>
    <surname>Löwenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre
Daniel den Hoed Cancer Centre
Department of Hematology
P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 439 1598</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.lowenberg@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50732">
    <organisation>Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)</organisation>
    <website>http://www.hovon.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Vrije University Medical Centre (VUMC)
PO Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2693</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@hovon.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder14495-0">
    <name>Amgen (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder14495-1">
    <name>Novartis (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004336</fundRef>
  </funder>
  <funder id="Funder14495-2">
    <name>Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14495-3">
    <name>Roche Nederland B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14495-4">
    <name>Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14495-5">
    <name>Johnson &amp; Johnson (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">21565532</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neoadjuvant pre-radical prostatectomy gene therapy (HSV-tk gene transduction followed by Ganciclovir) in patients with poor prognostic indicators</title>
      <scientificTitle/>
      <acronym>Genetherapy 1</acronym>
      <studyHypothesis>This phase I dose-escalating study is designed to analyse the safety and effects of adenovirus-mediated thymidine kinase gene transfection into prostate cells, followed by systemic Ganciclovir treatment in patients with poor risk confined prostate carcinoma. Three weeks after gene therapy, radical prostatectomy will be performed, enabling the evaluation of the histological effects.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To study the safety and toxicity of adenovirus-mediated thymidine kinase gene therapy for the neoadjuvant treatment of prostate cancer. This is established by patient monitoring from day 0 to day 14, during hospitalisation for surgery (day 21 - 28), and subsequently during routine follow-up at weeks 6 and 12, months 6, 9 and 12 and every 6 months thereafter. For this purpose, PSA, blood count, serum hepatic enzumes and creatinine measurements are performed according to routine clinical procedures. A clinical follow-up of one year will be used for safety and toxicity analysis.</primaryOutcome>
      <secondaryOutcome>To study and characterize the biological effects of and the immune response induced by adenovirus-mediated thymidine kinase gene therapy.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21565532</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A300009</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase I, non-randomised, non-controlled, dose-escalating study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-02-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f27fa459-c49c-43d1-acd4-95018d3c89a3">
	  <name>Dept. Urology</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men, 35 - 70 years old
2. Histologically proven adenocarcinoma of the prostate which is clinically localised (including bone scan, not Computed Tomography [CT])
3. Prostate Specific Antigen (PSA) greater than 4 ng/ml
4. Medically fit
5. Scheduled to undergo radical prostatectomy
6. Neutrophils = 2 x 10^9/l, platelets = 100 x 10^9/l, bilirubin less than 40 ng/l, Aspartate Aminotransferase (ASAT) less than 4 x normal, Haemoglobin (Hb) = 6.5 mmol/l, Creatinine less than 150 ng/l, Partial Thromboplastin Time (PTT) and Prothrombin Time (PT)
7. Living within one hour travel distance of the hospital
8. Written consent for gene therapy after appropriate information</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12</totalTarget>
      <exclusion>1. Prior androgen ablation hormonal therapy (except treatment with finasteride if discontinued greater than 3 months prior to inclusion)
2. Prior surgery or other invasive treatment for Benign Prostatic Hyperplasia (BPH) (i.e. Transurethral Resection of the Prostate [TURP], hyperthermia, laser prostatectomy etc.)
3. Patients on corticosteroids
4. Concurrent treatment with immunosuppessive drugs (Imuran, cyclophosphamide etc.)
5. Uncontrolled infections (defined as viral, bacterial of fungal infections requiring specific therapy)
6. Human Immunodeficiency Virus (HIV) positive patients
7. Immunocompromised patients</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-02-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intratumoral gene therapy with adenoviral vector coding for HSV-tk followed by Ganciclovir treatment. Patients are treated with gene therapy three weeks prior to radical prostatectomy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>HSV-tk gene transduction, Ganciclovir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15967266 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="03548a94-d9b2-4825-9761-475c8393258f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15967266"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14350-0</funderId>
      <contactId>Contact52253_14350</contactId>
      <sponsorId>Sponsor50741</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52253_14350">
    <title>Prof</title>
    <forename>C.H.</forename>
    <surname>Bangma</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. Urology
Erasmus MC
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4633607</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.j.vanalphen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50741">
    <organisation>Erasmus Medical Centre (Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Dr Molewaterplein 40/50</address>
      <city>Rotterdam</city>
      <state/>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder14350-0">
    <name>Erasmus Medical Centre (The Netherlands) - Revolving Fund</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">72821021</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Quality management: improvement of patient care in recently diagnosed rheumatoid arthritis</title>
      <scientificTitle/>
      <acronym>CAMERA</acronym>
      <studyHypothesis>It is possible to increase the efficacy of treatment in early Rheumatoid Arthritis (RA)-patients with Methotrexate (MTX) when treatment is intensified according to a strict and intensive, computer-assisted protocol, i.e. the number of patients in remission will increase.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of patients in remission, in which remission is defined as:
1. Number of swollen joints = 0 
2. Plus at least two out of three following criteria:
2.1. Number of swollen joints less than 3
2.2. Erythrocyte Sedimentation Rate (ESR) less than 20 mm/hr 
2.3. Visual Analogue Scale (VAS) general well being less than 20 mm</primaryOutcome>
      <secondaryOutcome>1. Disease activity during 1 year
2. Feasibility of computer assisted program in daily practice</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72821021</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="23fc6dd0-af59-4691-82cf-5c8486a27a0c">
	  <name>UMC Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. RA, defined according to the revised American College of Rheumatology (ACR) criteria for RA
2. A disease duration of less than 1 year, estimated by the rheumatologist
3. Aged greater than 16 years
4. No previous treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs)
5. Written informed consent by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>301</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>301</totalTarget>
      <exclusion>1. Abnormal renal function (Cockroft less than 75 ml/min)
2. Abnormal liver function (Aspartate Aminotransferase [ASAT]/Alanine Aminotransferase [ALAT] greater than 2 x normal), active or recent hepatitis, cirrhosis
3. Major co-morbidities like malignancies, severe diabetic mellitus, severe infections, severe cardio and/or respiratory diseases
4. Leukopenia and/or thrombocytopenia
5. Inadequate birth control conception, pregnancy, and/or breastfeeding
6. Chronic use of oral glucocorticoids
7. Treatment with cytoxic or immunosuppressive drugs within a period of 3 months prior to the study
8. Alcohol intake greater than 2 units per day or drug abuse, presently or in the past
9. Psychiatric or mental disorders which makes adherence to the study protocol impossible
10. Taking part into another clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In this study the efficacy of two treatment strategies will be compared: intensive treatment versus conventional treatment with MTX. In both treatment strategy groups, patients will be treated with MTX. Starting dose MTX in both groups is 7.5 mg/wk.

In the intensive strategy group, based on predefined scores of disease activity with the help of a computer program, MTX will be increased to 15 mg/wk after 6 weeks. Thereafter, MTX is increased, if necessary, every 4 weeks by 5 mg/wk until a maximum dose of 30 mg/wk or until the maximum tolerable dose.

In the conventional treatment group, patients come to the outpatient clinic once every three months. In case of inefficient results of treatment after 3 months, dose MTX is increased until 15 mg/wk. After three months, dose MTX is increased by 5 mg/wk until a maximum of 30 mg/wk or maximum tolerable dose, if necessary. 

In both groups folinic acid (0.5 mg/day) is prescribed to all patients. 

To patients with gastrointestinal side effects or with insufficient efficacy, MTX is given subcutaneously. Treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) is allowed next to study medication. Oral glucocorticoids are not allowed during the trial unless unavoidable which has to be approved then by another rheumatologist. Intra-articular injections should be avoided as much as possible, and if necessary this should be mentioned.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methotrexate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17519278 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="89a257d7-86d3-48b3-af08-4a6a520f6659" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17519278"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14376-0</funderId>
      <contactId>Contact52090_14376</contactId>
      <sponsorId>Sponsor50753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52090_14376">
    <title>Dr</title>
    <forename>A C A</forename>
    <surname>Marijnissen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>UMC Utrecht
Rheumatology &amp; Clin. Immunology, F02.127
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 9758</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.c.a.marijnissen@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50753">
    <organisation>University Medical Centre Utrecht (UMCU) (Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>PO Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder14376-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-10T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2005-11-16T00:00:00.000Z">26422175</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical trial of the effectiveness of a dental caries prevention program for young children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypotheses are that at study completion: 
1. Children of caregivers randomised to the intervention group will have a mean number of decayed, missing or filled tooth surfaces (dmfs) one less than that of children whose caregivers were randomised to the control group
2. The proportion of children of caregivers in the intervention group who are caries free will be 20% more than the proportion of children caries free in the control group</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of decayed missing and filled tooth surfaces 24 months following recruitment.</primaryOutcome>
      <secondaryOutcome>1. Percentage of children without dental caries
2. Parent caries-related knowledge
3. Parent caries-related behaviour
4. Oral health-related impacts/quality of life
5. Child weight
6. Financial costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the McGill Faculty of Medicine Institutional Review Board on the 6th January 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26422175</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-63155</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="712eae6a-155b-4220-be70-eaf75cfd60ff">
	  <name>Faculty of Dentistry</name>
	  <address/>
	  <city>Montreal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3A 2B2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Caregivers (parents) who have a child of five to seven months, either sex (inclusive), with whom they are attending the vaccination clinics of the study community health centre recruitment sites (CLSCs) and who live with that child for 50% or more of the time will be asked to participate
2. The subjects included are parent/infant dyads</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="5.0"/>
      <upperAgeLimit unit="Months" value="7.0"/>
      <gender>Both</gender>
      <targetEnrolment>821</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>821</totalTarget>
      <exclusion>Dyads will be excluded if parents are unable to understand the consent form and self-complete questionnaires for linguistic reasons</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Early childhood caries</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The test intervention is an educational one delivered by dental hygienists to parents of infants when the latter are 6, 12, 18 and 24 months old. Each of the four sessions lasts approximately 15 minutes.

The control group receive no intervention i.e. 'normal care'.

Trial details received: 12 September 2005</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14206-0</funderId>
      <contactId>Contact51921_14206</contactId>
      <sponsorId>Sponsor50352</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51921_14206">
    <title>Dr</title>
    <forename>Paul John</forename>
    <surname>Allison</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Faculty of Dentistry
McGill University
Rm 238D, Strathcona Building
3640, University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 398 7203 (00045)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.allison@mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50352">
    <organisation>McGill University (Canada)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>3640 University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.14709.3b</gridId>
    <rorId>https://ror.org/01pxwe438</rorId>
  </sponsor>
  <funder id="Funder14206-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-63155)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-11-16T00:00:00.000Z">26202234</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Psychological distress in people with head and neck cancer. Those receiving the test intervention will have reduced psychological distress compared to those in the control group. 

To test the effectiveness of the test intervention in reducing symptoms of psychological distress in people with head and neck cancer.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Psychological distress symptoms as indicated by the depression scale of the Hospital Anxiety and Depression Scale (HADS) at 4 months following randomisation.</primaryOutcome>
      <secondaryOutcome>1. Mean HADS anxiety and depression scale scores (measured at 8 weeks, 4, 8 months)
2. Quality of life, measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) Core 30 and Head and Neck (H&amp;N35) module
3. Coping strategies (measured using the Ways of Coping Checklist) 
4. Smoking and alcohol consumption behaviours
5. 2 year post-diagnosis survival
6. Recurrent head and neck cancer incidence
7. New head and neck cancer incidence 
8. Cost per depression averted</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of McGill University, Montreal, Canada on the 25 July 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26202234</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-75475</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e1a11ff7-a6f1-4c18-b8ac-52af7b871fd6">
	  <name>Faculty of Dentistry</name>
	  <address/>
	  <city>Montreal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3A 2B2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Are diagnosed with a primary cancer of the head and neck region (International Statistical Classification of Diseases and Related Health Problems [ICD-9] 140-149 and 161; lip, salivary glands, tongue, floor of mouth, other mouth, oropharynx, nasopharynx, other pharynx and larynx)
2. Age 18 years and older, either sex
3. Were diagnosed 6 - 12 months previously
4. Scored greater than 7 on one or both of the anxiety and depression scales of the Hospital Anxiety and Depression Scale (HADS)
5. Are able to understand and complete either English or French language questionnaires
6. Have signed a consent form</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Are undergoing palliative or terminal care only
2. Have a previous history of malignant disease affecting other parts of their body
3. Have been diagnosed with depression and are currently undergoing any anti-depressive therapy
4. Live beyond 90 minutes traveling time by car/taxi from the site where they are recruited AND are unable or unwilling to travel to the recruitment hospital to receive the intervention as an alternative. This exclusion criterion will be used because a small proportion of patients at these clinics travel considerable distances for treatment and a limit must be made concerning the traveling time necessary for the therapists in the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and neck cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Head and neck</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The test intervention is the 'Nucare program'; a psycho-educational intervention designed to teach cancer patients strategies to help them cope with having their disease. The intervention is a structured training package, delivered by trained therapists during 2-3 one-two hour sessions.
The control intervention is an attention placebo in which individuals are invited to talk with the therapists concerning any problems they have with their cancer and treatment.

Trial details received 12 Sept 2005</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14204-0</funderId>
      <contactId>Contact51920_14204</contactId>
      <sponsorId>Sponsor50352</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51920_14204">
    <title>Dr</title>
    <forename>Paul John</forename>
    <surname>Allison</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Faculty of Dentistry
McGill University
Rm 238D
Strathcona Building
3640, University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 398 7203 (00045)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.allison@mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50352">
    <organisation>McGill University (Canada)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>3640 University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.14709.3b</gridId>
    <rorId>https://ror.org/01pxwe438</rorId>
  </sponsor>
  <funder id="Funder14204-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-75475)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-11-08T00:00:00.000Z">04750658</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised open multicentre trial comparing stavudine versus abacavir, both combined with lamivudine/efavirenz, in Human Immunodeficiency Virus (HIV) infected antiretroviral naïve patients</title>
      <scientificTitle/>
      <acronym>ABCDE study</acronym>
      <studyHypothesis>To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of patients with lipoatrophy as assessed by physician and patient observation at 96 weeks.</primaryOutcome>
      <secondaryOutcome>1. Virological, clinical and immunological efficacy
2. Tolerability</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04750658</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ARV/01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised open multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e736f2b4-db25-49d1-a20c-61c9caac92d9">
	  <name>Infectious Disease Service</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. HIV positive confirmed by Western blot
2. Adult 18 - 70 years
3. No previous antiretroviral therapy
4. HIV-1 Ribonucleic Acid (RNA) greater than 1500 copies/ml (Polymerase Chain Reaction [PCR], Nucleic Acid Sequence Based Amplification [NASBA] or branched-chain Deoxyribonucleic Acid [bDNA]) within 12 weeks prior to study initiation
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>232</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>232 patients (116 per arm)</totalTarget>
      <exclusion>1. Prior antiretroviral therapy
2. Concomitant participation in another clinical trial
3. Signs of hepatic cirrhosis
4. Any of the following laboratory parameter alterations: 
4.1. Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than 5 times above the normal values
4.2. Creatinine clearance less than 50 ml/min
4.3. Amylases greater than 3 times above normal values
4.4. Hemoglobin less than 8 mg/dl
4.5. Neutrophils less than 500/µl
4.6. Platelets less than 30,000/µl
5. Pregnancy
6. Contraindicated drugs
7. Active infection within the last 4 weeks
8. Treatment for neoplasms</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human immunodeficiency virus (HIV) infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human immunodeficiency virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will centrally be stratified according to HIV-1 RNA greater than or less than or equal to 30,000 copies/ml and CD4 counts greater than or less than or equal to 200 cells/µl; and randomised to one of these arms:
1. Abacavir 300 mg twice a day (bid), plus lamivudine 150 mg bid, plus efavirenz 600 mg once a day (qd)
2. Stavudine 30 - 40 mg bid (according to less than or more than 60 kg body weight) plus lamivudine and efavirenz at the same doses as group 1</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Stavudine, abacavir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17106274 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="839bb869-56aa-4276-ab96-c8197a6ee705" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17106274"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14154-0</funderId>
      <contactId>Contact51849_14154</contactId>
      <sponsorId>Sponsor50273</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51849_14154">
    <title>Dr</title>
    <forename>Daniel</forename>
    <surname>Podzamczer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Infectious Disease Service
Hospital Universitari de Bellvitge
c/Feixa Llarga s/n
L'Hospitalet</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dpodzamczer@csub.scs.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50273">
    <organisation>Network of Research on AIDS (Red de Investigacion en SIDA [RIS]) (Spain)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>IDIBAPS
c/Villarroel 170</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08036</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder14154-0">
    <name>Network of Research on AIDS (Red de Investigacion en SIDA [RIS]) (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-31T00:00:00.000Z">16784092</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised placebo-controlled pilot trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acute stroke: the 'Stem cell Trial of recovery EnhanceMent after Stroke' (STEMS) pilot study</title>
      <scientificTitle/>
      <acronym>STEMS</acronym>
      <studyHypothesis>Loss of motor function is common after stroke and often leads to significant long-term disability. Stem cells can be mobilised into the circulation using granulocyte-colony stimulating factor (G-CSF), an approach that has been found to be effective in experimental stroke. We aim to perform a pilot randomised placebo-controlled dose-escalation trial of G-CSF (1 x 10^5 - 3 x 10^6 µ/kg given once or once daily for 5 days, in dosing blocks: 1 dose or 5 doses 1 x 10^5 µkg - 3 x 10^6 µ/kg, with level of 5 dose blocks depending on single dose data) in patients with motor weakness following ischaemic stroke, investigating its safety, feasibility of administration, tolerability, and effects on stem cell mobilisation, impairment, disability and dependency. The interaction between G-CSF and routine rehabilitation will be examined. 

The study will last 24 months with 42 patients recruited over 19 months allowing 3 months follow-up. The results will help inform the design (inclusion criteria, outcomes, size) of further trials including the planning of a large definitive trial assessing the safety and efficacy (motor recovery and functional outcome) of G-CSF.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Circulating CD 34+ (flow cytometry) stem cells - aim greater than 10 x 10^6/l
2. Clinical safety: death, recurrent stroke, deterioration, palpable splenomegaly, at 10 days
3. Laboratory safety: white cell count (WCC, differential), platelet count (PC)</primaryOutcome>
      <secondaryOutcome>Clinical efficacy: 
1. Impairment (SSS)
2. Disability (Barthel Index, [BI])
3. Dependency (mRS)
4. Cognition (Mini Mental State Examination [MMSE])
5. Depression (Zung)
6. Quality of life (EuroQOL)
7. Disposition (home, institution) 

Outcomes measurd at 10 and 90 days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Nottingham Local Research Committee on the 5th June 2003 and had Medicines and Healthcare Products Regulatory Agency Clinical Trial Authorisation on the 10th March 2003).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16784092</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Version  1.3  28/06/04</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised placebo controlled pilot trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d5fb5807-090f-4a76-ac5e-e1a3398e5a0c">
	  <name>University of Nottingham</name>
	  <address/>
	  <city>Nottingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NG5 1PB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinical stroke (lacunar or cortical)
2. 7 - 30 days post-onset
3. Arm and/or leg weakness (Scandinavian Stroke Scale [SSS], arm and/or leg motor power less than 6)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>42</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>42</totalTarget>
      <exclusion>1. Pre-morbid dependency, modified Rankin scale (mRS) greater than 3
2. Primary intracerebral haemorrhage
3. Dementia
4. Coma (SSS consciousness less than 4)
5. Malignancy
6. Sickle cell disease
7. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stroke (ischaemic)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subcutaneous human recombinant G-CSF (filgrastim from Amgen) versus placebo.
G-CSF - 1 x 10^5 - 3 x 10^6 µ/kg given once or once daily for 5 days, in dosing blocks: 1 dose or 5 doses 1 x 10^5 µ/kg - 3 x 10^6 µ/kg, with level of 5 dose blocks depending on single dose data.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17082474 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cb8aafc8-bc27-4237-9cec-1c7c517b389e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17082474"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13426-0</funderId>
      <contactId>Contact51065_13426</contactId>
      <sponsorId>Sponsor49462</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51065_13426">
    <title>Prof</title>
    <forename>Philip</forename>
    <surname>Bath</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Nottingham
Clinical Sciences Building
Nottingham City Hospital Campus</address>
      <city>Nottingham</city>
      <country>United Kingdom</country>
      <zip>NG5 1PB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49462">
    <organisation>University of Nottingham (UK)</organisation>
    <website>http://www.nottingham.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Clinical Sciences Building
Nottingham City Hospital Campus</address>
      <city>Nottingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>NG5 1PB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4563.4</gridId>
    <rorId>https://ror.org/01ee9ar58</rorId>
  </sponsor>
  <funder id="Funder13426-0">
    <name>The Stroke Association (UK) (ref: TSA 01/03)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-27T00:00:00.000Z">78563659</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The disturbance of fat metabolism (utilisation) known as combined hyperlipidaemia (CHL) is very common and affects up to 2% of the population. Patients who suffer from this disorder have a 20% higher risk to develop obstructive disease of the blood vessels of the heart and heart attack.

The patients with CHL have abnormalities of blood lipids (fat) similar to those observed in patients who suffer from another condition known as the 'metabolic syndrome' who are also at higher risk of developing heart disease, stroke and diabetes. One of the features of this metabolic syndrome is a reduced response to the hormone insulin. This hormone helps the tissues of the body (in particular the muscles and the heart) to use sugar. Sugar is very important for the heart since it contributes to generate the energy which is used to sustain its function.

In patients with the metabolic syndrome insulin is less effective and the heart tissue has difficulties in using sugar and develops a condition known as 'insulin resistance'. Previous studies have shown that this condition of insulin resitance can contribute to the higher incidence of heart disease in patients with the metabolic syndrome.

Pioglitazone is a drug licenced in the UK which acts by sensitising the liver and peripheral tissues (including the heart) to the effect of insulin, which results in improved insulin-mediated sugar disposal. Previous studies have demonstrated that pioglitazone lowers sugar and insulin levels in the blood and improves lipid (fat) metabolism (utilisation) in patients with diabetes. We expect similar beneficial effects in patients with familial CHL treated with pioglitazone.

We therefore hypothesise that patients with CHL will have insulin resistance at the heart muscle level as well as an abnormal function of the vessels supplying blood to the heart and that treatment with pioglitazone will improve these

To prove our hypothesis we will use a special scan called Positron Emission Tomography (PET) which permits to measure the utilisation of sugar by the heart in a totally non-invasive fashion. PET is also capable of providing information on the function of the vessels supplying blood to the heart. Patients with familial CHL will be studied by means of PET before and after 4 months of treatment with pioglitazone. In addition, we will assess the effect of the drug on blood lipids (fat).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Whole body glucose uptake
2. Myocardial glucose uptake
3. Basal myocardial blood flow
4. Coronary vasodilator reserve</primaryOutcome>
      <secondaryOutcome>Parameters of lipid and carbohydrate metabolism.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Hammersmith &amp; Queen Charlotte's and Chelsea Hospitals Research Ethics Committee (ref: 2002/6373).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN78563659</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>AD-4833 / EC414</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1e8f586b-d1e1-444a-b1d5-362f5b79f3fe">
	  <name>MRC Clinical Sciences Centre</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W12 0NN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients must be/have:
1. Male or female aged between 30 and 70 years
2. Familial Combined Hyperlipidaemia (CHL) that fits the diagnostic criteria
3. Inadequately controlled with conventional lipid lowering medication, with at least one of
the following:
3.1. Total cholesterol more than 5.0 mmol/l
3.2. Triglyceride more than 1.7 mmol/l
3.3. High Density Lipoprotein (HDL) cholesterol less than 1.0 mmol/l
3.4. Total cholesterol: HDL-cholesterol ratio more than 5.0
4. On stable lipid lowering medication (dose and drug) for the previous two months
5. A Body Mass Index (BMI) of less than or equal to 35 kg/m^2
6. Willing and able to comply with the conditions and requirements of the study
7. Signed and dated an informed consent form and be able to comply with the study procedures</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>26</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>26</totalTarget>
      <exclusion>Patients must not be/have:
1. Had a myocardial infarction, stroke or transient ischaemic attack in the previous six months
2. Had malignant disease in the previous five years (except basal cell carcinoma)
3. Undergoing haemodialysis
4. Any of the following conditions:
4.1. Type one or type two diabetes mellitus
4.2. Chronic uncontrolled asthma
4.3. An inability to tolerate PET scanning
4.4. New York Heart Association (NYHA) class II, III or IV congestive heart failure
4.5. Alcohol or drug abuse
4.6. Significant renal impairment (defined as creatinine more than 135 µmol/l)
4.7. Abnormal liver tests (defined as alanine aminotransferase [ALT] more than 2.5 times the upper limit of the reference range)
4.8. Known Human Immunodeficiency Virus (HIV) infection or viral hepatitis
5. Had treatment with corticosteroids in the previous four weeks (use of topical or inhaled corticosteroids is allowed)
6. Taken another investigational study drug or product within the previous three months
7. Donated and/or received any blood or blood products within the previous three months
8. Female patients who are any of the following:
8.1. Pregnant, planning pregnancy during the study or breast feeding
8.2. Of child-bearing potential and not planning to use a reliable method of contraception throughout the study (e.g. intrauterine device [IUD] or oral contraception)
9. Any other condition or circumstance that in the opinion of the investigator may compromise the patient&#146;s ability to comply with the study protocol</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Familial Combined Hyperlipidaemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hyperlipidaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with pioglitazone versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pioglitazone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18021872 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f2e984bf-73bd-468e-b864-fb61e978eab7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18021872"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13576-0</funderId>
      <contactId>Contact51241_13576</contactId>
      <sponsorId>Sponsor49641</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51241_13576">
    <title>Prof</title>
    <forename>Paolo</forename>
    <surname>Camici</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC Clinical Sciences Centre
Hammersmith Hospital
Du Cane Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W12 0NN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49641">
    <organisation>Takeda Europe R and D Centre (UK)</organisation>
    <website>http://www.tgrd.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Savannah House
11-12 Charles II Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1Y 4QU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.451362.7</gridId>
    <rorId>https://ror.org/05c0v3585</rorId>
  </sponsor>
  <funder id="Funder13576-0">
    <name>Takeda Europe R and D Centre (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-01T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-10-04T00:00:00.000Z">34513421</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Angioplasty with Stent in Symptomatic Intracranial Stenosis Trial-II</title>
      <scientificTitle/>
      <acronym>ASSIST&#150;II</acronym>
      <studyHypothesis>H0: Adjunctive stenting to optimal medical therapy is not superior to optimal medical therapy alone in reducing ipsilateral stroke risk in patients with symptomatic intracranial atherosclerotic stenoses.
H1: Adjunctive stenting to optimal medical therapy is superior to optimal medical therapy alone in reducing ipsilateral stroke risk in patients with symptomatic intracranial atherosclerotic stenoses.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Ipsilateral stroke, fatal or non-fatal, within 12 months
2. Events of clinically-driven emergency revascularization related to the treated stenosis
3. Modified Rankin score in 12 months</primaryOutcome>
      <secondaryOutcome>1. Stroke and death unrelated to the target stenosis
2. Acute myocardial infarction in 12 months
3. Follow up cerebral angiography or magnetic resonance (MR) angiography, CT and CT-perfusion in 6 months
4. NIHSS in 12 months</secondaryOutcome>
      <trialWebsite>http://www.strokecn.com</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34513421</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2004BA714B-7</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3c4773e0-6aca-42d3-9a50-6b89666f9b51">
	  <name>No. 6 Tiantan Xili</name>
	  <address/>
	  <city>Beijing</city>
	  <state/>
	  <country>China</country>
	  <zip>100050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18-75 years of age
2. ≥1 major atherosclerotic risk factors (arterial hypertension, hyperlipidemia, diabetes mellitus, hyperhomocystinemia and smoking)
3. Recurrent ischemic events (transient ischemic attack [TIA] and/or stroke) attributed to an intracranial stenosis ≥50% at digital subtraction angiography (DSA)
4. Evidence of perfusion deficit at the territory referable to the target stenosis in computed tomography (CT)-perfusion
5. The diameters of the parent arteries were between 2.0 to 4.0 mm, and length of stenoses &lt;12 mm
6. Modified Rankin score ≤2 prior to last ischemic event</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="75.0"/>
      <gender>Both</gender>
      <targetEnrolment>399</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>399</totalTarget>
      <exclusion>1. Stenosis of non-atherosclerotic origin (for example, vasculitis, Moya Moya disease and fibromuscular dysplasia)
2. Intracranial hemorrhage and major ischemic stroke (National Institutes of Health-Stroke-Scale [NIHSS] ≥8) in the same hemisphere as the target lesion within 6 weeks
3. A potential source of cardiac embolism
4. Concurrent intracranial tumors, cerebral arteriovenous malformation (AVM) and aneurysms
5. Presence of a neurological illness that can confound the diagnosis of TIA or stroke
6. Known contraindication to aspirin, clopidogrel, probucol, heparin, stainless steel, anesthesia, or X-ray contrast
7. Uncorrectable bleeding diathesis; previous stenting of the target artery
8. A positive pregnancy test
9. Life expectancy &lt;1 year because of other medical conditions
10. Patients were not eligible if they could not cooperate with the study procedures or provide informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ischemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Ischemic stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Stent-assisted angioplasty of the offending intracranial stenosis plus optimal medical therapy versus optimal medical therapy alone</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13375-0</funderId>
      <contactId>Contact51001_13375</contactId>
      <sponsorId>Sponsor49392</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51001_13375">
    <title>Dr</title>
    <forename>Wei-Jian</forename>
    <surname>Jiang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No. 6 Tiantan Xili</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+86 1067050137</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cjr.jiangweijian@vip.163.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49392">
    <organisation>The Ministry of Health of the People's Republic of China</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>No.1 The South Road Of Xizhimenwai</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100044</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">manluzhu@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.419897.a</gridId>
    <rorId>https://ror.org/01mv9t934</rorId>
  </sponsor>
  <funder id="Funder13375-0">
    <name>The Ministry of Health of The People's Republic of China</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-09-26T00:00:00.000Z">97731480</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimal perioperative analgesia in hand surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare two methods of analgesia, optimal perioperative analgesia OPA versus the usual analgesic treatment (UAT), in patients undergoing hand surgery, in terms of postoperative pain control, intensity and duration of the local inflammatory response, impact of pain on function and quality of life.

Trapeziectomy and carpal surgery, bone graph, wrist arthrodesis, distal radial arthrotomy, hand surgery/trauma of hand.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Reducing pain intensity at rest and during active movements measured at 8 months.</primaryOutcome>
      <secondaryOutcome>1. The impact of pain on Quality of Life (QOL)
2. The impact of pain on activities
3. Inflammation
4. Function</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Comité d'éthique de la recherche, CHUM (Centre Hospitalier de l'Université de Montréal) on the 24th March 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97731480</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-65009</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92cdc812-4ace-4899-9b13-c6e9353caac4">
	  <name>Hôpital Notre-Dame du CHUM</name>
	  <address/>
	  <city>Montréal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H2L 4M1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients, either sex, scheduled for trapeziectomy and carpal surgery:
1. Total and partial carpectomy
2. Bone graph
3. Wrist arthrodesis
4. Distal radial arthrotomy</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>220</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>220</totalTarget>
      <exclusion>1. Age under 18 years or older than 75 years
2. Pregnant
3. Allergic to morphine, local anesthetics
4. Suffering from other forms of chronic arthritis or other painful conditions treated chronically (every day) with analgesics (i.e. fibromyalagia)
5. Allergic or intolerant to NSAID (COX2 inhibitors)
6. Consuming anticoagulants which cannot be interrupted
7. Suffering from major cardiovascular problems
8. Suffering from cognitive or psychiatric problems, or drug abuse
9. Other recent hand surgery or axillary surgery with sequels
10. Living alone (no help at home)
11. Unable to understand French or English
12. Without phone access or likely to change address during follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hand surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Hand surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental group: non-steroidal anti-inflammatory drug (NSAID) 1 hour before surgery, 1 daily after surgery.
Both groups (OPA and UAT) will receive the same treatment until their admission in the recovery room.

Trial details received: 12 September 2005</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Non-Steroidal Anti-Inflammatory Drugs (NSAID)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13770-0</funderId>
      <contactId>Contact51467_13770</contactId>
      <sponsorId>Sponsor49866</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51467_13770">
    <title>Dr</title>
    <forename>Gilbert Alfred</forename>
    <surname>Blaise</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hôpital Notre-Dame du CHUM
Laboratoire d'Anesthésie
Porte FS-1136
1560 rue Sherbrooke Est</address>
      <city>Montréal</city>
      <country>Canada</country>
      <zip>H2L 4M1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514-890-8202</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">blaisegil@sympatico.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49866">
    <organisation>University Hospital of Montreal (CHUM) (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Campus Hôtel-Dieu
3840 rue Saint-Urbain</address>
      <city>Montréal</city>
      <country>Canada</country>
      <zip>H2W 4M1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410559.c</gridId>
    <rorId>https://ror.org/0410a8y51</rorId>
  </sponsor>
  <funder id="Funder13770-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-65009)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-26T00:00:00.000Z">64506738</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of NMDA-receptor antagonism on hyperalgesia, opioid use, and pain after major surgery in young and elderly patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Our primary aim is to determine whether perioperative NMDA-receptor antagonism has differential effects on postoperative pain, hyperalgesia and morbidity in younger and older patients. In order to achieve this aim, we propose to conduct the first randomized, double-blind placebo-controlled study designed to investigate age differences in the effects of perioperative oral administration of an NMDA-receptor antagonist (amantadine) in men undergoing radical prostatectomy. In addition, age differences in psychosocial factors and the pharmacological properties of amantadine and morphine will be measured to control for, and clarify, their contribution to the differences found.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Hyperalgesia and opioid consumption.</primaryOutcome>
      <secondaryOutcome>Assess age differences in the intensity and course of secondary hyperalgesia after surgery.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the University Health Network Research Ethics Board, Toronto, Ontario on the 12th November 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64506738</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-52682</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fed3fa8b-2166-4c45-895f-0e6a8bfc9b1c">
	  <name>Department of Anaesthesia</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 2C4</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Able to read and write English
2. Age 18 - 54 years or greater than 55 years, male
3. American Society of Anesthesiologists (ASA) class 1 to 3
4. Scheduled for elective radical prostatectomy
5. Body weight between 60 and 90 kg, Body Mass Index (BMI) less than or equal to 30</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>132</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>132</totalTarget>
      <exclusion>1. Significant Central Nervous System (CNS), respiratory, cardiac, hepatic, renal or endocrine dysfunction and/or any significant sequelae
2. Contraindications allergies to, and/or past adverse reactions to opioid analgesics or amantadine
3. History of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) axis I disorder or cognitive dysfunction
4. History of epilepsy or other seizures
5. History of chronic pain of at least 6 months duration
6. History of long-term opioid use for chronic pain
7. History of long-term use of amantadine or other antiparkinsonian drug
8. Ingestion of antiussive medication within 48 hours before surgery
9. History of alcohol or drug dependency/abuse of at least 6 months duration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative pain in radical prostatectomy</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Postoperative pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Amantadine versus Placebo comparison.

Trial details received: 12 September 2005</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Amantadine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13777-0</funderId>
      <contactId>Contact51474_13777</contactId>
      <sponsorId>Sponsor49873</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51474_13777">
    <title>Dr</title>
    <forename>Lucia</forename>
    <surname>Gagliese</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Anaesthesia
Toronto General Hospital
200 Elizabeth Street</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2C4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 340 4296</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lucia.gagliese@uhn.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49873">
    <organisation>University Health Network, Toronto (Canada)</organisation>
    <website>http://www.uhnresearch.ca </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>200 Elizabeth Street</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2C4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kfibiger@uhnres.utoronto.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.417184.f</gridId>
    <rorId>https://ror.org/026pg9j08</rorId>
  </sponsor>
  <funder id="Funder13777-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-52682)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-15T00:00:00.000Z">00079388</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Routine Screening in the management of Abdominal Aortic Aneurysms (AAA)</title>
      <scientificTitle/>
      <acronym>Management of AAA</acronym>
      <studyHypothesis>To establish prevalence and incidence of AAA in the community. Study effect of screening on mortality from ruptured AAA and on surgical workload and NHS costs.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Prevalence and incidence of AAA in men and women 65 - 80 years of age in community.</primaryOutcome>
      <secondaryOutcome>The effect of AAA screening on mortality from AAA and AAA surgical workload.</secondaryOutcome>
      <trialWebsite>http://www.scottunit.org</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN00079388</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>121/2133 and PA1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1989-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2015-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6c57a391-8c54-47d8-af79-8438d55083ef">
	  <name>Scott Research Unit</name>
	  <address/>
	  <city>Chichester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>PO19 6SE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women aged 65 - 80 years</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>16000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16,000</totalTarget>
      <exclusion>No specific exclusions</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1989-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2015-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Abdominal Aortic Aneurysms (AAA)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Screening for abdominal aortic aneurysm (AAA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>50% randomised to ultrasound screening. Surveillance of patients with detected AAA. All subjects considered for surgical AAA repair if clinical need.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17514666 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="350b2210-4340-454f-87ca-6043f7bbea88" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17514666"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13405-0</funderId>
      <funderId>Funder13405-1</funderId>
      <funderId>Funder13405-2</funderId>
      <contactId>Contact51042_13405</contactId>
      <sponsorId>Sponsor49435</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51042_13405">
    <title>Mr</title>
    <forename>R Alan P</forename>
    <surname>Scott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Scott Research Unit
CMEC
St Richard's Hospital</address>
      <city>Chichester</city>
      <country>United Kingdom</country>
      <zip>PO19 6SE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1243 831503</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">scottunit@rws-tr.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49435">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.dh.gov.uk/en/index.htm</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House 
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)151 794 5900</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dot.lambert@dh.gsi.gov.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.57981.32</gridId>
    <rorId>https://ror.org/03sbpja79</rorId>
  </sponsor>
  <funder id="Funder13405-0">
    <name>Department of Health (UK): 1989 - 1993 (ref: 121/2133)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13405-1">
    <name>DOH NHS R&amp;D Programme for Cardiovascular Disease and Stroke (UK): 1994 - 1999 (ref: PA1)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13405-2">
    <name>Charitable donations and 'own account funding' (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-09-14T00:00:00.000Z">18622460</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of an intervention to treat and prevent depression in older people following hip fracture</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>An intervention will reduce the incidence of depression and improve the symptoms of depression following hip fracture.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Rates of depression.</primaryOutcome>
      <secondaryOutcome>Functional outcome.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18622460</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cf5c58c6-95bc-45b6-a43c-af41c2e5192c">
	  <name>Wythenshawe Hospital</name>
	  <address/>
	  <city>Manchester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>M23 9LT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People over the age of 60 who have fractured their hip.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>People who do not satisfy the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression in orthopaedic patients</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Cognitive behaviour therapy (CBT) for prevention and nurse intervention for treatment versus no intervention</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16863598 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eccdacea-a14f-482c-9921-eef6b731ab11" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16863598"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13467-0</funderId>
      <contactId>Contact51115_13467</contactId>
      <sponsorId>Sponsor49513</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51115_13467">
    <title>Prof</title>
    <forename>Alistair</forename>
    <surname>Burns</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Wythenshawe Hospital
</address>
      <city>Manchester</city>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49513">
    <organisation>University of Manchester (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Wythenshawe Hospital</address>
      <city>Manchester</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5379.8</gridId>
    <rorId>https://ror.org/027m9bs27</rorId>
  </sponsor>
  <funder id="Funder13467-0">
    <name>Health Foundation (UK) (ref: orthopaedic study)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">18282824</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does vitamin D stop inpatients falling? A randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does routine vitamin D and/or calcium supplementation reduce falls in older inpatients?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Proportion of patients who fall
2. Total number of falls in the intervention and control groups</primaryOutcome>
      <secondaryOutcome>1. Compliance in both groups
2. Changes in functional outcomes
3. Changes in nutritional parameters
4. Vitamin D levels and change over time</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18282824</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-09-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="aa2786ff-99c3-4ac0-8d49-290fd8cd7955">
	  <name>Department of Medicine for the Elderly</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G51 4TF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All inpatients &gt;65 years old admitted to a Geriatric rehabilitation unit</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>216</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>216</totalTarget>
      <exclusion>1. Bedbound or terminally ill
2. Known hypercalcaemia

3. Known urolithiasis
4. Renal failure on dialysis
5. ALready on routine calcium and vitamin D supplementation
6. Those patients who are nil by mouth for medical reasons.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-09-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls, musculo-skeletal, nutrition</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Falls</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group: 800 IU cholecalciferol + 1200 mg calcium 
Control group: 1200 mg calcium only</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin D</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17656420 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51167f19-5667-4f2f-afd6-692f8fdd8da1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17656420"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13417-0</funderId>
      <contactId>Contact51058_13417</contactId>
      <sponsorId>Sponsor49453</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51058_13417">
    <title>Dr</title>
    <forename>Elizabeth</forename>
    <surname>Burleigh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medicine for the Elderly
Southern General Hospital</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G51 4TF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 201 1100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">liz.burleigh@sgh.scot.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49453">
    <organisation>South Glasgow Division of Greater Glasgow Health Board (UK)</organisation>
    <website>http://www.nhsgg.org.uk</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Southern General Hospital
1345 Govan Road</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G51 4TF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413301.4</gridId>
    <rorId>https://ror.org/05kdz4d87</rorId>
  </sponsor>
  <funder id="Funder13417-0">
    <name>South Glasgow Division of Greater Glasgow Health Board (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-01T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">83261243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>TREC2 - Rapid tranquillisation for agitated patients in emergency psychiatric rooms in Rio de Janeiro. A randomised trial of intramuscular Haloperidol versus intramuscular Haloperidol + Promethazine.</title>
      <scientificTitle/>
      <acronym>TREC - Rapid Tranquillisation Clinical Trial (Tranquilização Rápida-Ensaio Clínico)</acronym>
      <studyHypothesis>The trial was undertaken to test the risks and benefits of adding promethazine to haloperidol for rapid intramuscular tranquillisation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Tranquil or asleep by 20 minutes after medication is given</primaryOutcome>
      <secondaryOutcome>1. Asleep by 20 minutes
2. Tranquil or asleep by 40, 60 and 120 minutes
3. Physically restrained or given additional medication within 2 hours
4. Severe adverse events during the subsequent 24 hours
5. Another episode of agitation/aggression during the subsequent 24 hours
6. Needing additional visits from the doctor during the subsequent 24 hours
7. Overall antipsychotic load in the first 24 hours
8. Still in hospital after 2 weeks</secondaryOutcome>
      <trialWebsite>http://www.fotolog.net/trec</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83261243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2578e36d-7fbb-4a2c-9abb-704925f44967">
	  <name>INCQS-FIOCRUZ</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21045-900</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People are eligible for trial entry if:
1. It is clear that they need acute intramuscular sedation because of disturbed and dangerous behaviour thought to be due to serious mental illness
2. The clinician is uncertain about the benefits and risks of the comparator 
medications</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>People are not eligible for trial entry if the clinician believes that one treatment represents an additional risk for the patient</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Serious mental illnesses combined with overt aggression or violence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Aggression or violence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Haloperidol (up to 10 mg intramuscular [IM])
2. Haloperidol (up to 10 mg IM) with promethazine (up to 50 mg IM)
Doses are not fixed and are at the discretion of the attending doctors.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Promethazine, haloperidol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17954515 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4d5fe09e-5267-4c76-a8a0-e2c4287467d6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17954515"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13445-0</funderId>
      <funderId>Funder13445-1</funderId>
      <contactId>Contact51091_13445</contactId>
      <sponsorId>Sponsor49489</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51091_13445">
    <title>Dr</title>
    <forename>Gisele</forename>
    <surname>Huf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>INCQS-FIOCRUZ
Av. Brasil 4365 Manguinhos
Cx. Postal: 926 </address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21045-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 3865 5112</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gisele@ensp.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49489">
    <organisation>National School of Public Health (ENSP), Oswaldo Cruz Foundation (FIOCRUZ) (Brazil)</organisation>
    <website>http://www.ensp.fiocruz.br</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Rua Leopoldo Bulhões 4036/816 Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21041-210</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418068.3</gridId>
    <rorId>https://ror.org/04jhswv08</rorId>
  </sponsor>
  <funder id="Funder13445-0">
    <name>The National Council for Research and Development (Consejo Nacional de Desarrollo Cientifico y Tecnologico [CNPq]) (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13445-1">
    <name>Regional Health Authorities (Brazil) - donated drugs</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-12T00:00:00.000Z">97145188</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Patient involvement in prostate cancer treatment decisions</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>How many and which patients want to choose their own radiation dose?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measure is choice acceptance. At the end of the interview, the patient is asked whether he wants to choose one of the two treatment options, or whether he wants to leave the decision to the physician. The response to this question is choice acceptance. Choice acceptance is confirmed by telephone 2 days later. This measure is obtained about 10 days after the first consultation.</primaryOutcome>
      <secondaryOutcome>1. Substitute preferences of physicians 
2. Quality of life measures
3. Decision evaluation measures 
4. Coping measures
5. Knowledge measures 
6. Treatment preferences</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics committee CWOM number 0012-0284. Ethics approval date 16 March 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97145188</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Dutch Cancer Society 2001-2379; NTR63</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d09c575d-28b0-4c73-977d-5dc5aaa0ebbd">
	  <name>Radboud University Nijmegen MC</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with prostate cancer referred for radiotherapy with curative intent are eligible.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Male</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>Labile personality structure, as assessed by the physicians, and lack of understanding of the Dutch language.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control group is usual care (150 patients). Intervention group is usual care plus decision aid (150 patients).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17634489 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51cf5dbf-38a7-438e-bd6b-3ea83ba4e5bd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17634489"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13635-0</funderId>
      <contactId>Contact51311_13635</contactId>
      <sponsorId>Sponsor49712</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51311_13635">
    <title>Dr</title>
    <forename>PFM</forename>
    <surname>Stalmeier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Radboud University Nijmegen MC
MTA 138
PO Box 9101</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 3610592</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.stalmeier@mta.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49712">
    <organisation>Dutch Cancer Society (The Netherlands)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>PO 75508</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1070 AM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5700500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rc@kwfkankerbestrijding.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453041.7</gridId>
    <rorId>https://ror.org/0368jnd28</rorId>
  </sponsor>
  <funder id="Funder13635-0">
    <name>Dutch Cancer Society</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-11T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-09-09T00:00:00.000Z">51767272</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial of empiric broad-spectrum antibiotics and invasive diagnostic techniques in the setting of Ventilator-Associated Pneumonia</title>
      <scientificTitle/>
      <acronym>VAP</acronym>
      <studyHypothesis>To evaluate whether the use of two empiric broad-spectrum antibiotics and invasive diagnostic techniques will improve clinical resolution, decrease length of stay and reduce mortality of critically ill patients with a clinical suspicion of late Ventilator-Associated Pneumonia (VAP).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality at 28 days.</primaryOutcome>
      <secondaryOutcome>1. Duration of stay in ICU
2. Adjudicated diagnosis of pneumonia
3. Clinical and microbiological response to treatment
4. Adequacy of initial treatment
5. Emergence of resistant organisms
6. Candida colonization and infection
7. Multiple organ dysfunction
8. Duration of mechanical ventilation
9. Hospital length of stay
10. Antibiotic use and costs of care</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Queen's University Health Sciences &amp; Affiliated Teaching Hospitals Research Ethics Board on the 12th October 1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN51767272</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-50377</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a33a12b-5351-437a-8080-d9d77af1fc4f">
	  <name>Kingston General Hospital</name>
	  <address/>
	  <city>Kingston</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K7L 2V7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients greater than or equal to 16 years old, either sex
2. Greater than 96 hours in the Intensive Care Unit (ICU)
3. Mechanically ventilated (greater than or equal to 48 hours)
4. Develops a clinical suspicion of pneumonia while ventilated</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>740</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>740</totalTarget>
      <exclusion>1. Unstable candidate for bronchoscopy as defined by the bronchoscopist
2. Patients not expected to survive greater than 72 hours or anticipate withdrawing treatments within 72 hours from the point of randomisation
3. Known or suspected history of anaphylaxis to penicillins, cephalosporins, carbapenems, meropenem or ciprofloxacin
4. Women who are pregnant or lactating
5. Patients already infected or colonised (respiratory tract only) with an organism not sensitive to study drugs
6. Patients already infected with pseudomonas species
7. Already on study drugs
8. Immunocompromised (post-organ transplantation, Human Immunodeficiency Virus [HIV], neutropenic [less than 1000 absolute neutrophils], corticosteroids [greater than 20 mg/day of prednisone or equivalent for more than 6 months])
9. Prior randomisation in this study
10. Enrolment in other interventional study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Clinical suspicion of ventilator associated pneumonia in critically ill patients</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will undergo bronchoscopy with bronchoalveolar lavage or endotracheal aspirates. Following sampling patients will be randomised again to receive either meropenem and ciprofloxacin or meropenem alone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Broad-spectrum antibiotics</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17182987 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7dc4e4fd-e32f-4dfe-aa13-a4e8114f70e0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17182987"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13560-0</funderId>
      <funderId>Funder13560-1</funderId>
      <funderId>Funder13560-2</funderId>
      <funderId>Funder13560-3</funderId>
      <contactId>Contact51227_13560</contactId>
      <sponsorId>Sponsor49629</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51227_13560">
    <title>Dr</title>
    <forename>Daren Keith</forename>
    <surname>Heyland</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kingston General Hospital
76 Stuart St
Angada 4 Rm 5-416</address>
      <city>Kingston</city>
      <country>Canada</country>
      <zip>K7L 2V7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 549 6666 ext. 3339</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dkh2@post.queensu.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49629">
    <organisation>Queen&#146;s University (Canada)</organisation>
    <website>http://www.queensu.ca/homepage/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Fleming Hall 
Jemmett Wing</address>
      <city>Kingston</city>
      <country>Canada</country>
      <zip>K7L 2V7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 533 6081</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marlins@post.queensu.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410356.5</gridId>
    <rorId>https://ror.org/02y72wh86</rorId>
  </sponsor>
  <funder id="Funder13560-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-50377)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13560-1">
    <name>Physician Services Inc. (PSI) (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13560-2">
    <name>Bayer (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13560-3">
    <name>AstraZeneca (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/100004325</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-09-07T00:00:00.000Z">31371499</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dexamethasone adjuvant therapy and intramuscular ceftriaxone in bacterial meningitis amongst adults in an area of high human immunodeficiency virus (HIV) prevalence in Blantyre, Malawi</title>
      <scientificTitle/>
      <acronym>SAM Trial (Steroids in Adult Meningitis)</acronym>
      <studyHypothesis>1. Dexamethasone, by limiting the host inflammatory response in bacterial meningitis, will reduce mortality and morbidity
2. Ceftriaxone is as effective given intramuscularly (IM) as it is when given intravenously (IV) and may therefore be used in rural areas where IV therapy is unavailable</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality at 40 days</primaryOutcome>
      <secondaryOutcome>1. Death or disability at 40 days
2. Clinically apparent hearing loss at 40 days
3. Death at six months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31371499</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P.98/99/30R</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Malawi</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bff7ca7d-e031-4705-9680-bb1b74983e6d">
	  <name>27 Oatlands Rd</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX2 0EU</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All adults admitted to the Queen Elizabeth Central Hospital, Blantyre with a preliminary diagnosis of bacterial meningitis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>420</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>420</totalTarget>
      <exclusion>1. Age less than 16 years
2. Steroids received within the 24 hours preceeding admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bacterial Meningitis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Meningitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dexamethasone 16 mg twice daily for 4 days versus placebo.
Ceftriaxone 2 mg twice daily for ten days given either IV or IM.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dexamethasone, ceftriaxione</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18077809 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0a69ba11-b292-45d1-9cc7-21f438f8f0cf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18077809"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13373-0</funderId>
      <contactId>Contact51000_13373</contactId>
      <sponsorId>Sponsor49391</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51000_13373">
    <title>Dr</title>
    <forename>Matthew</forename>
    <surname>Scarborough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>27 Oatlands Rd</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX2 0EU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mattscar@talktalk.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49391">
    <organisation>College of Medicine Research Committee (Malawi)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Private Bag 360
Chichiri</address>
      <city>Blantyre</city>
      <country>Malawi</country>
      <zip>BT3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10595.38</gridId>
    <rorId>https://ror.org/04vtx5s55</rorId>
  </sponsor>
  <funder id="Funder13373-0">
    <name>Meningitis Research Foundation (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000403</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-11T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-01T00:00:00.000Z">58144540</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Increasing physical activity in obese children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Compared to children with free access to targeted sedentary behaviors, children with contingent access to sedentary behavior will exhibit greater increases in physical activity, larger reductions in sedentary behaviors, and more favorable changes in fitness, body composition, diet, and motivation to be physically active.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Physical activity, measured by pedometer counts.</primaryOutcome>
      <secondaryOutcome>1. Time in sedentary behaviour
2. Aerobic fitness (peak maximal oxygen consumption)
3. Body Mass Index (BMI)
4. Percent body fat (bioelectrical impedance and skinfold measurement)
5. Food intake and macronutrient composition
6. Motivation to be physically active (self-report)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Children's Hospital of Eastern Ontario (CHEO) Research Ethics Board on the 11th June 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58144540</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-53574</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8d774c45-8f27-428a-9f3b-2bc8f37f8cc4">
	  <name>Children's Hospital of Eastern Ontario</name>
	  <address/>
	  <city>Ottawa, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1H 8L1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 8 - 12 year old children, either sex, who are overweight or obese defined as a Body Mass Index (BMI) above the 85th BMI percentile for age and sex (CDC, 2002)
2. Engaging in 15 hours of targeted sedentary behaviour per week, including TV/VCR/DVD use and video game playing
3. Engaging in less than 30 minutes of moderate to vigorous physical activity
4. No conditions that would limit physical activity
5. Agreement that the child or parent would not participate in any other exercise or weight control program during the course of the study
6. No regular participation in swimming or strength training because these activities cannot be measured properly by accelerometry
7. Willingness of the parents to enforce or maintain the contingencies or lack of as reflected by their assigned study group
8. Parent providing signed informed consent, and child providing signed informed assent</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="12.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>Children with developmental disabilities, who are often obese, will be excluded from participating in this initial trial in order to reduce the heterogeneity of the sample.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: Contingent Group - 
The experimental (contingent) group is designed to increase child physical activity levels and decrease time spent in targeted sedentary behaviors by making access to sedentary activity contingent on physical activity. After data from activity monitors are downloaded, participants in the experimental contingent group will be told how much time they earned in each of the following two weeks for TV/VCR viewing and video games played via TV (e.g. Nintendo etc.). Parents will be taught how to program the TV allowance, which is an electronic device that records and helps budget TV/VCR viewing and video game playing. We acknowledge that targeted children may watch TV with parents or friends outside the house, or play computer games on a PC computer, and this will be measured by the concomitant use of self-report measures of sedentary activity. It is important to note that these potential sources of contamination also existed in previous clinical research that reduced access to TV viewing in obese children, and marked increases in physical activity were still obtained. Parents will be asked to implement the contingencies for two weeks beyond 12-week post-treatment to encourage physical activity between weeks 10 and 12, and this fading of contingency management may provide an opportunity for parents to implement their own contingencies. 

Control: Non-Contingent group -
Participants in the non-contingent control group will also visit the laboratory bi-weekly to have their physical activity monitors downloaded. They will also be given a TV allowance for monitoring purposes (and to control for this device in the home), but parents will be explicitly told that children should have free access to targeted sedentary activities independent of physical activity. The control group is designed to control for contact with investigators, feedback on physical activity levels, passage of time, the effects of wearing the activity monitors, and the presence of the TV allowance in the home.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13457-0</funderId>
      <contactId>Contact51100_13457</contactId>
      <sponsorId>Sponsor49503</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51100_13457">
    <title>Dr</title>
    <forename>Gary Scott</forename>
    <surname>Goldfield</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Children's Hospital of Eastern Ontario
Research Institute</address>
      <city>Ottawa, Ontario</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 3288</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ggoldfield@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49503">
    <organisation>Children's Hospital of Eastern Ontario (Canada)</organisation>
    <website>http://www.cheo.on.ca/english/hub.shtml </website>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>401 Smyth Road</address>
      <city>Ottawa, Ontario</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder13457-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-53574)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-08-26T00:00:00.000Z">95608630</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass graft (CABG): a randomized controlled trial</title>
      <scientificTitle/>
      <acronym>CH0401</acronym>
      <studyHypothesis>Strict glucose control in critically ill patients alters the cytokine balance towards a more pro-inflammatory state.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cytokine levels</primaryOutcome>
      <secondaryOutcome>Complement concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95608630</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CH0401</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a303d87-bf2d-4c53-acc0-40eb50d4efe6">
	  <name>Geert Grooteplein 10</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults, after uncomplicated CABG
2. Non-diabetics</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Diabetes
2. Renal failure
3. Use of anti-inflammatory drugs
4. Recent myocardial ischemia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery bypass graft</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery bypass graft</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Strict glucose control (blood glucose between 80-110 mg/dl) versus placebo (blood glucose &gt;200 mg/dl).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Insulin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16356228 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51a225d4-314f-4cdf-b693-784caec8807e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16356228"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13411-0</funderId>
      <contactId>Contact51049_13411</contactId>
      <sponsorId>Sponsor49443</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51049_13411">
    <title>Dr</title>
    <forename>Cornelia</forename>
    <surname>Hoedemaekers</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Geert Grooteplein 10</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.Hoedemaekers@ic.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49443">
    <organisation>Radboud University Nijmegen Medical Centre (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Geert Groteplein 10</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 3617273</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.vanderHoeven@ic.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.10417.33</gridId>
    <rorId>https://ror.org/05wg1m734</rorId>
  </sponsor>
  <funder id="Funder13411-0">
    <name>The Department of Intensive Care, Radboud University Nijmegen Medical Centre</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-08-22T00:00:00.000Z">13438073</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A pragmatic cluster randomised controlled trial of a guideline-based educational outreach intervention to improve quality of adult respiratory care in South African primary care clinics: the PALSA (Practical Approach to Lung Health in South Africa) trial</title>
      <scientificTitle/>
      <acronym>PALSA (Practical Approach to Lung Health in South Africa)</acronym>
      <studyHypothesis>The trial was undertaken to test whether PALSA improves the quality of respiratory care for patients with cough and/or difficult breathing in real world primary care clinics.

Priority respiratory diseases among adults attending primary care services, including tuberculosis (TB), lower and upper respiratory tract infections, obstructive lung disease (asthma and chronic obstructive pulmonary disease), and human immunodeficiency virus (HIV) co-infection.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Sputum testing for tuberculosis
2. Inhaled corticosteroid prescriptions
3. Antibiotic prescriptions
4. Cotrimoxazole prescription among patients with tuberculosis</primaryOutcome>
      <secondaryOutcome>1. TB case detection
2. Mortality
3. Smoking cessation advice received
4. Smoking cessation
5. Readiness to quit smoking
6. Frequency and severity of respiratory symptoms
7. Health-related quality of life (Euroqol)
8. Health care utilisation
9. Cost of care</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 13/08/2007: The study was approved by the research ethics committee of the Faculty of Health Sciences, University of the Free State. The Free State Department of Health gave permission for the trial.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13438073</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-11-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8a9f32b0-320c-4f6c-8527-41d5995c8a11">
	  <name>Institute for Clinical Evaluative Sciences</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M4N 3M5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Forty primary care clinics in a high tuberculosis and HIV burden province of South Africa (Free State). Data will be collected from patients 15 years and older who provide written consent and who present with any one of the following:
1. Difficult breathing on the day of interview or during the last 6 months
2. Current cough for 7 days or more
3. Recurrent cough in the last 6 months
4. Current cough and a temperature in excess of 38°C and/or a respiratory rate of 30 breaths per minute or more</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1999</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 primary care clinics, 1999 patients</totalTarget>
      <exclusion>Patients referred elsewhere urgently by their nurse practitioner will be excluded.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-11-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory diseases</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Cough and/or difficult breathing</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Educational outreach to groups of intervention clinic nurse practitioners, based on a clinical practice guideline on integrated adult respiratory case management and delivered with accompanying support materials.

Prescribing provisions for intervention clinic nurse practitioners will be expanded to include cotrimoxazole prophylaxis for symptomatic HIV infection, inhaled steroids for asthma (with review by a physician within one month) and a short course of oral corticosteroids for exacerbations of obstructive lung disease.

Control clinic nurse practitioners will receive no new training. Usual training, received by both intervention and control groups, includes short off-site training on the use of essential drugs including asthma medications and antibiotics, and the national TB protocol. Due to staff and budget restrictions, fewer than 5% of staff in any year attend these courses.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Inhaled corticosteroids, antibiotics, cotrimoxazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16195293 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0a38b97b-e118-4f95-baca-20858dda4020" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16195293"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13044-0</funderId>
      <funderId>Funder13044-1</funderId>
      <funderId>Funder13044-2</funderId>
      <funderId>Funder13044-3</funderId>
      <contactId>Contact50575_13044</contactId>
      <sponsorId>Sponsor48955</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50575_13044">
    <title>Dr</title>
    <forename>Merrick</forename>
    <surname>Zwarenstein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Clinical Evaluative Sciences
G1 06
2075 Bayview Ave</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M4N 3M5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 4804055 ext. 7439</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">merrick.zwarenstein@ices.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48955">
    <organisation>University of Cape Town Lung Institute (South Africa)</organisation>
    <website>http://www.lunginstitute.co.za/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 34560
Groote Schuur</address>
      <city>Cape Town</city>
      <country>South Africa</country>
      <zip>7937</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7836.a</gridId>
    <rorId>https://ror.org/03p74gp79</rorId>
  </sponsor>
  <funder id="Funder13044-0">
    <name>International Development Research Centre (Canada) (IDRC File No. 101489)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000193</fundRef>
  </funder>
  <funder id="Funder13044-1">
    <name>Free State Department of Health (South Africa)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13044-2">
    <name>Medical Research Council (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
  <funder id="Funder13044-3">
    <name>University of Cape Town Lung Institute (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-08-16T00:00:00.000Z">20244858</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Six-week high-intensity exercise program for middle-aged patients with knee osteoarthritis: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Short-term high-intensity exercise improves self-reported pain, function and quality of life in middle-aged patients with moderate to severe knee osteoarthritis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Knee injury and Osteoarthritis Outcome Score (KOOS, a disease specific questionnaire, assessing pain, other symptoms, activities of daily living, sport and recreation function and knee-related quality of life). Time points of interest were 6 weeks and 6 months.</primaryOutcome>
      <secondaryOutcome>1. 36-item short form health survey (SF-36, a generic measure of general health status)
2. Five tests of functional performance: 
2.1. Åstrands bicycle-ergometre test
2.2. Rising on one leg from sitting on lowest possible height
2.3. One-leg hop
2.4. Lateral step-up
2.5. One-leg semi squatting
2.6. Heel-rising on one leg</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Research Ethics Committee at Lund University (Sweden) (ref: LU 99-98), and is in compliance with the Helsinki Declaration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20244858</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-10-08T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11546ad6-a0af-4630-8d4e-74cb5c56e4e3">
	  <name>Spenshult Hospital for Rheumatic Diseases</name>
	  <address/>
	  <city>Oskarström</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-313 92</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 35 - 65 years
2. Living in a defined geographic area
3. Diagnosis of radiographic knee osteoarthritis according to Kellgren &amp; Lawrence grade III or more (i.e joint space narrowing and definite osteophytes)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>61</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>61</totalTarget>
      <exclusion>1. Inflammatory joint disease
2. Anterior cruciate ligament injury
3. Known symptomatic injury to the menisci
4. Hip symptoms more aggravating than the knee symptoms
5. About to have knee replacement surgery within 6 months
6. Co-morbidities not allowing exercise</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-10-08T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knee osteoarthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A six-week high-intensity supervised exercise session twice a week, or a non-intervention control group.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15924620 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5aeef8f6-d6f5-45a1-9853-1c346b9bcec0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15924620"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13365-0</funderId>
      <funderId>Funder13365-1</funderId>
      <funderId>Funder13365-2</funderId>
      <funderId>Funder13365-3</funderId>
      <funderId>Funder13365-4</funderId>
      <contactId>Contact50988_13365</contactId>
      <sponsorId>Sponsor49380</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50988_13365">
    <title>Dr</title>
    <forename>Ingemar</forename>
    <surname>Petersson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Spenshult Hospital for Rheumatic Diseases</address>
      <city>Oskarström</city>
      <country>Sweden</country>
      <zip>S-313 92</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ingemar.petersson@spenshult.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49380">
    <organisation>The Swedish Rheumatism Association (Sweden)</organisation>
    <website>http://www.reumatikerforbundet.org</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Alströmergatan 39
Box 12851</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>S-112 98</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.bagge@reumatikerforbundet.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.484681.7</gridId>
    <rorId>https://ror.org/00zps9v98</rorId>
  </sponsor>
  <funder id="Funder13365-0">
    <name>The Vårdal Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-1">
    <name>The Swedish Rheumatism Association in Stockholm (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-2">
    <name>The Swedish Rheumatism Association in Gothenburgh (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-3">
    <name>The Swedish Research Council (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-4">
    <name>The Department of Research and Development at Spenshult Hospital for Rheumatic Diseases (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-08-02T00:00:00.000Z">74481308</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Chronic and Acute Effects of Artificial Colourings and Preservatives on Children's Behaviour</title>
      <scientificTitle/>
      <acronym>FABiC - Food And Behaviour in Children</acronym>
      <studyHypothesis>1. Do children show a behavioural response to the withdrawal and introduction of artificial food colourings and preservatives (AFCPs)?
2. What are the characteristics that differentiate responders to AFCPs and non-responders &#150; baseline attention deficit hyperactivity disorder (ADHD) symptom severity and/or their genotype?
3. Can any response that is found in the stage one trial be replicated in a blind acute challenge?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Direct observation of classroom behaviour
2. Parent and teacher ratings of hyperactive behaviour
3. Continuous performance test assessment of sustained attention</primaryOutcome>
      <secondaryOutcome>Sleep</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74481308</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>pwh/ab/16/1/2491</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0ab050b9-3403-4497-be86-58899b98f6e5">
	  <name>School of Psychology</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO17 1BJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Stage 1 - Chronic exposure - 120 three year old children and 120 eight year old children from the general population.
Stage 2 - Acute exposure - 45 eight year old children selected as being responders or non-responders in the Stage 1 challenge.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="8.0"/>
      <gender>Both</gender>
      <targetEnrolment>297</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>153 3 year-olds and 144 8/9 year-olds</totalTarget>
      <exclusion>Those on special diets.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperactivity</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Hyperactivity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A within subject double blind food challenge exposure to two additive mixes and one placebo mix - all children receiving all mixtures in a randomised order</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artificial food colourings and preservatives (AFCPs)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17825405/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0a0bd005-bd8b-4445-bf68-d5212b4d137d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17825405/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13243-0</funderId>
      <contactId>Contact50836_13243</contactId>
      <sponsorId>Sponsor49230</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50836_13243">
    <title>Prof</title>
    <forename>Jim</forename>
    <surname>Stevenson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Psychology
University of Southampton
Highfield</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO17 1BJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8059 2583</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jsteven@soton.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49230">
    <organisation>University of Southampton (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Research Support Office
University of Southampton
Highfield</address>
      <city>Southampton</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>SO17 1BJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8059 8672</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@rso.soton.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5491.9</gridId>
    <rorId>https://ror.org/01ryk1543</rorId>
  </sponsor>
  <funder id="Funder13243-0">
    <name>Food Standards Agency (UK) (Grant T07040)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000354</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-07-22T00:00:00.000Z">07092892</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind study of dexamethasone for the treatment of H5N1 Avian Influenza</title>
      <scientificTitle/>
      <acronym>DL Study</acronym>
      <studyHypothesis>We have started to see new cases of H5N1 infection. Five new cases confirmed in the last week all from different provinces of southern Viet Nam suggesting widespread (and therefore difficult to control) distribution of the virus. We suspect that this epidemic will prove more extensive than 2004. There is more than 80% mortality in the confirmed cases and most severe cases have been in children and teenagers. All patients are managed in a dedicated ward with barrier nursing and medical care. All patients are treated with oseltamivir for five days. Some patients have been given steroids some have not. There is no evidence on which to guide treatment, drugs, doses or duration. We have documented massive cytokine release in the patients from 2004. Our TaqMan real time Polymerase Chain Reaction (PCR) results are available within 24 hours of a sample being taken.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality</primaryOutcome>
      <secondaryOutcome>1. Duration of ventilation
2. Duration of supplemental oxygen
3. Duration of hospitalisation
4. Viral load in clinical specimens
5. Cytokine levels
6. Adverse effects</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07092892</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>061330</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned>No patients with H5N1 in Viet Nam since August 2005, only four patients recruited in total.  Data being analysed.</reasonAbandoned>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Viet Nam</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5910c1d6-1487-4f32-afea-cd2230415b24">
	  <name>Hospital for Tropical Diseases</name>
	  <address/>
	  <city>Ho Chi Minh City</city>
	  <state/>
	  <country>Viet Nam</country>
	  <zip>5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with confirmed TaqMan Influenza A positive, or H5N1 PCR
2. Patients with history of clear close exposure to sick poultry, Chest X-Ray changes consistent with H5N1, low white count and strong clinical suspicion of H5N1 infection</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>4</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>4 - recruitment terminated as not enough patients</totalTarget>
      <exclusion>No consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Avian Influenza</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Avian influenza</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dexamethasone</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13264-0</funderId>
      <contactId>Contact54113_13264</contactId>
      <sponsorId>Sponsor49275</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54113_13264">
    <title>Dr</title>
    <forename>Jeremy</forename>
    <surname>Farrar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital for Tropical Diseases
The Hospital for Tropical Diseases
Oxford University Clinical Research 
190 Ben Ham Tu</address>
      <city>Ho Chi Minh City</city>
      <country>Viet Nam</country>
      <zip>5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+84 8 836 2225</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jeremyjf@hcm.vnn.vn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49275">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Offices
Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2JD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder13264-0">
    <name>The Wellcome Trust (UK) (grant ref: 061330)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-07-22T00:00:00.000Z">83988447</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of intestinal helminth infections in early childhood on immune response, inflammation, anaemia and malnutrition</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To test whether anthelminthic treatment of children six to 36 months of age decreases severe anaemia, decreases wasting malnutrition, and decreases anorexia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Haemoglobin less than 70 g/l
2. Mid upper arm circumference less than -2 Z scores of international reference
3. Maternal report of anorexia</primaryOutcome>
      <secondaryOutcome>1. Weight-for-height less than -1 Z scores of international reference
2. Height-for-age less than -2 Z scores on international reference
3. Inflammation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83988447</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>063122</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9c1b562b-4021-4306-83a4-4c24c39c37f7">
	  <name>Cornell University</name>
	  <address/>
	  <city>Ithaca NY</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>14853</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Six to 24 months of age
2. Informed consent
3. Residing in selected communities based on geographic catchment area</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="24.0"/>
      <gender>Both</gender>
      <targetEnrolment>2500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2500</totalTarget>
      <exclusion>1. Haemoglobin less than 70 g/l
2. Refusal of informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Anaemia, protein-energy malnutrition, anorexia</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2>Anaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blind Randomised Controlled Trial (RCT) of mebendazole versus an identical-looking but inert placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mebendazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder13269-0</funderId>
      <funderId>Funder13269-1</funderId>
      <contactId>Contact50883_13269</contactId>
      <sponsorId>Sponsor49263</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50883_13269">
    <title>Ms</title>
    <forename>Rebecca J</forename>
    <surname>Stoltzfus</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cornell University
Division of Nutritional Sciences
120 Savage Hall</address>
      <city>Ithaca NY</city>
      <country>United States of America</country>
      <zip>14853</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 607 255 7671</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rjs62@cornell.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49263">
    <organisation>Cornell University (USA)</organisation>
    <website>http://www.cornell.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Division of Nutritional Sciences

</address>
      <city>Ithaca, NY</city>
      <country>United States of America</country>
      <zip>14853</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 607 255 2946</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">crf1@cornell.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5386.8</gridId>
    <rorId>https://ror.org/05bnh6r87</rorId>
  </sponsor>
  <funder id="Funder13269-0">
    <name>The Wellcome Trust (UK) (grant ref: 063122)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13269-1">
    <name>Burroughs Wellcome Initiative (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-07-08T00:00:00.000Z">56511757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To find out which prosthetic valves represent the better option for patients requiring AVR.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Post-operative pressure gradient across the prosthetic valve and effective valve orifice area.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56511757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P00715</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7251541a-a6b0-44cf-90e1-8d1569c30331">
	  <name>Surgical Unit</name>
	  <address/>
	  <city>Papworth Everard</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB3 8RE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Inclusion criteria:
1. Patients who require elective AVR with a tissue valve for symptomatic aortic valve stenosis (peak valve gradient equal to or greater than 50 mmHg as measured by echocardiography), with or without concomitant artery bypass grafting
2. Patients = 65 years of age at the time of surgery</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Patients who are already enrolled in another major cardiovascular trial
2. AVR performed primarily for aortic valve regurgitation
3. Active aortic valve infection
4. Active malignant disease
5. Renal failure requiring dialysis
6. Any previous cardiac surgery
7. The need for additional cardiac procedures other than coronary artery bypass grafting
8. Emergency operations
9. Patients unable to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Aortic valve replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Aortic valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards Lifesciences).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17532416/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2f7aaa76-cb37-4b0a-81d6-db8bf41619da" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17532416/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13081-0</funderId>
      <contactId>Contact50617_13081</contactId>
      <sponsorId>Sponsor49000</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50617_13081">
    <title>Mr</title>
    <forename>Steven</forename>
    <surname>Tsui</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Surgical Unit
Papworth Hospital NHS Trust</address>
      <city>Papworth Everard</city>
      <country>United Kingdom</country>
      <zip>CB3 8RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49000">
    <organisation>Papworth Hospital NHS Trust (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Surgical Unit</address>
      <city>Papworth Everard</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>CB3 8RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412939.4</gridId>
    <rorId>https://ror.org/01qbebb31</rorId>
  </sponsor>
  <funder id="Funder13081-0">
    <name>Edwards LifeSciences Ltd (UK) - Industrial grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-12T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-07-05T00:00:00.000Z">94451985</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of perioperative n-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine whether perioperative intravenous (IV) N-acetylcysteine preserves renal function in high-risk patients undergoing Coronary Artery Bypass Graft (CABG) surgery with Cardiopulmonary Bypass (CPB) compared with placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was the proportion of patients developing postoperative renal dysfunction, defined by an increase in serum creatinine level greater than 0.5 mg/dL (44 micromol/L) or a 25% increase from baseline within the first 5 postoperative days.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes included postoperative interventions and complications, the requirement for renal replacement therapy (RRT), adverse events, hospital mortality, and ICU and hospital length of stay.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94451985</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="be571e97-0ba4-44a0-b1ac-ef71156e39f1">
	  <name>375 South Street</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>Canada</country>
	  <zip>N6A 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Elective or urgent coronary artery bypass graft surgery patients with at least one of: pre-esisting renal dysfunction, age greater than or equal to 70, diabetes mellitus, impaired left ventricular function or undergoing concomitant valve or redo surgery.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>295</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>295</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery bypass graft surgery</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery bypass graft surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>We randomized patients to receive four (two intraoperative and two postoperative) doses of intravenous N-acetylcysteine 600 mg or placebo over a 24-hour period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Intravenous N-acetylcysteine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16030279&amp;query_hl=7&amp;itool=pubmed_DocSum Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="26a786fa-fbe4-4e5e-abc7-4cd867fa973c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16030279&amp;query_hl=7&amp;itool=pubmed_DocSum"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13067-0</funderId>
      <funderId>Funder13067-1</funderId>
      <contactId>Contact50600_13067</contactId>
      <sponsorId>Sponsor48983</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50600_13067">
    <title>Dr</title>
    <forename>Karen</forename>
    <surname>Burns</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>375 South Street</address>
      <city>London</city>
      <country>Canada</country>
      <zip>N6A 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48983">
    <organisation>The Physician Services Incorporated Foundation (Canada)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>5160 Yonge Street, Suite 1006</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M2N 6L9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.453633.4</gridId>
    <rorId>https://ror.org/0385yzn06</rorId>
  </sponsor>
  <funder id="Funder13067-0">
    <name>The Physician Services Incorporated Foundation (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13067-1">
    <name>The Lawson Health Research Institute Internal Research Fund (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">35617647</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessing three day pentamidine for early stage human African trypanosomiasis (Angola)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pharmacokinetic studies have shown that pentamidine has a large volume of distribution and elimination occurs over a long period. The objective of the study is to assess the efficacy of 3 days Intramuscular (IM) pentamidine treatment compared to the standard 7 days IM pentamidine treatment regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of cases with favourable progress at 6 months, based on clinical state and laboratory status.</primaryOutcome>
      <secondaryOutcome>1. Proportion of cases with favourable progress at discharge, 3 and 12 months based on clinical state and laboratory status
2. Cure rate at 18 months, based on based on clinical state and laboratory status
3. Frequency and severity of adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. World Health Organization (WHO)/Ethics Review Committee (ERC) on the 4th December 2003
2. Instituto de Combate e Control o Das Triponosommiases (ICCT) (Angola) on the 18th October 2004
3. Wandsworth Local Research Ethics Committee (UK) on the 3rd December 2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35617647</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A30765</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-12-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Angola</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d25038bd-8fb8-4cea-91cc-1701144c27d9">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged more than or equal to 14 years and less than 60 years
2. Parasite positive (on examination of lymph juice, by Capillary Tube Centrifugation [CTC] or miniature Anion-Exchange Centrifugation [mAEC] on whole blood)
3. Alternative diagnoses excluded clinically and by appropriate laboratory investigations
4. Capable of and giving informed consent to the study</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>440</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>The total target was 440 patients, but only 18 were recruited in this site.</totalTarget>
      <exclusion>1. Stage II Human African Trypanosomiasis (HAT): defined as parasites in cerebrospinal fluid (CSF), or having more than or equal to 6 cells/mm^3 in CSF; or more than 100 red cells/mm^3 ("bloody tap")
2. Pregnant
3. Previous HAT
4. Known allergy or reactions to pentamidine
5. Diabetes mellitus
6. Difficulty to comply with follow-up (patients of no fixed abode and refugees, for example)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-12-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human African Trypanosomiasis (HAT)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human African Trypanosomiasis (HAT)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This will be an open, randomised comparison of two pentamidine treatment regimens, given over three days or seven days with a non-inferiority trial design.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pentamidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13006-0</funderId>
      <contactId>Contact50532_13006</contactId>
      <sponsorId>Sponsor48910</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50532_13006">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48910">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder13006-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">48295733</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of rectal artesunate in pregnancy - an assessment of pregnancy outcomes in a randomised controlled trial in Bangladesh</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of the risks associated with the use of artesunate in pregnancy in comparison to placebo. 

This study follows up pregnant women exposed to treatment within a larger trial: ISRCTN83979018 - Evaluate impact of rectal artesunate on resolution of severe malaria and mortality (Bangladesh).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>As this study is a sub-study within a larger trial that has mortality as the main outcome, this should be considered as the same outcome for this trial.</primaryOutcome>
      <secondaryOutcome>1. Proportion of anomalies in live-born, proportion of stillborn and late foetal deaths (artesunate versus placebo)
2. Determination of effect on foetal viability in second and third trimester and inadvertent  exposures in first trimester (artesunate and placebo)
3. Determination of neonatal and maternal mortality (artesunate versus placebo)
4. Assessment of developmental delays (artesunate versus placebo)
5. Determination of proportion of children with low birth weight (artesunate versus placebo) in the subgroup of patients assessed prospectively</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval was obtained on 10.11.03 from the Secretariat Committee on Research Involving Human Subjects and (continuing review) on 19.10 2005 from the World Health Organization (WHO) Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48295733</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A30248</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-11-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Bangladesh</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8ea07507-7b9d-4a50-ab8d-f2b9339a9e7d">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant women
2. Consent of patient or parent/guardian
3. Participation in survival benefit of early treatment with rectal artesunate</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>684</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>684</totalTarget>
      <exclusion>1. Males
2. Non pregnant female enrolled into study ISRCTN83979018
3. Absence of informed consent from patient or parent/guardian</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-11-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Artesunate use in pregnancy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A single dose of either 400 mg artesunate suppository or an identical placebo suppository is given.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12977-0</funderId>
      <funderId>Funder12977-1</funderId>
      <funderId>Funder12977-2</funderId>
      <funderId>Funder12977-3</funderId>
      <funderId>Funder12977-4</funderId>
      <funderId>Funder12977-5</funderId>
      <funderId>Funder12977-6</funderId>
      <funderId>Funder12977-7</funderId>
      <contactId>Contact50500_12977</contactId>
      <sponsorId>Sponsor48878</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50500_12977">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48878">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12977-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-1">
    <name>European Commission (Belgium)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000780</fundRef>
  </funder>
  <funder id="Funder12977-2">
    <name>WHO Global Malaria Programme</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-3">
    <name>US Agency for International Development (USAID) (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-4">
    <name>Irish Aid (Ireland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-5">
    <name>Karolinska Institutet (Sweden)</name>
    <fundRef>http://dx.doi.org/10.13039/501100004047</fundRef>
  </funder>
  <funder id="Funder12977-6">
    <name>Sall Family Foundation (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100007098</fundRef>
  </funder>
  <funder id="Funder12977-7">
    <name>University of Oxford Clinical Trial Service Unit (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="26">
    <isrctn dateAssigned="2005-04-05T00:00:00.000Z">46147225</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III, double-blind, randomised, placebo-controlled trial to evaluate efficacy against radiological pneumonia and invasive pneumococcal disease in Gambian infants</title>
      <scientificTitle/>
      <acronym>PVT</acronym>
      <studyHypothesis>To assess the efficacy of a nine-valent pneumococcal conjugate vaccine in children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>First episode of radiological pneumonia</primaryOutcome>
      <secondaryOutcome>1. Clinical or severe clinical pneumonia
2. Invasive pneumococcal disease
3. All-cause admissions</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46147225</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC096</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase III, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Gambia</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c6ef39be-1461-4359-98eb-1a847a24eb26">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Infants aged at least 6 weeks and less than one year
2. Resident in study area
3. Written informed consent obtained from mother</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Weeks" value="6.0"/>
      <upperAgeLimit unit="Years" value="1.0"/>
      <gender>Both</gender>
      <targetEnrolment>17500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Approx. 17500</totalTarget>
      <exclusion>1. Aged less than 6 weeks or more than 1 year
2. Not resident in study area
3. Planning to move out of study area within 4 months
4. Previous receipt of Diphtheria, Pertussis, Tetanus (DPT)-Haemophilus influenzae type b (Hib) vaccine
5. Uncertain prior vaccination record
6. Serious chronic illness
7. Inclusion in previous vaccine trial
8. Failure of family to give consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pneumococcus/vaccines</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group:
Nine-valent pneumococcal/polysaccharide protein conjugate vaccine which contains 2 µg of type 1, 4, 5, 9V, 14, 19F, 23F polysaccharides, 4 µg of type 6B polysaccharide and 2 µg of type 18 oligosaccharide linked to the diphtheria toxoid protein CRM197, reconstituted with DPT-Hib (Tetramune™) from the same manufacturer

Placebo group:
Lyophilised placebo cake reconstituted with Tetramune™</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15794968 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="dbfa319c-6053-4e08-90e4-135c801573e3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15794968"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12796-0</funderId>
      <funderId>Funder12796-1</funderId>
      <funderId>Funder12796-2</funderId>
      <funderId>Funder12796-3</funderId>
      <funderId>Funder12796-4</funderId>
      <contactId>Contact50264_12796</contactId>
      <sponsorId>Sponsor48635</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50264_12796">
    <title>Dr</title>
    <forename>Felicity</forename>
    <surname>Cutts</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cuttsf@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48635">
    <organisation>National Institute of Allergy and Infectious Diseases - Division of Microbiology and Infectious Diseases (USA)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>6610 Rockledge Drive, Rm 6037</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20892</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 3014022126</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ehorigan@niaid.nih.gov</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.419681.3</gridId>
    <rorId>https://ror.org/043z4tv69</rorId>
  </sponsor>
  <funder id="Funder12796-0">
    <name>National Institutes of Health (NIH) (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100000002</fundRef>
  </funder>
  <funder id="Funder12796-1">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12796-2">
    <name>Bill and Melinda Gates Foundation (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100000865</fundRef>
  </funder>
  <funder id="Funder12796-3">
    <name>United States Agency for International Development (USAID) (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100000200</fundRef>
  </funder>
  <funder id="Funder12796-4">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-04-04T00:00:00.000Z">57684245</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised comparison of out patient psychodynamic versus cognitive behavioural group psychotherapy in patients with somatoform pain</title>
      <scientificTitle/>
      <acronym>MASOPA</acronym>
      <studyHypothesis>Somatoform disorder with pain as a leading complaint (International Statistical Classification of Diseases and Related Health Problems - tenth revision [ICD10]: F45).

The study was designed to compare efficacy of psychodynamic and cognitive behavioural group psychotherapy in patients with somatoform pain. Therefore, a total of 150 patients are randomised to one of either therapies. Both therapies are manualized and supervisioned by video.  Patients living more than one hour driving distance to the university hospital who cannot take part in out patient therapy serve as controls by receiving care as usual.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain intensity and pain disability.  Due to the chronic condition, a one year follow-up will service as the primary outcome.</primaryOutcome>
      <secondaryOutcome>Pain intensity and pain disability.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN57684245</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="373c3d3e-75f5-4381-890f-c62d50ea997d">
	  <name>Untere zahlbacher 8</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-55131</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients were included if they had persistent pain (&gt;6 months) without an adequate physical explanation after a broad multidisciplinary check and if they could understand German.

Patients were referred by their general practitioners or specialists in or outside the university hospital. A total of 150 patients will be randomised to one of either therapies, patients living more than one hour driving distance to the university hospital cannot take part in out patient therapy and will serve as controls by receiving treatment as usual (n = 70). Due to the chronic condition, a one year follow-up will serve as primary outcome. A two year follow-up is intended.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>Age &lt;18 or &gt;65, psychosis, severe substance dependency, missing understanding of German language, and a request to retire because of disease.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Somatoform pain</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Somatoform pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients receive out patient psychotherapy for 6 months. They were randomised into psychodynamic versus cognitive behavioural therapy. Therapy was manualized. Sessions took place twice a week and once a week respectively. The total amount of therapy was 3600 minutes in psychodynamic and 2750-3000 minutes cognitive behavioural therapy. Groups consist of 8-10 patients starting therapy together, they were closed for further participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12881-0</funderId>
      <contactId>Contact50387_12881</contactId>
      <sponsorId>Sponsor48756</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50387_12881">
    <title>Dr</title>
    <forename>Ulrich T</forename>
    <surname>Egle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Untere zahlbacher 8</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>D-55131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6131 177381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">egle@psychosomatik.klinik.uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48756">
    <organisation>German Research Foundation (Deutsche Forschungsgemeinschaft)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Kennedyallee 40</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>D53175</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)228 8851</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmaster@dfg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.424150.6</gridId>
    <rorId>https://ror.org/018mejw64</rorId>
  </sponsor>
  <funder id="Funder12881-0">
    <name>German Research Foundation (Deutsche Forschungsgemeinschaft)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-03-10T00:00:00.000Z">11886401</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of rectal versus oral acetaminophen antipyresis in children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This randomised, double-dummy and placebo controlled study was conducted to compare the antipyretic efficacies of two different rectal doses of acetaminophen: 15 mg/kg and 35 mg/kg to that of a standard oral dose of 15 mg/kg, over a six-hour period, to allow detection of late antipyresis that may occur with rectal acetaminophen. The results of this study will provide further evidence on the comparative antipyretic efficacy of different doses of rectal acetaminophen versus the standard oral one.  

Our study hypothesis was that a single dose of 15 mg/kg oral acetaminophen is more effective than either 15 mg/kg or 35 mg/kg rectal acetaminophen, in reducing the temperature of febrile children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to maximum antipyresis following administration of a single dose of acetaminophen.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes included the temperatures at one, two, three, four, five, and six hours from administration and possible side effects such as hypothermia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Institutional Review Board and the Ethics Committee at the American University of Beirut, as well as the Board of the Middle East Hospital, approved this study.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11886401</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lebanon</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="954d6841-ae3e-4ed7-8f5f-d5670fe29ad7">
	  <name>American University of Beirut Medical Center</name>
	  <address/>
	  <city>Beirut</city>
	  <state/>
	  <country>Lebanon</country>
	  <zip>113-6044/C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 6 months and 13 years
2. Rectal temperature greater than or equal to 38.5 °C
3. Consent of treating physician
4. Written consent of parent and oral consent of child if older than 10 years
5. No antipyretic intake for 8 hours prior to enrolment</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="13.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>1. Presence of concurrent or previous hepatic disease
2. Chronic and/or serious disease such as malignancy, septic shock, malabsorption syndromes etc.
3. Any condition interfering with the absorption of oral or rectal acetaminophen such as vomiting or severe diarrhoea, ileus, rectal bleeding etc.
4. Hypersensitivity to acetaminophen</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fever</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Fever</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: A single dose of oral acetaminophen (15 mg/kg) plus placebo rectal suppository (size equivalent to a 35 mg/kg rectal acetaminophen suppository)
Group 2: A single dose of oral placebo (equivalent to a 15 mg/kg oral acetaminophen) plus a rectal suppository containing 15 mg/kg acetaminophen and 20 mg/kg placebo.
Group 3: A single dose of oral placebo as in group 2 plus a rectal suppository of 35 mg/kg acetaminophen.

Rectal temperature readings at baseline and hourly for a total of 6 hours.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acetaminophen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/16143048 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="20ba54d4-65aa-483a-a73e-58dabd3a5708" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16143048"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12917-0</funderId>
      <contactId>Contact50428_12917</contactId>
      <sponsorId>Sponsor48797</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50428_12917">
    <title>Dr</title>
    <forename>Mona</forename>
    <surname>Nabulsi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>American University of Beirut Medical Center</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>113-6044/C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)3 628528</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mn04@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48797">
    <organisation>American University of Beirut (Lebanon) </organisation>
    <website>http://www.aub.edu.lb/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Medicine, Medical Practice Plan
Riyad El-Solh</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>11-02-36</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)1 350000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">resdean@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22903.3a</gridId>
    <rorId>https://ror.org/04pznsd21</rorId>
  </sponsor>
  <funder id="Funder12917-0">
    <name>American University of Beirut (Lebanon) - Medical Practice Plan of the Faculty of Medicine (grant ref: AUB A/C 686056)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-03-07T00:00:00.000Z">15342873</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Interventions to prevent falls and injury in elderly people with impaired vision</title>
      <scientificTitle/>
      <acronym>VIP Falls Prevention Trial</acronym>
      <studyHypothesis>Study objectives:
1. To demonstrate the efficacy of two interventions:
1.1. A strength and balance retraining programme and vitamin D supplements
1.2. A home safety programme, in preventing falls and injuries in people living in the community aged 75 years and over with visual impairment (visual acuity 6/24 or less)
2. To demonstrate the efficacy of the two programmes in improving independence, level of physical activity and quality of life
3. To determine the cost effectiveness of the two interventions in comparison with other falls prevention strategies
4. To determine the vitamin D status in a sample of people 75 years and over with visual impairment and compare this with an age and sex matched control group drawn from the same general practices at the same time

Summary of study design:
We will assess the effectiveness and cost effectiveness of two falls prevention programmes in a randomised controlled trial with one year of follow up. The two interventions will be individually delivered at home:
1. An exercise programme for one year consisting of a set of leg muscle strengthening and balance retraining exercises and a walking plan, modified for use by visually impaired people and individually prescribed by a physiotherapist. Participants in this intervention arm will also receive vitamin D (Calciferol) supplements.
2. An injury prevention programme of home safety assessment and modification designed specifically for visually impaired people and delivered by an occupational therapist.

We will recruit 400 men and women living in the community and aged 75 years and older with visual acuity of 6/24 metres or less. Potential participants will be recruited from low vision clinics at two city hospitals and one university department and from those registered with the Royal New Zealand Foundation for the Blind. 

The trial has a two by two factorial design. There will be 100 people randomly allocated to each of four groups:
1. The home exercise programme and vitamin D supplements, plus the home safety programme
2. The home exercise programme and vitamin D supplements
3. The home safety programme
4. A control group with no falls prevention intervention who will receive their usual care and health services, plus social visits.  

Falls, injuries and healthcare resource use as a result of falls will be monitored for one year.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Falls and injuries resulting from falls.</primaryOutcome>
      <secondaryOutcome>1. Self perceived health status (36-item short form health survey [SF-36])
2. Fear of falling
3. Physical activity level (human activity profile)
4. Visual disability (VF-14)
5. Mobility and physical independence (Nottingham extended activities of daily living [ADL])
6. Muscle strength and balance (4-test balance scale, chair stand test)
7. Use of health care resources as a result of falls and injuries
8. The incremental costs and cost effectiveness of delivering each intervention (if the intervention is effective in reducing falls)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Otago and Auckland Ethics Committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15342873</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>02/265</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="18d61978-7c48-4647-a552-6eca7d90f9e3">
	  <name>Department of Medical and Surgical Sciences</name>
	  <address/>
	  <city>Dunedin</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>9001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Community living women and men aged 75 years and older
2. Visual acuity 6/24 metres or less</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>391</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>391</totalTarget>
      <exclusion>1. Cannot walk around their own residence
2. Receiving physiotherapy at the time of recruitment
3. Cannot understand the trial requirements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls in elderly people</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Falls</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Home environment programme
2. Home exercise programme
3. Both home environment and exercise programmes
4. Social visits</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16183652 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0348c380-0ea5-4af5-9484-7aecd16eb7f4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16183652"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12913-0</funderId>
      <contactId>Contact50424_12913</contactId>
      <sponsorId>Sponsor48793</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50424_12913">
    <title>Prof</title>
    <forename>A John</forename>
    <surname>Campbell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medical and Surgical Sciences
University of Otago Medical School
PO Box 913</address>
      <city>Dunedin</city>
      <country>New Zealand</country>
      <zip>9001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)3 4747007 ext. 8506</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">john.campbell@stonebow.otago.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48793">
    <organisation>Health Research Council of New Zealand (New Zealand)</organisation>
    <website>http://www.hrc.govt.nz/</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>PO Box 5541
Wellesley Street</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 379 8227</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@hrc.govt.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452999.a</gridId>
    <rorId>https://ror.org/00zbf3d93</rorId>
  </sponsor>
  <funder id="Funder12913-0">
    <name>Health Research Council of New Zealand (New Zealand) (ref: 02/265)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001505</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-02-15T00:00:00.000Z">04176397</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Procalcitonin guided reduction of the duration of antibiotic therapy in Community Acquired Pneumonia</title>
      <scientificTitle/>
      <acronym>ProCAP-Study/ProResp II-Study</acronym>
      <studyHypothesis>In patients with Community Acquired Pneumonia (CAP), guidelines recommend antibiotic treatment for 7 to 21 days. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications. 

Objective: 
To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia. 

Hypothesis:
Procalcitonin guidance could significantly shorten antibiotic duration with a similar clinical and laboratory outcome.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total antibiotic use, recorded on days 4, 6, and 8 and at follow-up after 6 weeks.</primaryOutcome>
      <secondaryOutcome>Measures of laboratory and clinical outcomes, recorded on days 4, 6, and 8 and at follow-up after 6 weeks.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the institutional review board of University Hospital Basel. Written, informed consent was obtained from all included patients or their legal representatives.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04176397</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EKBB 232/03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="67654285-367f-40dc-a8a7-9db706b01ce4">
	  <name>University Hospital</name>
	  <address/>
	  <city>Basel</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>4031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The criterion for inclusion in the study was a suspected CAP as the main diagnosis. This was defined as presence of a new infiltrate on chest X-ray accompanied by one or several acquired respiratory symptoms and signs:
1. Cough
2. Sputum production
3. Dyspnoea
4. Fever over 38.0°C
5. Auscultatory findings of abnormal breath sounds and rales
6. Leukocytosis more than 10 x 10^9 cells/L or leukopenia less than 4 x 10^9 cells/L in the absence of a hospital stay within 14 days before admission</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Cystic fibrosis or active tuberculosis
2. Immunocompromised patients, i.e. patients infected with Human Immunodeficiency Virus (HIV) infection and a CD4 count below 200
3. Neutropenic patients with a neutrophil count less than 500 x 10^9/ml
4. Under chemotherapy with neutrophils 500 - 1000 x 10^9/ml with an expected decrease to values less than 500 x 10^9/ml
5. Immunosuppressive therapy after bone marrow or solid organ transplantation
6. Nosocomial pneumonia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Community Acquired Pneumonia (CAP)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control group: 
Receive antibiotics according to usual practice.

Intervention group:
In the procalcitonin group, antibiotic treatment was based on serum procalcitonin concentrations as follows: 
1. Strongly discouraged: less than 0.1 µg/L
2. Discouraged: less than 0.25 µg/L
3. Encouraged: greater than 0.25 µg/L
4. Strongly encouraged: greater than 0.5 µg/L

Reevaluation of the clinical status and measurement of serum procalcitonin levels was recommended after 6 - 24 hours in all patients from whom antibiotics were withheld. Procalcitonin levels were reassessed after 4, 6, and 8 days. Antibiotics were discontinued on the basis of the procalcitonin cutoffs defined above. In patients with very high procalcitonin values on admission (e.g., greater than 10 µg/L), discontinuation of antibiotics was encouraged if levels decreased to levels less than 10% of the initial value (e.g., 1 µg/L, instead of less than 0.25 µg/L).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16805922
2006 Other publications in https://pubmed.ncbi.nlm.nih.gov/16603606
2007 Other publications in https://pubmed.ncbi.nlm.nih.gov/17702966</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="73351721-ff80-46eb-bfd7-e902f6165828" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16805922"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="a6a9cd0a-28bc-41f6-b367-b5d9f2c464da" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16603606"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="2c3e5b0c-f341-4022-b222-d22bb0eeb7aa" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17702966"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12858-0</funderId>
      <funderId>Funder12858-1</funderId>
      <funderId>Funder12858-2</funderId>
      <funderId>Funder12858-3</funderId>
      <funderId>Funder12858-4</funderId>
      <funderId>Funder12858-5</funderId>
      <funderId>Funder12858-6</funderId>
      <contactId>Contact50348_12858</contactId>
      <sponsorId>Sponsor48718</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50348_12858">
    <title>Prof</title>
    <forename>Beat</forename>
    <surname>Muller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospital
Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)61 265 2525</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Happy.Mueller@unibas.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48718">
    <organisation>University Hospital Basel (Switzerland)</organisation>
    <website>http://www.universitaetsspital-basel.ch/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)61 265 2525</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Happy.Mueller@unibas.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410567.1</gridId>
    <rorId>https://ror.org/04k51q396</rorId>
  </sponsor>
  <funder id="Funder12858-0">
    <name>University Hospital Basel (Switzerland):</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-1">
    <name>1. Clinic of Pulmonary Medicine</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-2">
    <name>2. Clinic of Endocrinology</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-3">
    <name>3. Emergency Unit</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-4">
    <name>4. Department of Internal Medicine</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-5">
    <name>5. Department of Central Laboratories (infrastructure)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-6">
    <name>BRAHMS AG (Germany) - assay material</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-02-14T00:00:00.000Z">01928173</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>British study of Risedronate In Structure and symptoms of Knee osteoarthritis</title>
      <scientificTitle/>
      <acronym>BRISK</acronym>
      <studyHypothesis>To determine the efficacy and safety of risedronate in patients with knee Osteoarthritis (OA). The British study of Risedronate In Structure and symptoms of Knee osteoarthritis (BRISK), a 1-year prospective, double-blind, placebo-controlled study enrolled patients (40 - 80 years) with mild-to-moderate medial compartment knee OA. The primary aims were to detect differences in symptoms and function. Patients were randomised to once-daily risedronate (5 mg or 15 mg) or placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The outcome instrument for assessment of OA symptoms was evaluation of risedronate efficacy on symptoms of OA was the Western Ontario and McMaster Universities (WOMAC) OA index. The visual analogue scale (VAS) of the index was used, in which patients assessed each question using a 100 mm scale, with a higher score representing greater symptom severity. The total index score for the signal knee corresponded to the weighted composite of the 24 question scores standardised to a 100 point scale; scores were also determined for the subscales of pain (five questions), stiffness (two questions) and physical function (17 questions).

The outcome measure for assessment of joint structural changes was mean change from baseline in minimum JSW of the medial compartment of the knee. Radiographs of the knee were taken at baseline and at 1 year using a standardised radiographic method with fluoroscopic positioning of the joint in a semi-flexed position.</primaryOutcome>
      <secondaryOutcome>Other symptom outcome measures included a Patient Global Assessment (PGA) of disease, consumption of pain medication and the use of walking aids. For the PGA, patients answered the following question using a VAS: Considering all the ways your OA affects you, how have you been in the last 48 hours? Results for the question were expressed as values on a 0 - 100 mm scale.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The subjects gave their written, informed consent before entering the study, which was conducted in accordance with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice (GCP) and was approved by the UK Multicentre Research Ethical Committee (MREC).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01928173</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2000024</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d55c88f2-945d-4cb5-835d-a2444fac43a3">
	  <name>Consultant Rheumatologist</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE1 7EH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female subjects aged 40 - 80 years 
2. Mild-to-moderate medial-compartment knee OA
3. Diagnosed according to the clinical and radiological criteria of the American College of Rheumatology
4. OA in at least one knee, designated as the signal knee, was required to meet the following clinical and radiographic criteria.

Clinical inclusion criteria:
1. Presence of daily knee pain for at least 1 month out of 3 months prior to the study
2. At least one of the following: 
2.1. Age greater than 50 years old
2.2. Morning knee stiffness of less than 30 minutes
2.3. Knee crepitus

Radiographic criterion for inclusion:
1. A Joint-Space Width (JSW) of between 2 - 4 mm in the medial tibiofemoral compartment in the semi-flexed Anterior-Posterior (AP) view
2. A requirement for a narrower width than in the lateral compartment of the same knee 
3. Patients were also required to have at least one osteophyte in either the medial or lateral compartments of the tibiofemoral joint</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>285</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>285</totalTarget>
      <exclusion>1. The presence of rheumatic diseases that could be responsible for secondary OA
2. Use of intra-articular hyaluronic acid in the signal knee
3. Knee injury or diagnostic arthroscopy of the signal knee in the 6 months prior to enrolment
4. History of knee surgery (including arthroscopy requiring an incision of internal joint components) in the signal knee at any time
5. Intra-articular corticosteroids in the 3 months preceding enrolment
6. The presence of non-OA causes of knee pain in the signal knee (e.g. anserine bursitis, fibromyalgia and osteonecrosis)
7. Use of bisphosphonates within 12 months prior to enrolment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to:
1. 5 mg of Risedronate
2. 15 mg of Risedronate 
3. Placebo 

Patients were treated once daily for one year.

Knee radiographs were performed at baseline and at one year, urine and serum samples were collected at baseline and at months three, six and twelve and the Western Ontario and McMaster Universities OA Index was also performed.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Risedronate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15899049 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e2395d24-7384-4472-99d7-a5201fe4f602" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-03-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15899049"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12891-0</funderId>
      <contactId>Contact50398_12891</contactId>
      <sponsorId>Sponsor48767</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50398_12891">
    <title>Prof</title>
    <forename>Tim</forename>
    <surname>Spector</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Consultant Rheumatologist
Professor of Genetic Epidemiology
Twin Research &amp; Genetic Epidemiology Unit
St Thomas Hospital</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE1 7EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48767">
    <organisation>Procter and Gamble Pharmaceuticals (USA) </organisation>
    <website>http://www.pgpharma.com/index.shtml</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Mason, Ohio</city>
      <country>United States of America</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418758.7</gridId>
    <rorId>https://ror.org/04dkns738</rorId>
  </sponsor>
  <funder id="Funder12891-0">
    <name>Procter and Gamble Pharmaceuticals (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-02-10T00:00:00.000Z">73387335</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Zinc supplementation during acute childhood diarrhoea: a cluster randomised trial in rural Pakistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesis being tested is that distribution of zinc through existing government and private health care system will reduce incidence of childhood diarrhoea, and antibiotic use by at least 30%. 

The objectives of this trial are:
1. To evaluate if the administration of zinc supplement for 14 days to children with acute diarrhoea will lead to:
1.1. Reduction in use of Oral Rehydration Sachets (ORS) in the community, and 
1.2. Reduction in use of antibiotics and anti-diarrhoeal medications at the community level
2. To document the acceptance of the treatment as well as the adherence to the treatment instructions
3. Reduction in the severity of diarrhoea and improved recovery rates
4. Reduction in rates of hospitalisation and need for intravenous rehydration
5. Reduced child mortality due to diarrhoea</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. ORS use rate
2. Antibiotic use rate
3. Overall drug use rate for diarrhoea
4. Incidence/prevalence of diarrhoea
5. Duration of diarrhoea/episodes in days
6. Duration of  use of ORS, antibiotics and zinc
7. Prevalence /incidence of vomiting
8. Hospitalisation rate for diarrhoea
9. Hospitalisation rate for all causes
10. Total expenditure per household and per episode of diarrhoea</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the World Health Organization (WHO) Ethical Review Committee on the 26th January 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73387335</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/HNI04006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33d76bcb-f97c-448c-ba2d-8a9f8e22eeb8">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children with diarrhoea from 6 to 59 months and 2 to 6 months presenting to any health care facility including both public and private
2. Informed consent</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="2.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>5000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>5000 children (2500 per group)</totalTarget>
      <exclusion>1. Chronic and recurrent diarrhoea
2. Children less then 2 months or above 5 years</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Childhood diarrhoea</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Non-chronic diarrhoea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of 10 to 20 mg elemental zinc daily through oral rehydration versus the existing program of oral rehydration alone in management of acute diarrhoea for 14 days. No placebo is being used in the control clusters.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Zinc supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12885-0</funderId>
      <contactId>Contact50391_12885</contactId>
      <sponsorId>Sponsor48760</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50391_12885">
    <title>Dr</title>
    <forename>Olivier</forename>
    <surname>Fontaine</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 22 791 2894</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">fontaineo@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48760">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12885-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-02-04T00:00:00.000Z">72335887</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting</title>
      <scientificTitle/>
      <acronym>EArly discharge after trans-radial Stenting of coronarY arteries: The EASY study</acronym>
      <studyHypothesis>1. Discharge on the same day after uncomplicated trans-radial coronary artery stenting is safe and effective. 
2. Hospitalized patients can be safely returned to the referring center the same day following trans-radial coronary artery stenting. 
3. Abciximab given as a single bolus with optimal trans-radial coronary artery stenting is as safe and effective as bolus + 12 hrs perfusion and does not hamper early discharge. 
4. Same-day discharge is cost-effective and increases patient satisfaction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary end-point of the study is the composite of death, myocardial infarction, repeat hospitalization, urgent revascularization, severe thrombocytopenia, access site complications and major bleedings at 30 days following stent implantation.</primaryOutcome>
      <secondaryOutcome>The secondary end-point is the composite of death, myocardial infarction, repeat target vessel revascularization at 30 days, 6 months and 1 year following stent implantation. Other secondary end-points include the total hospital stay (days) between the index procedure and the first 30 days follow-up, the number of unsolicited medical visits in relation with the percutaneous procedure, index of patient satisfaction and direct and indirect costs.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72335887</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00169819</clinicalTrialsGovNumber>
      <protocolSerialNumber>H4S-CA-0050</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbb7ded2-8284-4cd1-a6b6-63bae0b2abeb">
	  <name>2725 Chemin Ste Foy</name>
	  <address/>
	  <city>Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>G1V 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Approximately 1000 patients undergoing 'adhoc' percutaneous coronary intervention (PCI) will be randomized.

Inclusion Criteria:
1. Patients with documented ischemic coronary artery disease and scheduled for possible coronary artery stenting are eligible. 
2. Patient must be &gt;18 years of age. 
3. Patient and treating interventional cardiologist agree for randomization. 
4. Patient will be informed of the randomization process and will sign an informed consent. 
5. Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>CLINICAL:
1. Patients with recent (&lt;72 hrs) Q-wave (ST elevation) acute myocardial infarction
2. History of LV ejection fraction ≤30%
3. Unstable clinical condition 
4. Any complication compromising ambulation 
5. Concurrent participation in other investigational study requiring prolonged hospitalization 
6. Required prolonged hospitalization 
7. In&#150;cath lab transient vessel closure 
8. Resuscitation per PCI 
9. Hemodynamic collapse during PCI 
10. Severe entry site complication upon investigator decision 
11. Social isolation 
12. Serious cognitive disorders 
13. Femoral sheath (artery) 
14. Persisting chest pain 
15. No ASA prior PCI 
16. Allergy to ASA or thienopyridines precluding treatment for 30 days 
17. Any significant blood dyscrasia 
18. PCI without stent implantation (except for bifurcation lesion or re-dilatation for in-stent restenosis) 
19. International Normalised Ratio (INR) &gt;2.0 
20. Contraindication to Reopro administration 

ANGIOGRAPHIC:
1. Residual dissection of grade ≥B of NHBLI classification
2. Compromised or sub-occluded branch with diameter ≥ 1 mm 
3. Timi &lt;3 post-stenting 
4. Thrombus post-PCI</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Angina</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Angina</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with stable or unstable angina referred for catheterization and possible percutaneous intervention are eligible.

After diagnostic trans-radial catheterization, patients receive a bolus of Abciximab and undergo dilatation and stent implantation. At the end of the uncomplicated procedure, patients are randomized between group 1: No perfusion of Abciximab and discharge 4-6 hours after PCI and group 2: Standard 12 hours Abciximab perfusion and overnight hospitalization. In case of complications, patients are included in a registry and receive standard 12 hours Abciximab perfusion. Electrocardiogram (ECG) and biology tests (creatine kinase [CK] CK-myocardial band [CK-MB], troponins) are performed before, 4-6 hours after and the next day after PCI. Clinical follow-up is performed at 24 hours, 30 days, 6 months and 1 year after PCI.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Abciximab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17145988 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8fccedc4-86f9-4240-999d-aa15032df1b0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17145988"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12839-0</funderId>
      <contactId>Contact50319_12839</contactId>
      <sponsorId>Sponsor48690</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50319_12839">
    <title>Dr</title>
    <forename>Olivier</forename>
    <surname>Bertrand</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>2725 Chemin Ste Foy</address>
      <city>Quebec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 8711 ext 3136</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olivier.bertrand@crhl.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48690">
    <organisation>Laval Hospital Research Center (Canada)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>2725 Chemin Ste Foy</address>
      <city>Quebec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 8711</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olivier.bertrand@crhl.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder12839-0">
    <name>This Study is an Investigator Initiated Trial, which is supported by unrestricted grants from Eli-Lilly and Bristol-Myers-Squibb (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-01-17T00:00:00.000Z">57616765</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multicenter, randomized, double-blind, placebo-controlled investigation of long-term safety and efficacy of LCAP (leukocytapheresis using "Cellsorba FX") in patients with refractory, chronic active ulcerative colitis</title>
      <scientificTitle/>
      <acronym>MICELL-UC</acronym>
      <studyHypothesis>Study hypothesis added as of 8 June 2007: Assessment of long-term safety and efficacy of leukocytapheresis with Cellsorba FX in comparison to sham-leukocytapheresis for patients with refractory, chronic active ulcerative colitis (CAI 6-10).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measures added as of 8 June 2007: 

The primary efficacy parameter is the 7-item Clinical Activity Index (CAI). A sum score will be calculated summing up all items that are differently weighted. The range of the sum score is 0 to 29 points. A sum score of less than four (or less than or equal to 4) points at the end of the therapy will be assessed as remission or success.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures added as of 8 June 2007: 

1. Inflammatory Bowel Disease Questionnaire (IBDQ), German translation. This questionnaire consists of four domains and 32 items. Domains are simply the sum of specific items, i.e. bowel symptoms, systemic symptoms, emotional functions and social functions.
2. Endoscopic Index (EI), which includes 4 items with different weights. The range of the sum score is 0 to 12 points.
3. Cumulative steroid dose over intensive and maintenance phase.
4. CAI, item-wise analysis.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval information added as of 8 June 2007: 

Approvals of the following ethics committees were obtained on 19 August 2004: 
1. Hannover Medical School (MHH)
2. University (LMU) of Munich
3. University of Erlangen
4. Medical association of Mecklenburg-Western Pomerania (Rostock)
5. University of Munster
6. Charité, University of Berlin
7. Medical association of Rhineland-Palatinate (Mainz)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN57616765</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1.6 - 07/2004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>The trial will be terminated due to unsatisfactory patient enrolment: during the scheduled period of 24 months, less than 50% of patient enrolment has been completed.</reasonAbandoned>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c967e54f-7de2-4002-9719-9b5f04281aa6">
	  <name>Apheresis Research Institute</name>
	  <address/>
	  <city>Cologne</city>
	  <state/>
	  <country>Germany</country>
	  <zip>50935</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ulcerative colitis with chronic active disease state
2. Colitis endoscopically covering at least 15 cm
3. Clinical Activity Index: 6-10
4. No long term remission using combined standard therapy including 5-Aminosalicylate (ASA), prednisolone and/or azathioprine
5. Cumulative steroid dosage within the last 2 months in total at least 600 mg
6. Steroid dosage constant 10 mg per day during 2 weeks before start of treatment (pre-treatment phase)
7. Negative test of pregnancy for female patients
8. Patient is able to understand and sign informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>95</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Planned number of recruitment added as of 8 June 2007: 95 (less than 50% achieved).</totalTarget>
      <exclusion>Exclusion criteria added as of 8 June 2007: 
1. Age &lt; 18 or ≥ 80 years 
2. Effective response to conventional Ulcerative Colitis (UC) therapy 
3. Diagnosis of proctitis or mild UC (usually controlled by aminosalicylates and suppository steroid therapies) 
4. Active symptoms which would exclude the patient from undergoing routine diagnostic colonoscopy i.e. evidence of active bowel obstruction, intestinal perforation, significant GI hemorrhage or known high-grade stricture 
5. Body weight is less than 40 kg 
6. Any malignant disease currently or in history 
7. Renal failure and/ or hepatic failure (Glutamate Oxalate Transferase [GOT], Glutamic-Pyruvic Transaminase [GPT], total billirubin, creatinine &gt; twice the normal value) 
8. Chronic hypotension (80 mmHg or lower systolic) 
9. Therapeutic anticoagulation (Cumarine) or coagulation disorder 
10. Active bacterial or viral infection, especially acute or chronic Hepatitis B or C virus infection, or HIV infection 
11. Severe cardiovascular disease (New York Heart Association [NYHA] III-IV or Canadian Cardiovascular Society [CCS] III-IV), which would not permit any extracorporeal treatment 
12. Breast feeding, pregnancy, drug abuse or dementia 
13. Participation in another clinical study in the last 3 months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Refractory, chronic active ulcerative colitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Ulcerative colitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that this study was terminated on 25 April 2007 due to unsatisfactory patient enrolment. 

Interventions provided at registration:
Extracorporeal leukocytapheresis (LCAP; verum group) versus sham-leukocytaphersis (placebo group)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12783-0</funderId>
      <funderId>Funder12783-1</funderId>
      <contactId>Contact50247_12783</contactId>
      <sponsorId>Sponsor48618</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50247_12783">
    <title>Dr</title>
    <forename>Reinhard</forename>
    <surname>Klingel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Apheresis Research Institute
Stadtwaldgürtel 77</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50935</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49-221-406 317 0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">afi@apheresis-research.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48618">
    <organisation>Asahi Kasei Medical Europe GmbH (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Lyoner strasse 44-48</address>
      <city>Frankfurt</city>
      <country>Germany</country>
      <zip>60528</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.492258.0</gridId>
    <rorId>https://ror.org/040cmp171</rorId>
  </sponsor>
  <funder id="Funder12783-0">
    <name>Source of funding added as of 8 June 2007:</name>
    <fundRef/>
  </funder>
  <funder id="Funder12783-1">
    <name>Asahi Kasei Medical Europe GmbH, Lyoner Strasse 44-48, 60528 Frankfurt (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-01-05T00:00:00.000Z">64013427</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III study of safety, tolerance, efficacy, pharmacokinetics, and costs of therapy with voriconazole or placebo in the prophylaxis of lung infiltrates in patients undergoing induction chemotherapy for acute myelogenous leukaemia</title>
      <scientificTitle/>
      <acronym>Voriconazole prophylaxis</acronym>
      <studyHypothesis>Voriconazole is superior to placebo in the prophylaxis of lung infiltrates until day 21 after start of induction chemotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of lung infiltrates</primaryOutcome>
      <secondaryOutcome>1. Incidence of fever and other signs of infection
2. Incidence and type of documented bacteremia
3. Rate of patients with systemic open-label antifungal therapy
4. Time to initiation of systemic open-label antifungal therapy
5. Duration of absolute neutrophil count &lt;500/µl
6. Rate and type of proven, probable and possible breakthrough invasive fungal infections
7. Rate of patients with fever of unknown origin
8. Incidence and severity of adverse events
9. Trough voriconazole plasma level 
10. Direct costs of systemic antibiotics, antifungals and antivirals and diagnostic imaging
11. Overall costs in terms of the diagnosis related groups applied to the study patients</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64013427</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NRA 150 0009</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>This trial was prematurely terminated on 19 January 2006 due to establishment of a new standard treatment, which made the placebo group of the trial ethically unjustifiable.</reasonAbandoned>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a7edf721-40c1-465a-b9c8-78db8db61d3e">
	  <name>University Hospital of Cologne</name>
	  <address/>
	  <city>Cologne</city>
	  <state/>
	  <country>Germany</country>
	  <zip>50924</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with first induction chemotherapy for acute myelogenous leukaemia (AML):
1. Newly diagnosed or relapsed, de novo or secondary AML
2. First induction chemotherapy cycle
3. Expected neutropenic phase of a minimum duration of 10 days
4. Age greater than 18 years
5. Legally signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Planned: 150 patients, analyzed: 25 patients.</totalTarget>
      <exclusion>1. Known proven, probable or possible invasive fungal infection at randomization or in patient history
2. CT with any signs of a fungal infection according to the EORTC/MSG criteria, i.e. with any infiltrate (Ascioglu, et al 2002)
3. Any current fever unless explained by non-infectious causes 
4. Antibacterial prophylaxis other than TMP/SMX
5. LFT (AST/ALT/bilirubin) more than 3x the upper normal limit
6. Subjects who are receiving and cannot discontinue one of the following drugs at least 24 hours prior to randomization: 
6.1. Drugs with a known possibility of QTc prolongation (e.g. terfenadine, astemizole, cisapride, pimozide, quinidine)
6.2. Drugs whose plasma levels may be increased by voriconazole therapy (e.g. sulphonylureas, ergot alkaloids, sirolimus, vinca alkaloids) 
7. Subjects who have received the following drugs within 14 days prior to randomization: Potent inducers of hepatic enzymes that will reduce voriconazole levels (e.g. rifampicin, carbamazepine and barbiturates)
8. Concomitant therapy with absorbable antifungals
9. Patient has a diagnosis of acute hepatitis or cirrhosis due to any cause
10. Known hypersensitivity or other contraindication to voriconazole
11. Patient unwilling or unable to comply with the protocol
12. Diseases or disabilities preventing the patient from participating in the trial
13. Females of childbearing potential without negative serum pregnancy test at baseline or within 72 hours prior to start of study drug

Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002 Jan 1;34(1):7-14.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Acute Myelogenous Leukaemia (AML)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Voriconazole 200 mg twice a day (bid) orally (po) or placebo

This trial was prematurely terminated on 19 January 2006 due to establishment of a new standard treatment, which made the placebo group of the trial ethically unjustifiable.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Voriconazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12362-0</funderId>
      <contactId>Contact49833_12362</contactId>
      <sponsorId>Sponsor48579</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact49833_12362">
    <title>Dr</title>
    <forename>Oliver</forename>
    <surname>Cornely</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospital of Cologne
Department of Internal Medicine</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 221 478 6209</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">oliver.cornely@uni-koeln.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48579">
    <organisation>University Hospital of Cologne (Germany)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Kerpener Strasse 62</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411097.a</gridId>
    <rorId>https://ror.org/05mxhda18</rorId>
  </sponsor>
  <funder id="Funder12362-0">
    <name>Pfizer GmbH, Karlsruhe (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-11-24T00:00:00.000Z">97670178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of vitamin A deficiency by supplementation alongside routine vaccinations: a randomised controlled trial in Ghana infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The primary objectives of the proposed trial are to:
1. Measure the effect of 400,000 IU of vitamin A given in two divided doses of 200,000 IU to mothers, and 3 doses of 50,000 IU of vitamin A given to their infants concurrently with Diphtheria, Pertussis and Tetanus (DPT)/Polio immunisations, on vitamin A status of the infants at 26 weeks of age
2. Compare the effect of such a regimen to that of the previously recommended regimen of 200,000 IU of vitamin A given to mothers and 3 doses of 25,000 IU of vitamin A given to their infants concurrently with DPT/Polio immunisations
3. Measure the side effects of 50,000 IU of vitamin A administered with DPT/Polio immunisations

The outcomes to be monitored for the above objectives include serum retinol levels, modified Retinol Dose Response (mRDR) tests, incidence of side effects such as bulging of the anterior fontanel and vomiting, and incidence of severe morbidity.

The secondary objectives are to:
4. Measure the effect of the maternal dose on breast milk retinol levels up to 9 months post partum
5. Examine if any impacts on infant vitamin A status are sustained beyond 6 months of age up to 9 months of age

Outcomes to be monitored for the secondary objectives include breast milk retinol concentrations and mRDR testing of infants at 9 months of age.

Related to the main objectives, the following hypotheses will be tested:
1. Giving 400,000 IU of vitamin A to mothers within 6 weeks of delivery, plus 50,000 IU given to their infants with their DPT/Polio immunisations, will improve infants' vitamin A status as measured by mean serum retinol, or by proportions below 20 ug/dl, or proportions of abnormal mRDR at 6 months of age. The proportion of infants with serum retinol concentration below 20 ug/dl will be reduced by 66% from 43%, which was achieved by the 25,000 IU-dosing regimen. Similarly, the proportion of infants with mRDR ratio greater than or equal to 0.06 will be reduced by 66% from 44%, which was achieved by 25,000 IU-dosing regimen.
2. Giving 50,000 IU of vitamin to infants with their DPT/Polio immunisations will produce no clinically significant side effects

The following additional hypotheses will be tested for the secondary objectives:
3. Giving 400,000 IU of vitamin to mothers in the post partum period will result in a greater improvement in breast milk retinol levels than that achieved with 200,000 IU, and that this improvement will be sustained up to 9 months
4. The improvement to infant vitamin A status at 6 months of age, due to the newly proposed supplementation regime, will be sustained beyond 6 months up to 9 months of age</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Serum retinol levels, assessed by carrying out mRDR testing of infants at 6 weeks, 6 months and 9 months
2. Modified Retinol Dose Response (mRDR) tests
3. Incidence of side effects such as bulging of the anterior fontanel and vomiting
4. Incidence of severe morbidity</primaryOutcome>
      <secondaryOutcome>1. Breast milk retinol concentrations, assessed at 6 weeks, 6 months and 9 months for an assessment of the impact of the different supplementation regimes
2. mRDR testing of infants at 9 months of age</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Ethical Review Committee of the Ministry of Health (Ghana) on the 24th September 2001
2. London School of Hygiene and Tropical Medicine Ethics Committee on the 29th April 2002</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97670178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ghana</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f41a5075-0fec-48a5-90b2-377d54cb44b7">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers normally resident in the study area
2. Informed consent obtained from the mother</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1,400 mother-infant pairs.</totalTarget>
      <exclusion>1. Mothers unable to give informed consent
2. Mothers considered to be at high risk of adverse outcome in puerperal period
3. Multiple deliveries
4. Severe adverse reaction to vitamin A supplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin A Deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Nutritional deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1st Group: 
1. Mothers 200,000 IU Vitamin A shortly after delivery
2. Infants: 25,000 IU Vitamin A with each Diphtheria, Pertussis, Tetanus (DPT) vaccine 1, 2 and 3

2nd Group: 
1. Mothers 200,000 IU Vitamin A at infant's Bacillus Calmette-Guerin (BCG) vaccine and another 200,000 IU Vitamin A at infant's 1st DPT
2. Infants: 50,000 IU Vitamin A with each DPT 1, 2 and 3</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12807-0</funderId>
      <contactId>Contact50278_12807</contactId>
      <sponsorId>Sponsor48649</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50278_12807">
    <title>Dr</title>
    <forename>Tracey</forename>
    <surname>Goodman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20, Avenue Appia </address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">goodmant@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48649">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12807-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-27T00:00:00.000Z">17448795</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Hereditary non-polyposis colorectal carcinoma (HNPCC) - a prospective randomized trial for the comparison of prophylactic or extended surgery versus oncological resection in colon or rectum carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17448795</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>70-2993 Oh 1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8920858c-d599-4518-804c-fbb762cee8c0">
	  <name>Klink für Allgemeine und Viszeralchirurgie</name>
	  <address/>
	  <city>Düsseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>40225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Colorectal carcinoma fulfilling the Amsterdam-criteria for HNPCC or
2. Colorectal carcinoma in patients with known pathogenic mismatch repair gene mutation or
3. Colorectal carcinoma at the age of 50 or less and detection of microsatellite instability in a tumor biopsy and
4. Age between 18 and 65 years
5. Operability for subtotal colectomy/(restorative) proctocolectomy as estimated by the surgeon
6. Exclusion of metastases, local resection of the complete tumor likely to be possible
7. Elective tumorsurgical operation
8. Willingness of the patient to participate in surveillance required by the trial
9. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HNPCC-associated colorectal carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subtotal colectomy vs. oncologic resection (restorative proctocolectomy vs rectum resection/extirpation)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder11252-0</funderId>
      <contactId>Contact41695_11252</contactId>
      <sponsorId>Sponsor39440</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41695_11252">
    <title>Prof</title>
    <forename>Gabriela</forename>
    <surname>Möslein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klink für Allgemeine und Viszeralchirurgie
Universitätsklinikum Düsseldorf</address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)211/81-16397</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moeslein@uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39440">
    <organisation>Deutsche Krebshilfe e. V. - German Cancer Aid (Germany) </organisation>
    <website>http://www.krebshilfe.de/startseite-dkh.html</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Thomas-Mann-Strasse 40</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53004</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)228/72990-0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">deutsche@krebshilfe.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453370.6</gridId>
    <rorId>https://ror.org/01wxdd722</rorId>
  </sponsor>
  <funder id="Funder11252-0">
    <name>Deutsche Krebshilfe e. V. (70-2993 Oh 1)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-13T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-09-22T00:00:00.000Z">99307171</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparing Warfarin to Aspirin after tissue valve replacement with Epic prosthesis in the aortic position: multicenter randomised trial</title>
      <scientificTitle/>
      <acronym>WoA Epic</acronym>
      <studyHypothesis>Patients with prosthetic heart valves have a higher risk of developing valve thrombosis and arterial thromboembolism. However, antithrombotic therapy in the early postoperative period after Biological Aortic Valve Replacement (BAVR) is still controversial. Many regimens have been described. Thus, the aim of this study will be to compare the validity of two different regimens of therapy in the early postoperative period after BAVR with St Jude Epic prosthesis, and to evaluate the benefits, particularly in terms of survival and cerebral protection from thromboembolism and major bleeding.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99307171</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="74fee8c1-5a74-486b-bc43-75315adc2071">
	  <name>Via Gramsci 13</name>
	  <address/>
	  <city>Parma</city>
	  <state/>
	  <country>Italy</country>
	  <zip>43100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>This is a prospective randomised multicenter trial using patients who will be consecutively admitted to Cardiac Surgery Units. All patients undergoing Biological Aortic Valve Replacement (BAVR) with a St Jude Epic prosthesis and in sinus rhythm before the operation will be considered to participate to the study. The patients, after the operation, will be randomised to each group immediately before starting the specific aspirin (Acetylsalicylic Acid [ASA]) or warfarin therapy.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>The patients with the following characteristics will be excluded: 
1. History of cerebral ischaemia
2. Coagulopathy
3. Carotid atherosclerotic disease (stenosis greater than 50%, soft and ulcerated plaque)
4. Peripheral vascular disease
5. Concomitant mitral valve disease
6. Double valve replacement
7. Previous chronic anticoagulation therapy
8. Allergies to ASA or warfarin
9. Comparison of atrial fibrillation (AF) at any time during the study except for transient episode during the hospitalisation
10. Promptly cardioverted</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Biological Aortic Valve Replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will receive a specific regimen of therapy according to the result of randomisation. The administration of Low Molecular Weight Heparin (LMWH) will start on the first postoperative day, whereas warfarin and ASA on day 2. In patients receiving warfarin the use of LMWH will be continued until warfarin reached therapeutic levels as shown by a Prothrombin Time (PT) according to the International Normalised Ratio (INR; range 2.0 to 3.0). Anticoagulation with warfarin will be maintained for 3 postoperative months, then will be discontinued and substituted with ASA. Those with concomitant coronary artery bypass grafting will not receive any double therapy warfarin plus ASA.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Warfarin and aspirin (Acetylsalicylic Acid [ASA])</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Abstract results in https://pubmed.ncbi.nlm.nih.gov/15289387 PubMed Abstract:
2004 Other publications in http://circ.ahajournals.org/cgi/content/full/110/5/496 Full text:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="12e74191-c806-4388-b388-7c27918a0dd8" outputType="abstract" artefactType="ExternalLink" dateCreated="2004-08-03T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15289387"/>
	<description>PubMed Abstract:</description>
	<productionNotes/>
      </output>
      <output id="294b82ae-95e3-40a4-86de-b64772c4d5ee" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-08-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://circ.ahajournals.org/cgi/content/full/110/5/496"/>
	<description>Full text:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12360-0</funderId>
      <funderId>Funder12360-1</funderId>
      <contactId>Contact44833_12360</contactId>
      <sponsorId>Sponsor42579</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact44833_12360">
    <title>Dr</title>
    <forename>Andrea</forename>
    <surname>Colli</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Via Gramsci 13</address>
      <city>Parma</city>
      <country>Italy</country>
      <zip>43100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 349 5928935</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">colli.andrea@libero.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor42579">
    <organisation>University of Parma (Italy)</organisation>
    <website>http://www.unipr.it/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Cardiac Surgery Unit
Via Gramsci 13</address>
      <city>Parma</city>
      <country>Italy</country>
      <zip>43100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 349 5928935</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">colli.andrea@libero.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.10383.39</gridId>
    <rorId>https://ror.org/02k7wn190</rorId>
  </sponsor>
  <funder id="Funder12360-0">
    <name>Company of Saint Paul (Compagnia di S Paolo) (Italy)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12360-1">
    <name>Ministry for Universities and of Scientific and Technological Research (Ministero dell&#146;Università e della Ricerca Scientifica e Tecnologica [MURST]) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-22T00:00:00.000Z">83465214</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of vitamin A deficiency by supplementation alongside routine vaccinations: a randomised controlled trial in Tanzanian infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The primary objectives of the trial are to:
1. Measure the effect of 400,000 IU of vitamin A given in two divided doses of 200,000 to mothers, and 3 doses of 50,000 IU of vitamin A given to their infants concurrently with Diphtheria, Pertussis and Tetanus (DPT)/Polio immunisations, on vitamin A status of the infants at 26 weeks of age
2. Compare the effect of such a regimen to that of the previously recommended regimen of 200,000 IU of vitamin A given to mothers and 3 doses of 25,000 IU of vitamin A given to their infants concurrently with DPT/Polio immunisations
3. Measure the short-term side effects of each of the two doses of 200,000 IU given to mothers, and of the 50,000 IU of vitamin A administered with each of the three DPT/Polio immunisations

The secondary objectives are to:
1. Measure the relative effect of the two different maternal dosing regimens on the breast milk retinol concentration up to at 6 and 9 months post partum
2. Measure the effect of the maternal doses of vitamin A on the relative incidence of short-term side effects in the mother over the 48-hour period after the first and second 200,000 IU maternal doses of vitamin A
3. Measure the effect of the maternal doses of vitamin A on the breast milk retinoic acid concentration 3 hours after the first and second 200,000 IU maternal doses of vitamin A
4. Examine if any relative impacts on vitamin A status are sustained at 9 months of age

Related to the main objectives, the following hypotheses will be tested:
HYPOTHESIS 1: Giving 400,000 IU of vitamin A to mothers within 6 weeks of delivery, plus 50,000 IU given to their infants with their DPT/Polio immunisations, will improve infants' vitamin A status to a significantly greater degree than giving 200,000 IU of vitamin A within 6 weeks of delivery, plus 25,000 IU given to their infants with each of their three DPT/Polio immunisations. This will be measured by mean serum retinol concentration, or by proportions below 20ug/dl, or proportions with abnormal modified Retinol Dose Response (mRDR) at 6 months of age. The proportion of infants with serum retinol concentration below 20ug/dl at 6 months of age will be approximately 37% in the comparison group infants and 27% or less in the group of infants allocated to receive the higher dose regimen.
HYPOTHESIS 2: Giving 50,000 IU of vitamin A to infants with their DPT/Polio immunisations will produce no significant increase in the incidence of short-term side effects, relative to 25,000IU.

The outcomes to be monitored for the above objectives include serum retinol concentrations, mRDR tests, and incidence of side effects such as bulging of anterior fontanelle and vomiting, and incidence of severe morbidity.

HYPOTHESIS 3: Giving 400,000 IU of vitamin A to mothers in the post partum period will result in a greater improvement in breast milk retinol concentrations at 6 months post partum than that achieved with 200,000IU, and that this improvement will be sustained up to 9 months.
HYPOTHESIS 4: Giving a second 200,000 IU dose of vitamin A to mothers in the post partum period will result in no significant increase in the incidence of short-term side effects, relative to no second dose.
HYPOTHESIS 5: Giving a second 200,000IU dose of vitamin A to mothers in the post partum period will result in no significant increase in the prevalence of potentially toxic breast milk retinoic acid concentrations 3 hours after the second maternal dose, relative to no second dose.
HYPOTHESIS 6: At 9 months of age, the vitamin A status of infants who were allocated to receive the higher dose regimen will be significantly better than the status of infants who were allocated to receive the lower dose regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Prevalence of Vitamin A Deficiency (VAD) (any: less than 20 mg/dL and severe: less than 10 mg/dL) at  6 months of age
2. Incidence of each of the following: 
2.1. Bulging fontanelle
2.2. Temperature greater than 37.5°C
2.3. Vomiting
2.4. Diarrhoea 
2.5. Inability to suck/feed during the two days following each vitamin A supplementation</primaryOutcome>
      <secondaryOutcome>1. Mean serum retinol concentration at 6 months of age 
2. Prevalence of VAD (any and severe) at 9 months of age 
3. Mean retinol concentration at 9 months of age</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Research Ethics Committees (REC) of: 
1. National Institute for Medical Research, Ministry of Health (Tanzania) on the 1st October 2001
2. Second year of trial approved by the London School of Hygiene and Tropical Medicine on the 5th August 2003
3. World Health Organization (WHO) Secretariat Committee on Research Involving Human Subjects (SCRIHS) - conditional approval on 11th April 2003, amendments approved on 8th October 2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83465214</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/RPC005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="51d988c1-993f-41ff-acc6-2780e7f7e3f7">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers normally resident in the study area
2. Informed consent obtained from the mother</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>770</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>770 infants</totalTarget>
      <exclusion>1. Mothers unable to give informed consent
2. Mothers considered to be at high risk of adverse outcome in puerperal period
3. Multiple deliveries
4. Severe adverse reaction to vitamin A supplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin A deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin A deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1st Group: 
1. Mothers 200,000 IU Vitamin A shortly after delivery
2. Infants: 25,000 IU Vitamin A with each Diphtheria, Pertussis, Tetanus (DPT) vaccine 1, 2 and 3

2nd Group: 
1. Mothers 200,000 IU Vitamin A at infant's Bacillus Calmette-Guerin (BCG) vaccine and another 200,000 IU Vitamin A at infant's 1st DPT
2. Infants: 50,000 IU Vitamin A with each DPT 1, 2 and 3

Time Frame: 
Recruitment should start in December 2001 and is expected to last for approximately 9 months. Hence the data required to address the primary endpoint will be available 15 months after the start of recruitment. Data required to address the secondary endpoints will be available 21 months after the start of recruitment. Assuming that the WHO-appointed micronutrient laboratory will be able to report the results of vitamin A-related analyses within six weeks of the completion of specimen collection, all laboratory and statistical analyses will be completed within 4 months of finishing field activities.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder11309-0</funderId>
      <contactId>Contact41760_11309</contactId>
      <sponsorId>Sponsor39505</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41760_11309">
    <title>Dr</title>
    <forename>Tracey</forename>
    <surname>Goodman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">goodmant@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39505">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder11309-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-11T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2004-07-28T00:00:00.000Z">12666644</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of Metered Dose Inhaler (MDI) with attached Bottle spacer for bronchodilator therapy in infants and young children with acute lower airways obstruction (South Africa)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the response to bronchodilator administered via a Metered Dose Inhaler (MDI) with bottle spacer compared to a MDI with conventional spacer in young children presenting to a health care facility with acute lower airways obstruction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The need for hospitalisation: this outcome has been chosen as this is clinically important and can be reliably measured. Differences between the two treatment groups for this primary outcome as a result of bias should be minimised by use of random allocation of treatment group with adequate allocation concealment and adequate blinding of the investigators deciding on hospitalisation.</primaryOutcome>
      <secondaryOutcome>1. Change in clinical score, measured as the difference between the clinical score at presentation to the clinical score recorded after the final bronchodilator treatment prior to discharge or hospitalisation
2. Change in oximetry, measured as the difference between oximetry recorded at presentation the room air to that recorded after the final bronchodilator treatment prior to discharge or hospitalisation
3. Number of bronchodilator treatments required prior to discharge (if not hospitalised). A bronchodilator treatment will be regarded as 5 puffs of salbutamol or a nebulisation
4. Need for systemic corticosteroids. Systemic steroids will be indicated for children with recurrent wheeze who require hospitalisation or who have required two or more bronchodilator treatments</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. University of Cape Town Research and Ethics Committee, University of Cape Town 
2. World Health Organization (WHO) Ethical Review Committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12666644</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/CAH ID 02002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2a1efb57-83ab-4d11-b498-396a1ed14b8b">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 3 months to 5 years
2. Able to use MDI - spacer as assessed by the researcher administering inhaled treatment
3. Acute episode of lower airway obstruction (wheezing or hyperinflation)
4. Informed consent of parent/guardian</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>396</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>396 children</totalTarget>
      <exclusion>1. Use of bronchodilator within the preceeding 4 hours
2. Known underlying cardiac or chronic pulmonary disease (other than asthma)
3. Presence of stridor or daily treatment with oral corticosteroids for more than 2 days prior</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute lower airways obstruction</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Acute lower airways obstruction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is an equivalence study.  Equivalence will be regarded as not more than an absolute 10% increase in hospitalisation with the bottle spacer. Assuming that hospitalisation with the conventional spacer will occur in 20% of children and that the spacers are equally effective, 198 children will be required in each group (total sample of 396 children) to demonstrate that hospitalisation with the bottle spacer is not more than 10% higher, with 80% power and a one-tailed a of 0.0505 i.e. given the above assumptions, the upper 90% confidence limit for a difference favouring the conventional spacer will be less than 10%.

Three different delivery systems will be compared:
1. Conventional spacer with MDI - a small volume (150 ml) valved spacer with an attached mask for children less than 3 years, and a mouthpiece for those 3 - 5 years
2. Modified 500 ml plastic bottle with MDI with attached mask for children less than 3 years
3. Jet nebuliser with attached mask or mouthpiece depending upon child's age</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/16905564 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1a72bd35-b4d6-41c3-838d-934befe108f1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16905564"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11300-0</funderId>
      <contactId>Contact41751_11300</contactId>
      <sponsorId>Sponsor39496</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41751_11300">
    <title>Dr</title>
    <forename>Shamim</forename>
    <surname>Qazi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39496">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder11300-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-11T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2004-07-28T00:00:00.000Z">32365107</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment and management of children aged 1 - 59 months presenting with wheeze and fast breathing: multicenter study in Pakistan and Thailand</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Using current World Health Organization (WHO) guidelines, children with wheezing are being over-prescribed antibiotics and bronchodilators are under utilised. To improve the WHO case management guidelines, more data is needed about the clinical outcome in children with wheezing/pneumonia overlap.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportions of children aged 1 - 59 months with auscultatory wheeze and fast breathing or lower chest indrawing:
1. Respond to up to three cycles of inhaled salbutamol: response defined as no fast breathing or lower chest indrawing present
2. Fail therapy at day 3 or days 5 - 7 of the initial successful bronchodilator therapy with inhaled salbutamol? Therapy failure defined as:
2.1. Relapse: develop fast breathing or chest indrawing afresh, that does not respond to three cycles of inhaled salbutamol
2.2. Development of any danger sign (except wheezing and fever in young infant)
2.3. Death 
2.4. Severe adverse reaction to salbutamol</primaryOutcome>
      <secondaryOutcome>In children aged 1 - 59 months with auscultatory wheeze and fast breathing or lower chest indrawing:
1. Proportion with audible wheeze at initial assessment
2. Proportion of responders to up to three cycles of inhaled salbutamol associated with:
2.1. Age 
2.2. Respiratory Syncytial Virus (RSV) isolation
2.3. Season
2.4. Number of previous wheezing episodes
2.5. Audible versus auscultatory wheeze
2.6. Family history of asthma
3. Proportion of relapses in children who showed initial improvement associated with:
3.1. Age 
3.2. RSV isolation
3.3. Season
3.4. Number of previous wheezing episodes
3.5. Audible versus auscultatory wheeze
3.6. Family history of asthma
4. Received any antibiotic for this or any concurrent illness before follow-up
5. Loss to follow-up
6. Withdrawal of consent</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received fron:
1. Institutional Review Board (IRB) of Pakistan Institute of Medical Sciences, Islamabad, Pakistan
2. IRB of Queen Sirikit National Institute of Child Health, Bangkok, Thailand
3. World Health Organization (WHO) Ethical Review Committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32365107</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/CAH ID 99025</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
	<country>Switzerland</country>
	<country>Thailand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d8fedca6-9b39-4dab-a4b7-6cf6ed6ec2cd">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 1 to 59 months
2. Audible/auscultatory wheeze
3. Respiratory rate above age specific cut off point or lower chest indrawing
4. Classified as no pneumonia with wheeze</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="1.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>1622</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1622</totalTarget>
      <exclusion>1. Presence of danger sign:
1.1. Up to two months: stopped feeding well, drowsy, convulsions, stridor in a calm child, fever
1.2. 2 - 59 months: convulsions, clinically severe malnutrition, unable to drink
2. Antibiotics during last 48 hours</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Wheeze and fast breathing</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Inhaled Salbutamol and reassessment after up to three cycles of bronchodilator therapy repeated at 15 minute interval if necessary
2. Metered Dose Inhaler (MDI) with spacer device</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15499063 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ce338e9-07fd-4fec-ae50-250cdba2bdf4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15499063"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11301-0</funderId>
      <contactId>Contact41752_11301</contactId>
      <sponsorId>Sponsor39497</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41752_11301">
    <title>Dr</title>
    <forename>Shamim</forename>
    <surname>Qazi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39497">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/child-adolescent-health/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder11301-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-07-12T00:00:00.000Z">51421587</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Swiss VISCOsupplementation Trial 1</title>
      <scientificTitle/>
      <acronym>SVISCOT-1</acronym>
      <studyHypothesis>To determine the comparative effectiveness, cost-utility and safety of preparations with different chemical structures and origins used for viscosupplementation in knee Osteoarthritis (OA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Western Ontario and McMaster Universities osteoarthritis index (WOMAC) pain sub-scores.</primaryOutcome>
      <secondaryOutcome>Cost-utility based on health related quality of life measured by EuroQoL and self-reported healthcare utilisation for osteoarthritis</secondaryOutcome>
      <trialWebsite>http://www.ispm.unibe.ch/research/ongprojects_epstat/sviscot-1.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN51421587</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ed76c208-c8e3-4b84-9c11-eceed8f885f6">
	  <name>Departments of Social and Preventive Medicine and Rheumatology</name>
	  <address/>
	  <city>Berne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>3012</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and non-pregnant women with radiologically confirmed symptomatic OA of the knee
for at least 6 months
2. Pain on most days for the previous 3 months
3. Fulfil American College of Rheumatology (ACR) clinical criteria for OA of the knee:
3.1. Have an ACR functional class rating of II to IV
3.2. Failed to respond sufficiently 
3.3. Intolerant to conservative treatment</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA) of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis of the knee</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be allocated to one of three different preparations, a cross-linked formulation
(Synvisc®) and non-cross-linked preparations of different origin (Orthovisc® and Ostenil®).
Patients will undergo up to three treatment cycles per knee (one cycle consisting of three
injections), with not more than one treatment cycle per knee every 6 months and the last
injection administered not later than 18 months post-randomisation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Orthovisc®, Ostenil®, Synvisc®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17968921 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="dee0db52-92fa-49cc-97a5-1529210695a9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17968921"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11225-0</funderId>
      <funderId>Funder11225-1</funderId>
      <contactId>Contact41660_11225</contactId>
      <sponsorId>Sponsor39405</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41660_11225">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Juni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Departments of Social and Preventive Medicine and Rheumatology
University of Berne
Finkenhubelweg 11</address>
      <city>Berne</city>
      <country>Switzerland</country>
      <zip>3012</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juni@ispm.unibe.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39405">
    <organisation>Swiss Federal Office of Social Insurance (OFAS) (Switzerland)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Effingerstrasse 20  </address>
      <city>Berne</city>
      <country>Switzerland</country>
      <zip>3003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.483062.b</gridId>
    <rorId>https://ror.org/03zv4m970</rorId>
  </sponsor>
  <funder id="Funder11225-0">
    <name>The Swiss Federal Office of Social Insurances (Switzerland) - funding protocol development and implementation</name>
    <fundRef/>
  </funder>
  <funder id="Funder11225-1">
    <name>The manufacturers do not provide any funding for the trial.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">15366053</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The impact of telephone and recorded delivery reminders on the response rate to research questionnaires</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15366053</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="91979152-5f5e-4444-9d6f-7361c17052fd">
	  <name>Primary Care and Population Sciences</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>N19 5NF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Non-responders of a larger randomised controlled trial</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>No telephone available</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Not applicable</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Telephone reminder
2. Recorded delivery reminder</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1997 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9243440 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="74599777-dc25-4e10-b044-337c7dd47c8a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1997-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9243440"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6009-0</funderId>
      <contactId>Contact7554_6009</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7554_6009">
    <title>Ms</title>
    <forename>Sharon</forename>
    <surname>See Tai</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Primary Care and Population Sciences
University College London Medical School
Whittington Hospital
Archway Campus</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>N19 5NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6009-0">
    <name>NHS Executive London (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">60825437</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind randomised placebo controlled study to evaluate the efficacy of Enzyme Potentiated Desensitisation (EPD) in seasonal rhinitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is enzyme potentiated desensitisation significantly superior to an identical placebo treatment when administered pre-seasonally to hay fever sufferers?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured during 12 week hay fever season: number of problem free days and post-treatment symptom scores.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Southwest England Multicentre Research Ethics Committee (MREC) and several local research ethics committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60825437</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SEO131</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-05-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-08-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="96d982c8-721a-400e-9a5a-ce27f6a0dd10">
	  <name>Complementary Therapy Centre</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO14 OYG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. To be recruited from GP lists aged 18 - 64 years
2. Either sex
3. History of seasonal allergic rhinitis extending mid-May to end-July
4. Positive skin prick test to mixed grass pollens</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Symptoms of sufficient severity to require regular treatment outside usual grass-pollinating season
2. History of predominant seasonal problem not corresponding with usual grass-pollinating season
3. Rhinitis complicated by nasal infection, rhino-sinusitis, nasal polyps, septal deviation, gross turbinate hypertrophy or intranasal mass
4. History of anaphylaxis or laryngeal oedema
5. Undergoing nasal surgery within 2 months
6. Receiving specific immunotherapy (high dose method) within preceeding 12 months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-05-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-08-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal rhinitis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Seasonal rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomised to receive two injections out of hay fever season, either EPD or placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Enzyme Potentiated Desensitisation (EPD)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18056902 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fbbdd162-dfff-4003-a39a-45bd37f347b5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18056902"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5969-0</funderId>
      <contactId>Contact7362_5969</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7362_5969">
    <title>Dr</title>
    <forename>George</forename>
    <surname>Lewith</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Complementary Therapy Centre
Royal South Hants Hospital
Brintons Terrace</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO14 OYG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5969-0">
    <name>NHS Executive South East (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">87471242</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial investigating the clinical and cost-effectiveness of a patient self-management programme (SMP) for basic footcare in the elderly</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To design and implement a new patient self-management programme for elderly patients seeking podiatry for basic foot problems. Access to NHS chiropody is often gained on "entitlement" rather than clinical need and in the elderly routine follow up is becoming a costly problem. The Department of Health has called on the profession to tackle this issue within the constraints of current funding levels. We have identified successful use of patient self-management programmes (SMP) for chronic low-grade conditions in other clinical fields and our key objective in this study is to develop a relevant programme for basic footcare in the elderly. We aim to test this, in terms of its clinical and cost-effectiveness, against conventional care in a (as yet unfunded) randomised controlled trial. The SMP will contain elements of information, giving training and education and telephone helpline support involving patients, relatives, carers, voluntary sector workers and podiatry services. We are currently validating a foot health disability measure as the primary outcome measure alongside measures of foot morbidity, patient satisfaction, quality of life and foot health knowledge.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>EuroQol, foot disability index - to be validated, foot morbidity Index, foot health knowledge questionnaire - based on SMP, patient satisfaction questionnaire.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87471242</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>rctc94 441772</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d87d5759-bdf1-46fb-a340-d38451978972">
	  <name>University of Leeds</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS2 9NZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Feasibility study - sample of 50 subjects, mostly new referrals to the NHS podiatry service in Calderdale.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>153</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>153</totalTarget>
      <exclusion>Diabetes mellitis, circulatory disorders.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Basic foot care</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Basic foot care</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patient self-management programme versus standard care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14615000</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2858bb54-74ef-4317-bf85-fc5760d0ff1a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14615000"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6102-0</funderId>
      <contactId>Contact7452_6102</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7452_6102">
    <title>Dr</title>
    <forename>Philip</forename>
    <surname>Helliwell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Leeds
Rheumatology &amp; Rehabilitation Research Unit
36 Clarendon Road</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS2 9NZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)113 233 4952</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.helliwell@leeds.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6102-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>